var title_f8_3_8240="Respiratory support system";
var content_f8_3_8240=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Respiratory support system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The VPAP III ST-A (ResMed, Inc) \"bilevel\" ventilator provides two different adjustable levels of positive airway pressure, a back-up rate, and adjustable alarms. Inspiratory pressure capacity is up to 30 cm H2O.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; ResMed 2010. Used with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_3_8240=[""].join("\n");
var outline_f8_3_8240=null;
var title_f8_3_8241="AFRS CT";
var content_f8_3_8241=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F77812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F77812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sinus CT scan of a patient with allergic fungal rhinosinusitis (AFRS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sinus CT scan of a patient with allergic fungal rhinosinusitis (AFRS) showing complete opacification of both anterior ethmoid and maxillary sinuses and hyperdensities within these same areas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel Hamilos, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_3_8241=[""].join("\n");
var outline_f8_3_8241=null;
var title_f8_3_8242="Paddle size";
var content_f8_3_8242=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pediatric and adult electrode paddles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Paddles and electrode pads designed for adults are recommended for children who weigh more than 10 kg (large circular paddles in picture). Of these, those 12 cm in diameter seem to be superior to those that are 8 cm in diameter. Infant paddles or pads are to be used for smaller infants weighing &lt;10 kg (small circular paddles above).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Scarfone RJ, Cho CS. Cardioversion and Defibrillation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_3_8242=[""].join("\n");
var outline_f8_3_8242=null;
var title_f8_3_8243="Rash - Juvenile dermatomyositis";
var content_f8_3_8243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 581px\">",
"   <div class=\"ttl\">",
"    Clinical images of typical juvenile dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 561px; height: 264px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEIAjEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6Q8Y+JNP8I+HLzXNZeRLC12ea0abmG5wgwO/LCvMf+Gk/h5/z96h/4CH/ABrV/ae/5IZ4n+lv/wClMVfN/wCzl8JdC+Jllrk2u3ep27WEkKRCykjUEOHJzuRv7o6YoA97/wCGk/h5/wA/eof+Ah/xo/4aT+Hn/P3qH/gIf8a83+HvwZ+FPj/+1f8AhHta8VSf2bMIZvNlgXOc7XX90cqdrYPHTpXzf4p0+LSfE+r6dbtI0FpeTW8bSEFiqOVBOABnA9KAPtgftJ/D0/8AL3qH/gIf8atab+0L4D1K9jtbW5vzNJ0zakCvgsjGDmu8+FOnebqMt7IPlRdi8d+9AnsfbbfFLw0oBM1zjGc+SaY3xY8LqRma65Bb/UHpXz7IgKjfkgDC+hxVQgNO4wQq7R9O9JgvM+if+FueFd6L591lztH7g1z11+0b8P7a5lglu7/fGxVsWpIyPxrxYQGWcOPkQH73t3r5/vZhc3txOBgSSM4Hpk5poZ9zD9pD4fF1UXeoZbGP9EP+NWl/aB8DFN5n1BVyQN1oRmvh3RLFrnUdNAO4zS4246Bf8mvTp9MjlhMirkqNq5HXBofkK59HN+0T4CXANxqOScAfZG/xpq/tG+AGcItxqJY9ALRs/wA6+Vr+zhWSAkBnOSwA6H0qKLSvJuorxYgzqr5XscjAH4cVN2PSx9V/8NI/D3dgXeoE5xxaH/GpJv2i/AERYSXWoDBH/Loec/jXxtFobQXWoQEqRGViWT0bKsG+h/rUGuRGW5gt9gRxGzAj+L2/DBp31JufZf8Aw0n8PP8An71D/wABD/jR/wANJ/Dz/n71D/wEP+NfDMkDqSSpx2PY1D060yj7s/4aT+Hv/P3qH/gIf8aP+Gk/h5/z96h/4CH/ABr4UpaAPuv/AIaS+Hv/AD96h/4CN/jR/wANI/D3/n71D/wEP+NfG+n6cBYR3Cx7vNX51boRnHH1rFntzb3kts7ZZGK57H3o3JUrn3I37R/w+VEc3eobWzj/AEQ9vxpn/DSfw8/5+9Q/8BD/AI18TQ2bSaa9yuDsOCp+vas4/kaBp3Pur/hpP4ef8/eof+Ah/wAa2/Bvxt8G+MPEdpoei3F49/chzGsluUU7ULnn6Ka/PmvV/wBlr/kufhz6XP8A6TS0DPq7xn8bfBvg/wAR3eh61cXiX9sEMgjty6jcgcYP0YVi/wDDSfw8/wCfvUP/AAEP+NfOX7TESz/H/W4XyFka0UkdcG3iFd54x+EHw08LeITotw/j6/vlsP7TddPW3mCQb2Qs37sEYK88dxQB6j/w0n8PP+fvUP8AwEP+NH/DSfw8/wCfvUP/AAEP+NeAfGX4Z+EvDHw98P8AijwdqOr3kGrTqqm+dMeWY2bO0RqQcrjmvE/egD7r/wCGk/h5/wA/eof+Ah/xo/4aT+Hn/P3qH/gIf8a+FPaj/GgD7r/4aT+Hn/P3qH/gIf8AGj/hpP4ef8/eof8AgIf8a+FKKAPuv/hpP4ef8/eof+Ah/wAaP+Gk/h5/z96h/wCAh/xr4UoHWgD7r/4aT+Hn/P3qH/gIf8aP+Gk/h5/z96h/4CH/ABr4UFFAH3X/AMNJ/Dz/AJ+9Q/8AAQ/40f8ADSfw8/5+9Q/8BD/jXwrSUAfdf/DSfw8/5+9Q/wDAQ/40f8NJ/D3/AJ+9Q/8AAQ/418KUUAfdf/DSfw8/5+9Q/wDAQ/40f8NJ/Dz/AJ+9Q/8AAQ/418KGigD7r/4aT+Hn/P3qH/gIf8aP+Gk/h5/z96h/4CH/ABr4Uo7UAfdf/DSfw8/5+9Q/8BD/AI0f8NJ/Dz/n71D/AMBD/jXwpR3oA+6/+Gk/h5/z96h/4CH/ABo/4aT+Hn/P3qH/AICH/GvhT+dHagD7r/4aT+Hn/P3qH/gIf8aP+Gk/h5/z96h/4CH/ABr4U70vagD7q/4aT+Hn/P3qH/gIf8aP+Gk/h5/z96h/4CH/ABr4U70UAfdf/DSfw8/5+9Q/8BD/AI0f8NJ/Dz/n71D/AMBD/jXwpRQB91/8NJ/Dz/n71D/wEP8AjR/w0n8Pf+fvUP8AwEP+NfClFAH3X/w0n8Pf+fvUP/AQ/wCNH/DSfw8/5+9Q/wDAQ/418KUUAfdf/DSfw8/5+9Q/8BD/AI0f8NJ/Dz/n71D/AMBD/jXwrSUAfdf/AA0n8PP+fvUP/AQ/40f8NJ/Dz/n71D/wEP8AjXwpR2oA+6/+Gk/h5n/j71D/AMBD/jR/w0n8PP8An71D/wABD/jXwqaSgD7r/wCGk/h5/wA/eof+Ah/xo/4aT+Hn/P3qH/gIf8a+FKKAPuv/AIaT+Hn/AD96h/4CH/GvQfh/420bx7osuq+HpJpLSKdrZjLGUO8KrHj0w4r806+1v2Lv+SVaj/2GJf8A0TDQB75RRRQB5b+09/yQzxP/ALtv/wClMVeK/ssWurX3w5+I1n4daJNWuEhht3lfaqMyyLuzg9ASRx1Fe1ftPf8AJDPE/wDu2/8A6UxV+f8AQB91/C74W674A8Y2V3HqtrqGky6X9hvE8kQNGyENGQBnec7huJBw1fH/AI9067l8b+IpY4WaNtTuvmH/AF2Yc1i6HbC5vdjIGUDJyMgV6voOnQi2KrHshK7VAGMnHPHvSbsS3Y830Hw1d6reKhRkiz87Y6V7To2lQ6ZYJDCoCKBnYMZ+tP02yitUUIjbSBkjt6VrRx4BAPIP9KSbKeuqKSRZBPPtmhY28xwPvHGAfSrW0DIHB7AjvTihbG37w459Ka0Cxiaw0kOlXjoSv7l1BA9VNfPIr6W12zaXQ71cMuIskKPVgD+ma8E8N6aL3xVBYFdytI64PsCf6UwOmg01rTw/YXUA8u4sphNIp+8fugj/AMeJrsxLFNbKiSMqSfOQeOPb9au29gxvoomCvHtadlI47jH61dOmrF5iqPlT7ox7Z/KkkxqyWpyM9rul2xL92QsOOn+c1JHE6zxq+Tyx4HB9j+ddZbadG8IkK5AUde/cmhrIIsbNgfe3e2cUWaFzJ6HJvEi3zu2FEwUOp6ZVcA/iBj8K5rW4PL1zTCQwSSOVenfGf6iu/vLMyREbdwZsL2yO49q5/wAT25EdhdvwlrcguxHRG+U/lkUbitZnIT2SbHjUgR5xj0ya5W6Ty7iRQRtDED869Tk0gyq4KMAclv6isLWfD++3/wBWEaIbUwOuec1MU0F9Tg6KmuIWgmaORSGHrURx2qxnX+GLr7bFbWpTa0GV3jo2emR7VH45sTDPFdqhCPmNieuRyM/gcfhWHo97NZXgkg/iG1hjqK7bWQt/ozC4khjRQZCiHI3EELz+RpN2Zm1yu5xNvKsdo8bg5ZvlcHjpyKpbTjNWJCzszSAKyYUpjGeMZ/lQ0DrCZUIZB19qe2pZWIIr1b9lr/kufhz/AHbn/wBJpa8pJBPSvVv2Wf8Akufh3/duf/SaWgZa/aQ/5OH1b/rrZ/8AoiKvoX4tfDXWPE/xFXXLTTNP1PTjog00wXGpz2REnnO+4mIZZcNjaTg59hXzh+1N/wAlz8R/S2/9Joq8o4oA+ov2jdC1Hwz8BfBGja1epfX9leCKSeMHacRybVGQCQq4UEgE7c18u0d6WgBOtHaiigBelJS0lAC0oB257UADI4zXu/wF+D9n4ot49b8Sl2sXJ+y2inb5wB272PYZ4A74NBUYuWx4QQM9QaQd6/QLUfhP4Jn0+Gzl8M2Xl42gxAq6e+a+YPjp8JYfBQGreHZ5LrQ3k8qRH5e2fnAJ7qccH1+tK62GoNpuOtjxuij9aKZAUoopKADNFApRQAlFFFABRRRQAtJR+dFAC0lAooAWkoo70AFLSUtACUUUUAFFFFABS0lBoAM0UUUAFHailoASiiigAr7W/Yu/5JVqP/YYl/8ARMNfFNfa37F3/JKtR/7DEv8A6JhoA98ooooA8t/ae/5IZ4n/AN23/wDSmKvz/NfoB+09/wAkM8T/AO7b/wDpTFX5/npQBt+Eo5H1PCk7AMvjqeelez6SHZYiUKIVx8xrzj4aWkdxHfTbCZYGVs54A5r1SwhKKNygsR8uelQ9xpJmjDGPKUY7ZAq3GowAq5yMUWakKueucH6Vdij5BCgke1A2tCo6bSMKSR2709YcgseADxip2i3yEMAM9DUkREa9QRjBJqku4EbW4kjdGPyyIUPsDwa8B05I/DPxPt21NSlv5pcMeyyAgN9Of519BSvlo+cqDz9K84+JfhYa3Z21zbIBewB4t/QMpYsg/PIz7imLlfQ6i3hZL91ZsRyWpRCe5Vt2R+DVYlZfJmcOMsCFxzk5AxXk3hy7nEUOnazHfQ3kLARszEZUAjAz17Diu6t724W0iZraIKWG1YydwAPU56UcxdrmzMcAopIQgAnHNMLE/eXKjjP+fpVNLiV5FLqqkfw56VejHmJ87cHsB1pXdxWRG0I+VmPBYZPpwcVS1DT4r20mDLlHXDoejA8E/Wtdk3KCMYXnH0oCh48k7T2A9KomxyWliQxG1lBF5bAI6t0cdFcH3HP51NPphmT5zyp+6KvahayORcWZUXcORhzxIv8AdP8AQ1Si1W2yYr4SWVwv345gVH4HpikS43RxHirwu0i+ZDGvndOvp/8AWriZtLulUP5JKY6j6V7PdS20zmC3JnMq4kZSThT1Cn1I4zSLpgMsjFI/MfnaPuoPT9KLApWVmeJWkklncxzxpll5AIyCDW5BqVzd20llDZCNJ3G+QITsGR0/Ku4ufDVoxcPGDGGA+UY7VHHAtpbtAihVRuDnqTRy9yZNWued6zCsF8DDv2gDLP1J7k0l7IgsVhZDHc7gGC/dZfX+Val0F/tlhKpcMCCnY1lXEDXGrC3Zwy8DPTAwDioTvv0NJLlKDwskMcrY2OSF59K9T/Za/wCS5+HP925/9Jpa821eEQzqF3jjG1u2K9J/Za/5Lp4c/wB25/8ASaWr3JQftS/8lz8R/wC7bf8ApNFXlFesftS/8lz8R/S2/wDSaKvJ6Bh3zR/OijtQAtKiNIwVAWYnAUDJJ9BTa9P/AGedLtr7x+by8CPHpdtJeojDIaQYVePYtn8KC6dN1JKC6m94M/Z58Sa/ZLdald2mlKVDrDLl5Np9QOh9jVTxp8AvEugWLXunTQavbxozyLApV1A64U/e7nivsbwuqNpEU5A3TASFj/Fkf/XrO8WXb2b6VBZ/I8haTA69MfzYflSk7K5tCnGdT2aR+dhHyk9MDGK+5vhC6rpeixgBIl0qzCKPURgn+f618pfG3Tbaw+JWrQ6cipBMyzCNRwrsBuA/4Fk/jX1Jo+jzR3htIpDFDaRJCpU45VFXH/jtTzXtY7MNhuX21ObtbQ9S1/UIrK3kcyhZfLJUd844rxnxOF1D4XeK4bpWdTps83zjneilw3/fQBqS6gv7K6YXbySk8opbdn0qPxOJh4H8W+YpRTo1x8p7HyzUy1OynhI4ek7Svc+Mz0BooP3RU9pazXl3DbWsbSzzOEjRRksxOABWp88iDFJX114D/Z+8NWujw/8ACSrLqGqOoeXbKUjjJH3Fx1x61wHx0+DFn4Y019c8JNO9lCQLuzkO9oFIGHB7rnrnpkUPTcv2cn0PBKKU9vQ0lBAUUCigA70dqKKAFxQR0pc0hNAhKKKO9AwozS0lAC1b0rTLzVr+Ky06B7i6lOEjQZJqotfRn7O+jW1n4audXZFN/dOFV2H3IwSMD6kE/lQa0abqO3Y5jRP2f9fv7ZXvNRsrGRukbAv+oriviD8Otf8AAs8I1mBDazkiG6ibdG5HbPY45xX24pXzI5I1+VwG4HTI6VjePNHg8SeGNX0O9RSl1bO0LEf6uVcFGH0bH4ZFa+z0uC5akuSKsz4M7ikHWl5wM05I3kkVERmdjhVUZJPtWRkNpK7DS/ht4s1SATWmjTmMjILYXP51g69oep6Bem01ixns5x0WVcZ+h6HqOlA3FrczsUn9aOlFAhe9JRRQAUUUUAAr7W/Yt/5JVqP/AGGJf/RMNfFVfav7F3/JKtR/7DEv/omGgD3yiiigDy39p7/khnif/dt//SmKvz/NfoB+09/yQzxP/u2//pTFX5/GgD0T4QZabVk4IMaHafqa9WsYx5EZzy49eleT/B5iNWvlx8rQ8/qRXr+nqogUv8qquQemBUy3LjE07ePYBuAIFWlZCxG4YGBx61j3uphYSsA3nt2/Ks/+0WjQF+Ruz8o5OKSYNPqdSxXqCOP1qBgp3FCNuMk5rh7nW7gM6oVDs20ZbtWbJ4uuLNtkgjDEYwGJ4p8yBRk9kehu3zHceMc81Wki3jBYbPTPauQh8WXbRKfJjYdNp9fXNXLXxYkxCyWwR85KHOSPT60uZFJSR0L6fBdeW8yLI6DA3DIA9B6VYktEEJQDbnoFHFZcWsrjGVKk9fYng1oRX6zKcPzTugdysbMRszAc9akCMMBgB2xVsHIYZqN+hBYn3qkCdyvvx9KhafnAOD1xRO/lqPesS8vnWR1QYY8ZNJuwnEtXbs4Lb/LZeciovORhifynxz8/zBqyJrpnBJbpgEe/NY18/mg7mYZ7CjmFbudXLqlnbRgK0KsDwowBVO41uJwWRkJXoF6Z75rh7qE7fkTae2eTmoEEwYrhif8AdxUqo+wOkrXOsm1cMWZHG4ksV/wqhdagtxaO7gAdxj9aqRWrEDdH8uM5xzU0thDC7Sm4UMRyp6H61fMQo2Zk6laT/aIb2yQSMVAdPX3rE01FivpRfBlnZwy7x98dx/KujLeQS1vISFyTjtn09qhlubPV4fs9wFSQZ2t3BqRy1Vjl/ELhtQIXO1R0PavRP2Wf+S5+Hf8Aduf/AEmlrzTU4ZILplmcu44JP6fpXpf7LX/JdPDv0uf/AEmlqugrW0D9qX/kufiP6W3/AKTRV5RXq/7Uv/Jc/Ef0tv8A0mirygUAHYUUUGgAFesfs/B4b/X7tR8sdrHGTnu0gP8A7Ka8nr3b9nPT/tOgeJWCgmae3gyfQCQ/1qZu0XY7stt9Zg5bH0ToHi0Wuli1n0+5UxjERGCHAGBVa1nvr3Vl1XU02pDGyxL2XjirsNvvto4DGAYxyR1JxxVPxNcvp/hq7eVv4OKznJrV9DuhGm6j5I2cnb/hj5P1y2k8QfGe0s1y7XF9DDnrhd4yfoBk/hX1ZZ3Gbq5upYpF8yQtGAOGyT/TFfPfwRsxqvxsubyQbhp9nPcn/eKiMfrJn8K+qtOgRgjKgIVehHSlBO0fQivWUatRvrL8jmXLXVw1wIwHXgKRzisrxlOsvgPxgHYFhpN0Qf8Atk2K73UrRZY12ptBGGC8GuD8a2AfwB40XGD/AGVcvuH+whOP0/WnK9xwrRqQbeh8Qn7gr074FacsuvXeryD/AI8IwkRI+7JJkBvwUN+YrzJfcZAFfS/wI8OQReAYbi7JEl/NJdEDrsXMa5/FXP41c3aJx5dGLrqU9lqeyL410i3hwkvmShSNsang4qhp6yaz9vS+TfbX0RhkRuhRl24/I1lS6RYuMwqylDkjvn3rpNAieMxq+QVGcDvgVm23qz2VSo0U3Tvd9z4IuIjBNJFnJRiufXBxUNSPuYGRmyWY/Wo+9bo+ZdugUUCigQUUUvegBKKKX6UAJ2ore8G+F9U8Xa3FpmjQebM3zO7cJEvdmPYV7in7NkbaSf8AipB/afT/AFH7nP160JXKUW9UfOFFbfi/wzqfhLWptL1mDyrhPmUjlZEPRlPcHFYtBLVhK+kvgXeA+E7CJioEvnW/+6QxYH8Nw/Ovm4V7T8GLsv4WmgjGZLe+Z8A8gMi4/VDUydlc7sA17Rp9Ue8QeJnsAltdWjusYCpJFyDj1z+NOuPEAvpPOjt3iUAKNzZOCQSePpWcJ4rnSbQ+XiVTsZj0z7fTvUtisEcMavAqMxILM3rxnFXzSatc7oUaNOXteX3j5K+IWitoHjbWdNIASK4Zov8Arm3zof8AvlhXpnwJ8N2p0yfXp0WW8DMsO4ZEarjJHueefamftP6J9k8QaRq8CA293aC3dwOskZ7/APAGT8qvfAq+z4caFj+7jnkhcDrhgGB/Ooexx06cXXkntuj6AsVUG1KECNh0Hc1h/FLwza+MPDd7plzEjXqxNLYzN1ilU8AH0boR707SNTht4EgvJVSWB9pz0P09qXWtXt57+E2cjSGNRyg+VhkMc/8AfIH410txUDno4epPE8s721Ph85yQeCKStfxfYHS/FGqWRAAhuXVfdSSVP5EVkVgYyjyycX0AUUUtBIlFHWigA619rfsXf8kq1H/sMS/+iYa+Ka+1v2Lv+SVaj/2GJf8A0TDQB75RRRQB5b+09/yQzxP/ALtv/wClMVfn9X6BftPf8kM8T/7tv/6UxV+ftAHffCNidZu4UGZJIuOfTNem3t5LKUtrGJnbA5x8hb+Hn0ryP4X3HkeLrUEn96Cn519AafAsceFwu1ioAHb/ACal7m0HoYVtok5fz7ufz8rnA6J+FE1qPMJ4KdT3H0remZolIDjPTAFZF0wJG0sCPXpmoaN6cLmNfaTbSbnkjB3HLLnB/CsyXRIYwGTLqeQG5rpEO44+6T3btUUsDMpPmL8vUY7UNHQqbicyLZLd2DpmPoR2qZBEXJYDcfWtK9092B+YN3xiuavVltTkTZKnnPakJUI1DpLOD93gY27cKR69RWtbWxDIQcEsMewxXH6Lq/mTiLezPkAIa77SmSeM7ewx9KcTmrUpUyygPl4AODzimzKoDZznHatGKEgDNQy27LH85zknqKoz2Ofui0g2hj9T2rCmtyGIPLHljnrXUXVsNxPf271k36BIzlcZoaE79DnblfJG3j1JrIur1Q+UPPXkVY1W4ZmJ+ZU6A5rAkDSyfj1PUiocuh006F1eQ+S/BkGcHJ61Zt9ShJ+ZAePSoLbTPPboOOK2bXQowoBGCen1+lVFSHL2a0GQ30bN8+V3DtV5JIpCG2Rvg4+Yf0qjeaO8AUIzDHY1mo8lvIc7mOelXsZ8kZbG9KiOwbcoXGNqoMGsDUtHjZzOmEdOhXv9a0bW43BSz4x0BGasyoHCsMEnqR60bmDjyuxysMSyzRm6j3SISm7qGGOD+ldx+zhaLafHrw+qk7SLkrn0+zS5/WucvYT8zhfm4I/Ou1+AMZb42eFZdykL9rXAHXNtKc5oWiscyTUjnf2pv+S5+I/pbf8ApNFXlSAMTzivVf2pv+S5+Ivpbf8ApNFXl1pA9zdQ28XLyusaj3JwKZoet/Cv4H6h450ZdVm1KDTrSXd5AdCzyBSQWx2GRiqHxO+Dup+CrZb2C7i1PTtoZpIQQyA5wSPTjrX154Kgs7CzW00tAtjaxfZYF9o/l5/EHNcl8RWt20nUbc/Mwt1Vl7BVTI/VqKnux5kdmGw6qVnRkfEAxkd6+nf2Z9OK+ArmaTCrd6gzDPG5URVH6lq+a9Rh+zahOg/hckfTNfYnwTsTp3w38MRPwZLdrg5/6aSMw/Qip+JXJpp0akk91dHo1tauhOWbpgAe1cb8Z3+yeD7hEJJJVN3Q8mu/icZIC4Pc5rzP4/S/8SCNM4Vpl/HFZV1amzpwM3LFQT7nB/sy6cTJ4x1qRfnlmisIm/N3H6R19G264g5wGQDPvXjXwEtU074cWc24b9Qvrm8bPb5hEv8A6LNeuRzkR7CAynrz3rWFrGFdNzd+7NDh1ZDw3p+FcF44xH4D8bgjGzRrofiYmH+FdxG6fM275jg7Txx0ryz4w37WPw08aSE4Z7VID/20lVf5E0qnQVK9pHxvo2nz6tq1jp1oM3F5MlvGP9pmAH6mvunRtBtLC0hsrODNvbRLbRnHREGAfxxn8a+Z/wBmLQf7U8fyapKmYNHtmuFJGR5zfJGPr8zMP9yvr6yVI0IzkgHGODRJXYqM3Tg2t2YU+nxAbQBzkcHOaz7jUH06yvrhgf8AQ4JJiW44VCf6V0TsrRumxkXBwfWuI8Xz+f4X8UwycE6Vdgv7eS3NZtWPSoTlJO/Q+JQOlFL6U3NbnhhR2o7UUAFHej60UAFKKSlXvQB9TfszxWeleC1unVFnv7hzK5HJjB2gZ9AQTj3r2wNsI24ZW5G3njsa+dfgFqEU/hLyJhlLWaSKRf8AZOGB/wDHm/KvQ7tLqK3DJLcrCcgKsh+71H9KmNRwue1DBRrwg4u2iM749+H7fxR4Nv5YkjfU9I3XNvKnLGMAGSM+2Mt9Vr5FPXivt/w/AscTiYiTqHB754IPtXyf8VvCbeDvGt7pyKfsMn+kWbn+KFuR+Ryp91NNO+5y42hGm1y/M5D1r0j4I6kbbWr+y7XMAcfVD/gT+Veb4rsfhJIsfj7TVbpKJYvxMbY/XFKWqOSjPkmpH0l4WlSVZYlVipbCZGcd8Y9/6Vs29hIZC0sgyOmR71j6FbfZ7tZFYqgXK465rpGChPNJIPAUVVPWJ34it71oGL8UfDCeJvhrrNiib722T7faHqd8YJIHuybl+pFeB/A+9KyataB9rbUuFHrtJB/mK+qLCV7eWJj0DdD6V8vXGmf8IR8eL3SkGyzlndYPQwyrvjHvjKj6inUjocdKq/aKT32PZ7dEvdO3liZ0AYjPAWr+nWdsyRt5u0uuAvXJA61S0bfNI8aKiquQ2f0ras4pYim58lW7KARx/wDqpQ1R3Tr8midj5p+O2itpXjVZeTDeW6Sq3qRlCPr8o/OvOa+l/wBo3QGvvBNtq8UZL6ZcbWOc4ikwDn/gYT86+aR0OelN7nn15c83PuJ3o717P8LPhtpt+tpd+Ig8zXBIS3DbQMKSAa9D8e/CDQ9X8LPJ4e0+Gw1eFN0PkkhZiP4GHqex9acYOSujKqvZNKXU+Ve/tSU+RHR2R1Kup2lTwQR1FNxipEJX2t+xd/ySvUf+wxL/AOiYa+Kq+1f2Lv8AklWo/wDYYl/9Ew0Ae+UUUUAeW/tPHHwM8T/7tv8A+lMVfn9X6A/tP/8AJDPE/wBLf/0pir8/qAN/wYGTXbeZc/umDfrX0zbDNtFIOsg3EDtmvn34c2Ru7y4bZlgFx6ctX0fp1sI7WDfgbVA55qL3bOyMbQRlzW7yH7uG9KomCEOFnlCkHooJOK62e0gaMsrNhuBWTLpF0GeY6m1qAMgLGCB9c0jaL5dyrBBbLbyk2U8rqN3mSkIuOnArHluZVCsLJCCM8vgnpzXOeLNc8TWC4syJIncRw+bbjdIPUDr15rhtW8Y+KYrl7GSVFmGFIiiGQeuPrVJp6EzqyhrY9Nubu6OT5EO1VJOTnaP84rm/ENxbDJmmtELZDAL0FcOJvFGoxZNzcuruIgoP3i3b6djWtongC7u9tzqryCPDEpn5iR0ofLsKE5yd4oboUY1TX4YLGZVlDb1fnGFGWH1Neu6JGYp/mJAcA49M1Ho2m6dpkVtHa26RvEPkCgZBPvWxZ2gD7vQ5/GlGNipycr8xqpE2DgHaOemabcx7gVYldpBJI4xVyBCVwCVzUcp3jk9eKuxlymHfIoRiO3I965zVkzEXIy3YV1OqqixIOlc1qCMw27SyE8/lRaw4wucdqOmSXO9kPyQpvI7etc00sIkAWRSM8d+K9PS2ge0eC4H7p0+cD+IY6VwXizwrZfZWuNKHluFO0IcKcH/Cs5Q1uW5NN21HWTIpwrnGe3rW5Z3cbquDg89a8mVtSsZo1Uyq+ThetXofFOoRBVYRMB6ritVocspq+qPVLkyNFuEkcq9f7v61k3MEUw/eQsHJzx61x0Hja+DAGCN+yjPArfsNU1TUoldLWCJP7zEk5I9PpTk0KD6IkXTirnYpAPQE1ZSAxt3yffrV6CC6kB84jzGAA296laydFYOUyOMA85qVrqFRva5j3cW6B85Jxiux+ACbPjF4dUjOFnAP/bvJXPXVuY15HH9K6P4Dsf8AhdHh8dj9o/8ASeSgwtqcf+1L/wAlz8Rf7tt/6TRVxnw4s1v/AB3odu+dhu0dvop3H9BXZ/tS/wDJc/Ef+7bf+k0Vc98GkL/ETTsPtZUmYAD72InOKDaik6kU+6PqHSJ9ZSyu3sbrykbguqjcWbrg9qzfEtpLDod4ZZGkeWIh2c/N710Why2oto0fJZQf3ffd2/maq+MkZtBu325by2yR2yKwmtD31XtO0Va737nxv4mXbq8+DkHFfbuhWy6bYaTZHhbaxt4FGf7sSj+Yr4j8T/8AITb3Ar7TvtRjXVxCu0hoUZSeigqCP6U4ytCJ51WDliaiXc6qKTfGWbADHHy15n8fpduhW6kZIlyPwFdwl8sSxIVYy7RuUJkDJ/XpXlnx8u9+nw7WyGDHb3rLES/dtG2W039ag3sa/gj9z4C8PWyuEZdPSXgcncWc/q1dvd3yRWcEmn3EgJIQo53Dbj19a4/w/arFoGkb1kYQaTbiQR9ceWD/AI1t2FzJdadatIyq8hAETkFQoGAeOhwK1hZR1KlGLd/M6K0vZUkRpXSRQmcjqPwryL9o3UDD8N7qJTgXl/DD/vKu9/5qK9PMSSRMsaoJFJG5ewHWvGP2nZdvhnSLcfx3DSj6gAf+zUm7NGTUWpJb2f4I2v2b9Kj0X4ctqNwQk2sXTS57+VHlE/8AHvNNeufb4UhZ5JCVxjcB06AGuM0nTE0/TdJ0qQhIdOsYbaUuflEgXDH8TuJrRliMFjDbwq7wxlkwpzvHGD9c9quMXLUqNCCUYvc6hW84KfM3IRkY6HIrz34gyeV4R8aXG/bEmmyxLj/aXZ+pNdTawNplhLJEzSLBjzU64GccH29K4D4u3S23wt8Wyxv80/2eAEj72ZUzj8M0mujHF8im4aqx8l9h9KT+dK3UU2tTxw+tL2pKKACig9KWgBKUelJRQB6j8DdVFrqGpaa7YF1GkqZPBKHBH4hv0r6N05hJaiByDGsYPrlm659TzXxz4S1A6Z4l026zhFmVX/3Dw36E19caLcGHU5LcA4BOzI6c8Vm1Z6nr4SpzUOVbo1/skszuWm2gAYAXAOD6VyHx08GnxJ4BlvbdN+q6ODcRkDl4cfvE/AfMP90+tehgAxqeA7cn2+lWrV/LKrkMuTkMMgg9j+taqJy1cTKas9j8+x2rU8M3/wDZXiPSr/OBb3McjfQMM/pmus+N3gr/AIQrxrNb2it/ZF4PtVkx7IfvJ9VbI+mD3rz5hSaOLZn2Npr7dRmiVvuNjnocmumkU7wJONmAB615p4E1Eanpem3juCZbVHc553r8jfqpP4138VyPKLIwPU5PelTeh0103JOJqRtyccgHByfSvE/2m7M2/iLwn4lhHVfskrDoGjcOufchyP8AgNeo2d3NNcukZLjsBx+tcz8a7D+1fhVrCyLm40yWK8jHoQ+xv/HHP5VrJ3Rl7OUJa+pd0CQySCSI/upAGB9QcGulZl3Bhk1wPw0u3ufDelS54MeG/Diu68wZU55PAFZ0th4jSbJtX03/AISDw1quiOFH9oWkkKFuiuRlD/30FP4V8PxxlLlI5lKkSBXU9ucEGvuezlaOeMq3zBs/jXyb8b9IXQvipr0EIIhlmW8j4xgSqJCB7AsR+FXMxi7nuPhZWi0GC8iBZLW48xsddhGP0ruX1mxj0rMd3H5pcbEzznNeffDm8FxolsjHKOg3CuistAtJ5y8pC5ct9M0qdRxSSPRq06VWbdR2sz5x+M1hHZ/EbVpbdQtvfP8AbIwOnz8t/wCPbq4c9a9k/aB0UWUekXinPzy27N3xwy5/Nq8bPapbu7nLiIqFRqOwlfa37F3/ACSrUf8AsMS/+iYa+Ka+1v2Lv+SVaj/2GJf/AETDQYnvlFFFAHlv7T3/ACQzxP8A7tv/AOlMVfAUab3Vfzr7+/acBb4G+JgOuLf/ANKYq+DdJtTcXyxA4zn9KHsVBXkkz2D4VeHpIo47iVCvngOF77B3r1/Odq9umBWZpFpHbJEkKYHlKB7KB0rUWI7w2cYrJaHoaSdy1DED25FPlj6hlBHfIyDToMD61LJjYMn35p37j5bmLeWVu8vm+UhmwQHIyQD6VjReGbGLzGS2hV5DuZ2XJJ6V0Vyx3E4AweMVVlbMu1ON360I3jR0MZ9OggfiEAfQD8hUEduWySOvOD2NbJiVj8ynJPrnFKLcjOACegqrjcUlZFC0tAkkkzrmRugHatWCANz0NTwW4TBA5qf5RGc//rouYNaigAAgHHHWqrx7AFz8gPU9TmrG/wCXGOMVWYL3yGYDOT607i5GUdTHyleT16/lXOXMW5+TgVuX2VKgv0NZ0q5OD1H+c0XEtDMliBj2e2Aa5y7tpI0kC8pnJT057e1dc6deMkcCs+5hD5ycr34qblxRzlvYQSKWWNDKxyQRnn0FQal4VsruYvJEFyo3ADHQYra8ho3DKAuzjHqD1qwkhAXcMkdD61UbEVKV9jkF8E2iIg+bep3ZxnHTr+Vb1lbLZW6RRjaR8p2jrzx+Va0Tb/mBwM9cUSx/ITkcHPTmhmPs2tDOZTglsZB6j1ph3MMOdw659asyqCM4z7Z9Kq9ec0IiUbIq3JVlKt/DzWl8D5z/AML88Mwd8XLn/wABpcVnyrkE5BHNWvgkm39o3w23I3Q3B/8AJeUVRzdTnv2pv+S5+I/922/9JoqxPggNvxO0M/KdzTJjPP8AqX/xrb/al/5Ln4j/AN22/wDSaKuL+HF6dO8feH7ndtVb6JWP+yzBT+hNIqDtJM+1NGhXb8qDJHXHNN8SQpPo91GBnMZH14pbCYwXEkZ6Dj3qzLMk0MitHgspHrUuzVjZykpJs+IvGcAivjxgqzJX1KN2zR5ipMkumWwkBXP/ACxXOfyFfPPxYsDaazepgALNu496+h7J21PRPDjRP5Zn0y1fOOoMK5rCDfIrdD0aj5MS5LqkzoLO6vVEUUSF0EWDIRwren61578doJf7Nty2JPlYlgOntXf2li9qnlI4eAN8qsTx6/0rk/jXGF8NfI2TzuJPseBU11eDZphqyjiYcvU39NtpfslgI2UuthAu3OOfKXH61p2WnvbwgQQRQqPmP8e4471R0KRZdM0q4Dcy2Vuygf8AXJa6aCRZolyxGOoHFbKOhwyrSTa9fzYWyyJAxmHJGCQMV5B8cLBNU8TeB9NlGYrq/WIgf3WeMH9M17MGI+7yueM+leW+OFW7+LvgmEEk2/m3P4qrMP8A0GpqWSS8ysLeVR32s/yZ10gluri8YQhmlV2C7sfMccHNXYriVp4murd4Jyo5DjZu46D16/nT9PhDlQ5yxwrDpzjnmpLixSSctLFlExs+Ygj1q43itCnWUnaQy5VjpT2xTBClSVOWdd27A+vevKPjdBNc/CzVXgfCW93byyjH3kyUGP8AgTIa9lG2GCYfMNyEHJzjHvXnXxAtll+GvjKMA4FkJOeg2yKwx+VN6tXJjU9ycUfIL9RijgdqG5x9K6Xwb4cOuahGspIt94Bx1bJqm1FXZx0KE681CG5zPFHavs/wV4A8MNo98H0WyuLWEmFGlXJZgcHmvCv2hvBGmeEtY0q70OP7PZ6lHITbZyI3QrnB9CHX9aFqriqQ5JON72PJe9JR2opmYUHvRRQAvPbr1r6z8N66t9pukaigDSTwpI4B6EqM5/HNfJg6817j8HNVWbwo1uzZksZymD3Rssv67qmSOzBP33F9UfQltukiDyZ54P8AWpDcqJGAPAGPpWJo+oB9IiG/zJlDYXuVz39qpXUsrS+Z9pGwtjagzx/eH48VpfsUqDnJxkM+KvhaLx34MurONQdVtN1zYN3LgfNH9HAx9cV8ZMPmOQQRwQexr7gsFlVUnWV9u4cng47H88V83/tBeFF0Dxq2oWke3TtWBuF2jCrN/wAtUH/Aju+jCp16mNWmor3Xsbfwhu5JPCIRM+ZbXEkSfiFYfqzV6hbXzgoGiADRgJls7jnB/XrXmHwQZX8L3UYALi9Y/wDji4/ka9Igto47USssrTpkrs7c+lSrps2pSjyJSNmCQQp5owqyneuw854X8uOKbcQDVNK1PTGfP2+1lt3YjgFwQp/PBrDL2uU88TebklWQldrZyMj8+lb9k7NGjqG5IyzLjB6/j2rXm5kRV9x37nn3wbun/wCEXtLaVQJIJZYnBPIIbP8AWvSDcRoSVcMc44rznRoV03xj4os4htVb77Qg9BIofj866xSZo5MRuzjLnacAAdKxi7XRMqak02brXQtpIwWRkbkHOMcd68N/akgDeLNEv1wftOmqhI7lJHGfyI/KvZrW7ZzbJPbsUClPlIOcDqR+NeUftIW0s2i+G77y9sUMtxbt32lgjqPyDVo2RKnaJo/CaRn0Oy3EBchTmvVLTz45mEflkE5+YZ7dK8f+Dr50WAejjB9+a9itSxYbvlPtUQZpOWp538f9MM/w8luioL2t3HKSBwA2U/mwr5mzxX178Y4fO+GHiFTnIgjcY/2ZUb+lfIXaqZjN3dxK+1v2Lf8AklWo/wDYYl/9Ew18U/Svtb9i7/klWo/9hiX/ANEw0GZ75RRRQB5d+06SPgb4nIODtt//AEpir4M0SXytWtXOcbwD+PFfeX7T3/JDPE/0t/8A0pir4CjcpIsi9VIIoHF2dz7EtFLLakEfNCvT6VeiG4k9u1Z+iyGXStKl4+e2jf8AAoK0wp2fLxjtWLPQhZ2JUkAU4zkHpQSZOvTrj2pkSMMhuOcYq2sIwFIGcdR60HalFFJkYhgRwDyTVd4cNuwMYrVZVJbjgdveoXiVgdx7U7mhnrH0x1GeO9PRPm4B9CanAOQw4BGRURfZl2PJouRIlaPaMdOnNVLhyXVegU0y4vWEYGfmbpSWlvNIQXzyMnPanzI5eVt3ZMSSvcgmoLliGAxxitX7KkcOFcNnsDVZYxPOY14IpO5qrWOfncSHcAAc8j0qnwWwTg9BWzqFn5TZ3rjPNc/dbgcpkd+Kd7GUknsSSp+8AHBx+dVmhJJI6ZyferVrOrj5sE8kUkoAJI+76UERunYzJbUvdpIsv7oIQYwOGPYk+uOKT7GDk4ORxxVtyVzt9fT1o28fLnHfPpQmb62KIiKnYFPHvxSnAjI5A61oFfkA7jpVWdMrk564rRMzbTMu6VdpQZB7HPSqjcA8Y+bke1X5lIdgR2qpIPkIHYZJ/GpOaoyrNhUORxV/4MLj9oHwiR08m6GfX9xKf61m3bYVvbrWn8Fzn49+Ef8AcvP/AEnkqzja6nK/tS/8lz8R/S2/9Joq8rido3EkbbXQhgR2Ir1T9qX/AJLn4j/3bb/0mirykCkB9naBqw1iz07VYm2reIkm7qMleQf+BZFdC8xhuzGGkYgZOD19q8V+C5e/+H0QW4dPst3JCwU5P8Lrj0+8fyr1jTIJsYbKxqOmclvqazk+h6K5ZR52zxf4y6I5vpJcEJJnFdr8NL83vgLwvPK3NvA9m/sY5GCj/vkrWv8AFTTRdaGJQo3REZPt0rjvg6+zw7rmnSZzaX6ygDnAlT/GP9axXuycTeX72jGp20Z65byCSEEHCkYxnp9K4z4vqZtFQADarce/FdZYlWQEEbCu7/61c18UAreHHYfdA3Z9B7e9OrrBmOGko4iHqT+FZfN8K+H2xz9hgGf9kKB/Suwt5dmzIUZwDj0rjPDls9n4b0S3m3B1sIlkXuGIzj9a6O0YjygSDyFAPHNUpaE1EnNtd3+ZsozPb7jjdxgD615XrUxb476Cj/MY7Wb8P3DmvTVbapUk8nAxXmN/EzfHfTS3AjsZ3Lf9sWUfqaio7tepphbJzv8Ays9HtZBlRjIY4BP86vux8ssHxj5WH+faufhGyURs2S2SAO59K1VllKMQOoyd1bRZg42s0PecGIIrkhsnPUelcX8TLlbT4c+LpGHymy8r8XkVR/OuqmGGTeMbj1HGfw+lebftDXr2Pw1u4FGBf3sELeyjfJ/OMU2F1G7XY+YbK3a6uEiUEg4r3j4W6OItRsHZB5aTRlsjtnP9K8r8FWXmzmUrnngV9A+AiVh3IqqwwDkVD96avsj0sDD2FBz6y/I9J8OXIj8FQAjZJIcuoHCvk5H5183ftR6uLzxpp2lxSBo9Nsl3j+7JIS5/8d8uvaLq8v8ATQ32fbLbTsHeFugbvtPbNfMHxbu5b74h6vcTqUZmjAU9lEahf0ArbnUtEeZXw7pxdTdNnIfzoo70UHGLzRS4PFK6Mn31ZT7jFADR1z3rtvhHqq6f4pFtMwEF8hg56b+qfrx+NcT3p8UjwyJLExWRGDKR2I6UFwlyNSR9Y2eo+UmzaVPlrECDwOe/4ZNa1sY2toma6UOsgGxD9weufWuZ0yYalFFMrAJPCkowP7wDf1rqooHWBWgWLHBO1cZHc1EHZHrTnFbE9iu5S43uWJIL5wg9BWX8SfDyeLPh9qtmqB723jN7ZnHPmIMkD/eTcPxFblk9xcNKr8IBnkZ/zjJq7bSG1uUI5ZWB+tXujgqyvJ3Pmn4E3v8ApOq2JI+ZEnQe6nBx+Yr220k/eMCd+PzBrxK505fAvxzuNPX5LGSciE9vJmG6P8tyj6g17IknlyZcbW6/jU3szOK0NOz+dt0qOBnhmHetPy3ADHqcHnsKoW0vyq+AVYcg1fibMCgnIxgEVrGxjVu2cLeQrF8StVVsBprO1lGe+Ayf+y1szQM+945DbueW7rWL4mby/iLYSZwJ9MK59SkpP/s1btvKXQQnuCeO+D/jWT3Z0LZPyRJYWkslvAHmUqD/AMshhmUdOTXM/He1S4+FV3IF2m31KCVBnPUOn8mrtrd0RN2wAAn5B/nrXI/GqRf+FU3yKB++vrZOPXcx/pQD10OO+DjGDSo2YHAfge+K9ctLlHkVjuK968z+F8SjQ/KKkMcsPeuvtEQOu2UQFyYy7chSQcfTmpiaSSbLfxIuA/w68RgjB+xuu3HTpXx/2r6h+JEzReAvEcMnmM6wLiQ/xAuvNfLw6Voc9RcrsFfa37F3/JKtR/7DEv8A6Jhr4pNfa37F3/JK9R/7DEv/AKJhoMz3yiiigDy79p0E/AzxPjrtt/8A0pir8/j0r9CP2j4zL8GPESAZz9n4/wC3iKvz9u0EdzKnTaxFF9bFcvu8x9beCJPP8HaDIepsYf8A0ED+lb3zIGwCK5j4bSCb4feHpBg4tFX/AL5JX+hrqHfC57Hr7VhLex6NJJpD4xk7ix3D8qtRA8ZyPr2qtBwemSO1W4zu9PbNI7khXTBx6nNVZOqnoCMmrgBPBOD9Kr3KggckYHWjYtIozEByQxxWTqd4IuQee4zWlOpCZJPzDiuX1OKTzgz5Cbcj3NLmCpFcpvWFsrqJrkkjPIqHUfEenQXqae15awXDYCwtIA3rzUkF4storjGcDIz0r578X+HNRk1ad5EeWaWRmLYyW561PtEnYiOHc4Nx1a6H0OkrYzyDgd+1Vrm7eFyykgAYz6iuU+Gkes23h/7Nqz+eijdCWOXjHPyn17GtK5uZPMMauFk7k85HpVthGN3Zj57yV/vHI/pREnmZDDBYd65XxteazHosraEhVx/rGC5fb0wo/LmuE8I+ItdsdRA1OWaa2dgrxzZ3emR6YockldsycZTmoRR6y8X2eUMvODipJuHIz8pGc1G10k0KBSDkArjvUkxYqCOuOlUndGLTU1chIB6k7Qc/pT84B3Bskdh+VRIQ0hV85647GrC/eGT696Zo9g285xjI5FV3BboAUxyfQ1czjggdOail2hQvY84q0c8kZ10AGJUHPSs9lyC3QYxWpMmGyCQ3Yn1rMCSGHEpHmbQG2jjNUc89jIugDHIM5yQB+daHwScN+0F4VUfwxXX/AKIl/wAKo3mcDPTkmr3wIjLftA6C3GEinx+NvL/jSbsctm2c3+1N/wAlz8RD/Ztv/SaKvKfpXq37U3/Jc/EX0tv/AEmiryimB7J+zpqSi513SZHwZoUu4ge7RkhgP+Av/wCO175Y3DlMK2c84r478F62/h/xVpmpKcLDKBIPWNuHH/fJNfXMciwTNECNqnIwO3b9Kifc6KUtLF7Xo/tulzI2MMuMevWvMvhbbm3ufFZbkGW1jx74lNejX11HFptxLKRtjG4AHqewFc34S04aRpREw/0y+m+0T47Hoi/gv8zWD1mmdlKTjSlB9TobBgsUaZwSTlfSpfENhFfWsdq3KM6mT/dBz+uKz3WSC1aUvtkVsKMfhVqOUhAxbBH3ix496a1TTM5Q+3F7Cx4kmDt8vJUA9AKuwbDtjZlyPutnqapwYYkNjdjkn09quLaDhi2Sc4U8EAc4q7McbfaL1vKRuUsAE+UcfrWDe6TE/iSDVnBMrQm3De2c5P5VtW7I4AVslwDmqWoJ5qMu9maE71VeCwxyM1LVwhrLTQsL84i2nPO4EcY9/wBKcDIZGXcoZeQPWqEd+XAaAL5QO3BGGUgdx+OKs283mBpS21nAGSOAOlUhyhKKuOlEigSO4YhQB6A15n8f0W4+HV4x5aHULZh/3zIv8jXpOoylTnaDg4I7CvOPi/GJPh9qS5LH7TbH8m6/rT2JjHn0PKPCURiWJUXqo5A/SvdPDgeCyVkZQuRvY9VOOhFeX+DdN8x7ZUAzkc+h7V7HbWkE0kjuHSRVCEocMCBzn1GayjrqerWcVaHkPa7aW4FvIiE8HjqMdiPevm3462y2/wASL5oyWjngt5VJ94VH8wa+ivEIY+ROJcOgVY7hOCG77xXg/wC0Qf8AistOjbb5semRK+313yEfoRWsF7xw4uCVG68jy00opKUcVqeQfQHwg8E6aug2+pyRJdX1ygcNIMrGD/CB/Wt3xV4Xs57SX7RbR+bHjemwDKE43CuF+Bni427HQruTHPmWxJ/Fk/qPxr2jWriKW2hkGJCSYvmPVSpP6YFTy6Ns9TDVbOKS0Pm7xR4IezSS60zMkQyWiI5X6VwzAjIbII4r6kv9OkQyFV3KwwCRwR614j8QtBFtdte2kZWJj86gd/WpjLoxYnDxd50/uPSPg7qwvfC1ujn97aObZ8n+Hqn6HH4V6Rp0rI5RCWB6HPTPavnb4P6x9h8QS2ErAQ36BR7SLyv6bh+Ne52k8jIhRwPmy+eMjtQ9GYQfNFM7CKYQAlWJk9M9alLBolY5yvf0rJspFJKOCSR1J71ct2k2kSsCD0FWpGcoLc8k/aR0h549F8TWoPm2xFjPjsMl4m/PeP8Avmuo0y++32NndnH7xFlx1wSORXTa/ptrq+i6hpV4R5V1GUP+yeqsPcEA/hXK+GNPl0/S47O7AMlv+7z64PBqJXbHHlUb9TobT/UfOhyDkjPT6VbjdSp2c/NjGayJ5HhQbSVJ4wDnNXtK2tvWQhymGBI5PNXGXQmULR5jn/HcTQ33hrUQvypdSWjn2lTI/VP1q7E48xlbgn7uO1autWUWo2MlnMCUf94rZ+6wOQR7g1k20LQnF0B5qjHHc/8A16T3CPwpGraS7F2nDAjgH+dcd8cHLfD+1ToDq8G4D08uWuotJhKm/wC6qZB9awvirbG5+HdwVUu1ndwXRCjJKhirH8A/6UmVF2Y3wLaiHSLRDgOEByPpXTmyikmWbYQ7EE4749RXP+H/AJNNt2XI/djbg8HNb1gZmuMhtysMKtJaDZznxZBg+GeuysFy8USe4JmT+lfLY6V9M/He6+y/DaeByN1zcwxD35L/APslfM/StDCo9RK+1v2Lv+SVaj/2GJf/AETDXxTX2t+xd/ySrUf+wxL/AOiYaCD3yiiigDi/jKti3wy17+1s/YBErTbeu0Op4/KvgjU/DN1aeEbfXruKWNb2fEG7oY+efxI4+lffnxa8Pf8ACV/D7VdENwLZbvyQZSM7QsyMfz24/GvnLxZ8JfEieGDBLr6ahpdkmVhaMBl29h+FNbXsYVJcslqa3wqjNv8ADnQ4myWWKQ8+8jMP0NdgE3Rc8DODXD/CW5lm8ItbTlmksLk25DcEJtBX+v5V3BUuTtPynBrnno2ezhHelFj7cjf83HerKkhgf7o9KrIh6jnjNWEDOPcrkn0qLnfFkobJz6dahlcB85BU809zgEk9e1NWPzEG0AHqKls6YpWuym67357HpQ1rHcKUdVI6AVdFsu4/Lk+oPFCxbAwGSM96EZVJRlojEfw9A2SkjRZ7LS2egQwkvI3mse57Vs7SqnJ3c54p+M8+2KaitzlnJ2sZNxo0TIGRjGwGQVrDm8PvJffLJk/3uldg7HyyOvao7YDduHJBwarQiUpRXuswG00Warhi7YwSa5nXvDS6jIrxMsb8DOM13Gq8gL3PQCsnO0AEYINNxTIUpQ1TMbT9GW2UBnLsONx4IqxcWwG7HQdKvg5JPTPOTUFySATgkeop2sOLbd2ZZgKybgpIwTkH2p4UZVgu3IBweoz2NWHG1evBGQKiZgRv5BxyP600zXcRsA5U4qvKMsD6U8kFc5wPeonwxXLfKapMwkVbhvkYZ6c1RkyUJX3/AJVauiCxYcA5H1qk/wAsZAOapPU5amxmXgBLgjgjApP2eZLpv2gdJZ1PkytdMDjt9nlxSajMtra3Vw3SGFpD+A4/XAqH9lf7VN8XtFlMgaFftAYE8jMEmP1q0rnFUm1JNbf5mb+1L/yXPxH/ALtt/wCk0VeU16t+1L/yXPxH/u23/pNFXlHakWBr670C9F5oGg3T7ne4063kcj+8IwD+oNfIo6819NfC69+0/DzQ3BJeGKSH8Vkb+hFTNaGlL4jsJG+0OuUJSI7kH989uPanKpuJAXPyt09QarpcvJcJHF8rEE7vT2qVB5bgAjaM5x2rE65SH6iQscaS/MV+UDPBx6+9QRO20wIgTaNy7uevqaTUmCQpKDnbIMDGc5FEOBtaR23M4yvZRigSbtYtWfyK4beqxoVB4z6k1VsL6W7uphMr/aIiYw4fAGOR+lVbi5TNxbbnWR4zgbc7vcntxVbw/FI0jyXsplWBW4U43bj+p71HO9kdNLS8pHaQXMW7KyDG0ZxwAT2p6KXkkYBc5LZxg46EfpmsizBAQEg4AfdnOB6VasdQEVpM0wO/JCe49cVqn3MWne8TP1Fj9pjMIUADlsZIz0NO8yRFWZxKUzkg4wRn1qlLPPPNK7DEYfdxg5Axn88VNuMsxKrIxAO0Y+Vjj7w/HioUm2d32bMuXEkyOizFWG7DEtyT2H6iuJ+K9wsHhFoeC11dQRZHcAmQn/x0CupvgWtmYI0bbj97lh6fz/SsDx9ZNe+BdQcBZDarHcocdCjAN/46WpyelkZ0+VTjJ9yh8OLMTOsg4wvzA+9erGzRoFcNsmQD94v8I9/WuK+GNvjTUnVPkc8k9x/kV6BIo2hscYxiqhG0TnxdR+2djmdWtlndSwZLhiqtjlH56+9fLfxb1I6r8RddnJ+WK4+zL9IgIx/6Dn8a+srqeK3uDc3AxBaK10xHog3H9Aa+JLud7q5muJTmSaRpG+pJJ/nTgtWZ4qpeEYkNB70vSk6VqcBPaXEtpcw3MDFZYXDqw7EHNfSmhX0mr2tpI7gRDa6JjruGef5V8y1758MdSjPg6ylcjzEDQMOpJU8H8iKzq6I7cFOza69D1S4t99sS+N23GB0rzfxhpscqPG/zfw4Nd9pkxv7QTAbFQ7WYn53/AA7CsfxPpK3iTSRcFTjAPJOOn4VMtUdUHyS1PmLUreXSdWxEWR43Dxt0II5FfQPhbUf7W0ezvYsgTIJGX+62SGH0yD+lefeMfDjSxOzri4AyCT7VrfB25ZvD17ZSk77W62rz90SDI/DKH86ad1ruc86fs5vl+Fnrml3IMI4LHoSa04ABbqZGOAOMiuU0qd42ZXO2TJDL6H1Htirr6lPGEbcxQdeO2KEyXFvRG5d+SqqFb58dz3rNjlimR0JAkbOfbHeoFlEgikeTeHO8qOpHoPanCKOF98ShUI3Zzk9envTaDkS3BInLbgQVxjI5qBrgpKUtztkBBxjqPX/61Tzxbs+SxRXO4AnGKrXVm8kMnzhWi5iGed2OfwppWDRmlBdO8bGQDbg/Pjhz3IqrcT+a6gJ9M+1Q2Qklt2ZWjZAuAR1OAM4/Op5YVWbaT+729Aeh4/OglpX0Bc714wHwWHTjGcU6BlMhiB3RyDbIjcjHQj6YrOdS6yM04KjACgY9gfyrRZWkUufvAcleM+vFBL0M2OFNHka0UE2QAaIk8xgnp9K1oCFcBXyQMgjsDUKosrkSKrADLKxzj2/GnpmJ1YMGgAzuIwRkn9OlFh6NHnH7Q6yN4c0mUsSjXrjHYfuxj+teDGvffj+fP8EaPOM4F+VP4xn/AANeBetWc89xOtfa37F3/JKtR/7DEv8A6Jhr4pr7W/Yu/wCSVaj/ANhiX/0TDQSe+UUUUAU9XQSadMrDKkAEfiK5iKxi8iaFx+6bII7YNdXqAzaSDnt0+tYrL/k1cXZGNSN2eE6LpE3hzxx4j06RGNlewx3Vu+OAVJUr/wCPfpXSooUfKx46+1dv4g0pb6LzY1AuI0YqcckelcVvXG/HDKPxrnrL3rnpZb8Dg+gRDMbAHtzU4GCvOARj6VHGqowwDgjmnsVyB1BPFYHppW2BYi8jeac5OQaswSIkbDbz0GfT1qIYdVOaZ5hRkTjaR1plTm2rF2MEgscY9qa8a5bGTnn9KYkyhOvA7VHPdJCrPI6opGck1S0ME+Z2QsjLHySOe1VJLnB+QFjjNc/qXiKCAYjPmkn7x6fQVhXniBjlppwmflKj+H/JqJSR3UsDKVnM6+TUFIIEi59qpSXhViDcYGeR0rgxrEfmACTEgk2sSeCMZB+nNRSamZUdiTs3lN+c7hio57HcsvhudjfaxAZWj+0AkfLkev1/OmrcBjtLhgP4lP8AOvP3uVC5f5mADAk9Tjjin/2rsmYQzMhUYLDozd/wq1K5jWwMJKyR36SAnOefSpJX35+XjpXH2+uO6jzEO3qXAxW3a6rFMFIIZX6Ef1rWLR5FbDTp6onlZNzqCcqOB6VUkB3s4YjK96vO6PjpycGqk4YKyoc9jQ4siFW7syuz7sKMZBOT2qKfJXHVh2FOiVlx5nzOOuKJhxnPOOtWhVJJaFSUkjtwcVVnxz6H5RVkLk9cevvVWXLEHGAD19KqxyVHdHKePrgWnhe4GcSXEiQp7j7zfyH50v7LBcfHDw+qsdhW5LAdP+PeWrmu6BeeIJbPyrdZbeJWflsZcnnj0GK9B+AvhKbSviPpV3KtvGY1mG2NeSDCw6/jW3s3a55bxS5+RK+p5f8AtS/8lz8RfS2/9Joq8or1f9qX/kufiL6W3/pNFXlHsazOoVeozXu3wGv2l8KajafeezuhIo/2ZF/xQ/nXhFeqfAG7Mesa1bA/6yzEoHqUcf0Y0MafLqeyR3BN2koHLDaMDAFaDqEQ+X0x+ZrPPBRwAR6DsatLcCVVI4xwAe9Y8p0c1wugZraEAAGMjI7U5Yj03ZU4B9vSnRI7B8DpwR7VDCXIG4hUJyAeppNDUtAu7czSNnGxSDu7gip4YzE8gTa6gZOeCc9aanCsrNkthjz71IgX5zHxn73rU8pfO3oTo8Ubl0Q/MSSM8Z7VBdCSRQqRLJtB3AfnipoRlFaRR64ojby2OfutnOKGroqM+V3RSW1nLxwYZWZcZHTrmr8BkidWcooXIwffvViIiYjaMDpu/u0gg3N7KORSUSnVctGQXGFDRsdysS24jqT1zVS/hEmgarbFRsntJoxntmNh/PFas0CzxliFJ4K8dMVVvhHFa3MpGY44JGIPcBSap7Exndr1KXwzkdfCemboyMwhs+uQDXVTXOy3fdxgck96xfB0Jt/COjIQN32RC3/fIq1eXZEJUrhjjnqOTgYrRP3UTNe0qSfmc94/1EW3w/8AFNwvLLp7Q9enmFY/5Oa+Q/4a+mPjLci1+GOrqMA3dxbW+Po5f/2SvmftThsY1371gpP50UetWYDgeK9M+Feog6RfWAI8yOQTKD3UgA/qB+deY1f0TU59I1CO6tzyvDKejr3BpNXRrRqezmpH1BpF88ii0tHUSEEsccRjHLH+grpZbWP7KsMXPA+Y9fcmuF8KX0E1rHcWYLW9wBIrMfmc46H6dPwrurM4gIdh5hHzH09qzh2OrET5tVscN4r08eYX4JI6Y7VxHgtRp/jG9sx8qXkIdQO7xtu/9BLV65rlj50bucEDoDx715fqOnFvFukPCzJKsxkDD0VSdv0OMH60NWHCXPHU6+Vgk6s0gDE7iG4zV1CHvNhJ8mVTkDjjvis+6SWZ081AQo+XaeWq3ZukbqxYnBAG8/dJ6j9KQLYkmH2Rt+GXbwAOw/zg1LaXxJDSlFYjIIOQwzxketW7iHehWSXCyDcEPTPasOES2bNCyoImbdllySf8KthdM6kyROHdfmCdAe/HUiqiCJixcMxMeQD/AA5OKrWuTMHZiwxtx0BHrV25nEbDCBWX7oHehMx20KNncCIfum2LBhdrn5guM49+tXYiCRuBCHoD6nvWbJHm6lkCp5knBBHB75FW7eJyEKyNgLgN1GDTE2Vtas0Se2eA5TzBgDrxzz+NXoGmIXYNyPyxPUVDexttDbih6nPt2/Op7FJJDuLDDHdx0oM7jZZGjBHCN796qK7bdmMxCTsfTt9OavXEIJBCgtux83PFUJIh9o2n5EAy2DyT9KQKRx3x0iC+ALfaxKx38Qx7+XKK8Ar3r46zkeCYItuA2op+OI5P8RXgvrVES3EzX2t+xb/ySrUf+wxL/wCiYa+Ka+1v2Lv+SVaj/wBhiX/0TDTJPfKKKKAIrs4t3z0/+vWQSCTite5GYWHFUFhwGzg5PammRJXKq/f3ben6153rVkbHULq3UfJu3J/unn/61emvGC2OgxXOeMdM8+zW7gUmWDl1x1Qnn8jzUVFeJvhZ+zqJvY4iJggGckY5o3ASIuDh8tnHpUmDtbCjrn8KHG5B39K5T3FJPUUZAyMZzUEzjJB+91wKnY5QEffHaqtwit87Haw5x70Eys0ZuoXr28UjK4BQZOa861nxaJZGUtK/zbQUBOD6CvR7qOQnzYtolRg4yMg1z+t3FmZXEtjFBcFskqnyseOR+tDd+pvgorm1Rxa3N1dECCyunfII3JwapXtnqN67NJGsLMclc85966+01WeytWEUpUFemOmSBj8hV5pLG8a6jkk8sSefOjuOdxZQvI7n5vyFQ4pntwk46taHmw8M3Mj7ftLjHpTJdLvbZfI+07kByK7qS5toLCNEVzOxaJyRwDuGCPwqrcTad9nt0lhl+2F2VmVsLsI4P+8KjlR1Rit7HFTaTdtz57EgUJpMwiZ3nLbOSAM8e/413NpFprahp+ZD5D7/ALSG6qVJOPcHin+JtTstP0RtB0lUaWQqLy4CYyud6pn1zVqCtds5ZOPOoxi7v+mcCL25jysoLAH+H2p+na15N/HFhhk8g9BUpDytvfG7ocVNZ2az3APlbjuwOO9VC9rs58XGMYs7uG5DbAzZGBkjuMUi3ERaQBxjPT0qnZ2bxRCOQEcZPPSnWlpFa/xAuwJIxx9a1vI+XtG7d9S1kEFV4AHWqaqVDZfIJzip0HzO25jvPAPRR7UyTqAOexrVCk0yJseUx/ixWfKVSN94O0LuJz0GKu3HGRn5Tz9Kw9ZcmEQpkmQbmx2UVWiOWbb0Og8LeLNKvbeG2P8Aolwg24cY3e9epfDfafGOnshDKRJgj/rm1fOZsV3Z2kA969I+Ak1zF8S9HgNxI0LibKE5HEL/AP1q1jVvGzPN9g4zTT6nmv7U3/Jc/Ef+7bf+k0VeUV6v+1N/yXPxF/u23/pNFXlHasztAcV3XwYn8rx9ax5wLiCeI4/65sw/VRXDVt+Cr46b4u0e8zgRXUe7/dLAH9CaBM+nFcGFDjgj8qfAR5Z/iwOfeklAjaVVwCrFeeg96ijwuG5C43Z9alqxrF6DnleMyQq5HmdMehq1FhF3MSQegA561TRzNKHVOQMj8B2qUSk7AAQEGM+/U1mzRbE1vMpc5j2kE9TzUoRljyWy45+vr/Oo2Ab7i4LDP5ZqOGdjF+7BZuhDfrQMuJuYBcH5u2fSn5G1cfe9R2qtG5JLZAA5/DvTvOCuu1SfpUlrcu283ymMN1bg4xxVqNUMYZy2QO5rOt5VLHdnI6ZHp0qw0gCDdyGGfrVJ2Je+hbkIWHC4yVJ4PrVDUY2uLOeH+KZDGT6ZXFNV9jZPIPHsKsrIihd3zZ6e1S9RrTYs6av2PR7SHr5cCxjPYAYFZ+oyrHtXjOQFb1/D/PWp5JyEZQAM569Pesm6/eyKQ7GTPU9/eqT0NKejuzzP4+3bQ+FtHsmbLXN7JcEe0aBR/wCjDXhmOK9K+PmqLeeOF0+Fsx6XbrbHngyHLufzbb/wGvNc9K1itDkqy5pthSUUUzMKXtSd6KAPVPhBroMT6PO/zxv51vk9QfvKPp1/OvbdGvFKMSwzn9fWvkawu5rG9gurZtk0LB1I9RX0J4a1eLUYbS/Rykc6btoPCnoQfoeKh6O5003zwcGeh3K+ZHzwmNvPXgVwF7brD4n0k5yHkcN/s5RgBXXxXjvnyzuCjJ9uKxfEiJBBFejGUcS7j14PP86T1HT912ZJMMog2gE52/XFO0hTKTHco3nDkj1P+FTbRLCFVl6ZRsdc1JYnbPEvXaOAe5qRqWmpLNBKtzlvmVewPTNQ3cKzAK4w27Iq55haVyc7m6e1VLhsHLAhx0I7VdhXYFFhCMoO4cYz2qUrvj3SEkt69uag8rc6neTnopp0+QUIXhjtY+lAgu1kaUSAAAKGdQen0q1bszKTGytzljnqMVG7456/1qWNv3YBCgtzhe2aCGEgE6FsDaOvvTIm2Hy4zjf0FRiQIdm04IJIHc05GBRWGFweTjvQQTv8rFe/v3pq4EzMVBOME47U4qHIJIyOaqiQlWJbkkYXp9aAPMf2gbkf2ZokCcLJcTy49cLGAf8Ax6vFq9Z/aBfN5oMQzhYJW/Evj/2UV5LVkvcK+1v2Lf8AklWo/wDYYl/9Ew18Umvtb9i7/klWo/8AYYl/9Ew0CPfKKKKAGTkCJiaqb19RS61dLZaZPcOCQgBx68gCvGvHHxFmsI/IgBErcBfT3rWnRlU2ObEYunh/jZ6brWuWWmK7zSA7RzivHfEvxau7u+bT9Bg8yZgVzjjBrxzWPHWratrsemW8j3E8zldqnIGT1NeqeFfDcei2oaUCS9cAySe/oKmpKNLRam2FviIqbVkzodKuJ5tPha7VUvAgEqjpn2qwzgY4JI5x6VBBFhhzipnDBvlI981wt3PcptpWYrPlASOBxmo1XBO7JB6Z9DQSPKQZO49cU4sAQP1oHLUiEYO4Z+UVl6nZi4i/1avzgA9R9K1mO1GbdlT146VSkYbsKGbPela5KqODumcdd6PGG2h5IuT15Bx2qgLK5ikUAB0AVcqew613F1aiVCrDtnI4xWFqWnxxhSshDAnODzis2rbHo0Mwqx916owGhAjVJhgrIZDnsDk/nwKz5o0ku1ZScE5JPrxWrJaXQZtsuY85DHnA4yKqpBeSufLnRxnPzRjioUk9z0lmCSu7lCVAArZ9jj3bFVnhed5IYlaR22gEeuOua3U02R5AJGQE9eMZrTtrIQoQOGPBNbRimclfNtLRRzNpors2LhzzxhRwK2bHSo7S+inQsSBtYk8Yx1xWjcsFPzJhMdQKYsiMRyOPWtVE8WriqlT4mPeIoihm6Egke9VpF2/d6A8571ckcCLOMntmqbvlOWG6tFdnMQCQgkEflTXf+71NKw2nIPWonOelUQyvcSE57YrP2GSQuRnIx+FW7peAByXJ/AUQoOMYrNvoZFBoeTkV23wSh2/E7RmxjAn/APRL1zUiEkCuz+DSFfiRpPHy7Zv/AEU9WjKS1PHv2pf+S5+Ivpbf+k0VeUdq9X/al/5Lp4j/AN22/wDSaKvKKsApQSuCDhgcg0UlAH1Zo2pJqmlaffkjbdWqTNjs2MMPzzU/KqzDuOK87+DGrLeeGZ9Okb99YOWQHvG5yPybP5iu+gl+VgpywHSlIqLJVk2FTtIkxgYFWN6tkEhdy4wO1Z80pJyoyQvGDVq3lG45XGRx78d6k0LRVjEArKODgntT4EVIBjlu+ajZwTkKpLdcUWhLJtkBDBsKMdqlrUaZYUKWAVfu9cUQlRKQoyPenOoUrIeWJ7Hp9ai+ZXJcAE84HIpbFFiRhnI+7kd+QKWR943IeOn0qONVBD4Pcmpo2VoRxgkcUARPvfiMkY9RTyQI+cZ6H0piSfvCVBGOtV7yUNkICXVcA9utKw0yeWRQGV2G09ee9Z9/qVvoek6hrN9zBZR7wh/5aufuJ/wJsfrQHZ50QgAsOf8A61eRfHjxMtxfQ+HLF8wWTebdMp4ecjAX/gI4+pNXGIpTsjyy+upr+9uLu7kMlxPI0sjnqzMck/nUFKeaTvWhzBRR2ooAKKKKAFFei/CnVs/adIlPJBngz64+Zfy5/CvOat6ZfS6dqFveQH95C4Ye/qPxoauVGTi7o+k7K88uF1JZXUY2kfn/AEq9LHHqenSlhweo965zStQW/t4LiI7oblAQx+n9OR+FbtjK0UKwgg7mx/8AXrG7vZnTJrdDoEeIpGrjCAA59uKsvLifcq7uOBVZ13yiUHuQadAWYb/bp60Eli3utzFtpAYg49DUisWkwQoz1z2NQ/K8e8DGTuIx3FNjLb2ckbeDx6VYFo71ZSAMqewqG6O4hDuwfQ96SecIV2tnI7VExJVflxnoR1oAuY+YDHzAlmOfWo3YpLuUE7fujtn60xPMQOzHnjBouHAVAGwCM7gOp7D/AOvQQyUSeYoLDgnI7k8U9gQgIIwDv56/SolXaNp4YHII4wcUkkm3Yv3nfjjvigkleVY0DbQAeOD0qAEM6BeQzEf/AF6gYN5qhgAo5xnpUoZRKCp24+ana4jyD4/3Ik8TaZAP+WVkGPsWkc/yxXl9dt8ZJ/O+IGoITnyUii59dgJ/UmuJqiGAr7W/Yu/5JVqP/YYl/wDRMNfFNfa37F3/ACSrUf8AsMS/+iYaAPfKKKKAMbxhj/hHL0k4wqnP0YV8f/FrWZLIXU7MGklOyIjtX1z4/k8rwdqrjGRFxnpnIxXxJ8SZ1uPDqCU5uTLg+2DWqqONOy7nJWw3tasW1dGl+z3owutWutTnG+VRhSffqa+glt1JHy15h8AbZYNGkIxuZh+VetAHjA9q4akrnuUqfLddiDyQpB96rXQ2KSD05rQK8dOlU7hW28ke9YanSympKrkDIPf0okGA31Bz796dCcDBGVz0pJBjJPK+orRO6Jv0EHGR96lwpJUYA9fSmbzvG1sN3HrULyoVY5JI4I9KGaKndiXkbJGVg5ZuPXmss6a6uDduDIR9wdAautqCxfKo+Y/dPXmqlxfFThiGPpWconTRp3ZTu9NM8eFYxZXjb71QtbFraFkkcgBsA9+K05Ltwo8rJTsB3rKu7rawibJyc596zaV7nWqDceXoPKx+ZgnLdA1EsMqSKQS0QP5VXg4GI1+761ML54ScgY9D3reJ51WlZ2iXozHLCQw+gIrOuoFSQlQAP50ouix+Y7VPf0p1w4fjsB19a3RxSpWdyA4EUefSoGIXkDkjj61K7bVBOOe1QRq1xwnyoP4u1UjKQzJkfaoyx6e3rTmQRKRksx6mr3lrbRBY+WPVj1NUblwFz7Um9DO5nTENcgL0WpI0w3pwcUyJWwxx8zE81biUYAY5NQtWS9CHHzHOM4wK7T4PDHxD0sHriX/0U9chIuD6113wfB/4WNpZJ7Sj/wAhPWqM3Y8Z/al/5Ln4i/3bb/0miryevV/2pf8AkufiP6W3/pNFXlNWQJRRRQB0vw91Z9K8VWTBtsVwwtpfQqxAz+Bwfwr387o0z93nmvmXSrdrvU7K3jJDyzJGCOxLAV9M3Mw+0y4OcPzmkxx3HBw8qEMAx6g9q00UFCmV46+4xisQMDKPkIBGAB61oQMfn52nbtGemahGhdhdoSW25TrkewqZJF8wgn5s5xnk1TtiXlA3bQDjHrVie2YKSoIz82V6560MaJJ3YsQgBXGDz39abE25VDlgTjnpTbdSxwCTkYOamljjkRcnoQc5xj2pWKuSLwQM4HY05sbs/wBztULHChmPA56+9DykEiTCs3FFhXIWl2uYy+FYkfSo5HCRRorf7xqGeUO2VwNvY1HPcRQRPeXUqQ28Kb2djwFHOaaQpStoZvjXxJH4V8PXGo7UOoSjybNW5Jfu2PRev1xXzRPI0zGWV3ed2LOzc5JOc59a6L4heKJPFOvvdLuSyiHl20TH7qDufcnk/WuYq0ZNhS0UlMQUUd6KACiiigAFFFB70Aei/C7WuJNIuGyOZbck9/4lH16/nXpUNw2SCTuXofUV87WtxLaXUVxbuUmiYOjDsRXuWg6tDrGmQ38BAlYFZI8/cbuP8KiSNIy6M6b7S+1Cx+9xt6cVZU4HQ4HPHasaO5BbCgO8Z2t/s+1W45H3Ec7W60kaI0DKRGXbHXOcd6jjyGYtyOwHSq7yZZdpzzg+9TmdSy/LxjrTGSAgkbeT3H92prSTdtZvTcKgREAZsjcR0FPaYIowikYxQBPNK0nyrxznBHWmKXWZVO0qOdp74pvng8kjPXHT8KIj5uGzwD8pP8qCWTIRPErspDAYP1zVe7kMKyNGq+btJTPQdsVYMb7i27r1BHU1WnJxsaMBgfrtoIK+nCdLCEXzo9yVw5X1q5YrmfDH5cdfQf8A6s1XL4OSMc4rM8T6gdM8LaxdlsbLZlUg4O9zsX9Wz+FNbiZ4B4l1BtW8RalqEhybi4eQewJ4/TFZlHSiqICvtb9i7/klWo/9hiX/ANEw18U19rfsXf8AJKtR/wCwxL/6JhoA98ooooA5v4jwyXHgjVo4QDIYgQD7MD/Svh34jXCTzWVugCHeWdfevvbxBb/a9GvIP78ZFfC3xU0s2HjMl12I68AdMg81lV0V0ehgYqq/Zv1O++CVyEheD0Oa9lKn5cdDXzx8J9QFvqvlucBumK+hIHMkakZ24HNYJ3imdtam4VGiRxtQsORis+45weP8irpEh3DIx2qpMhIyT9agTWhnlf3hxnmpA2F2kjmkdPmyKZj15qomMiNogG3IPqvpVKeE/OVHB681dBIc4PGaSVBKDuO3/aFVe5pCpyu5kpCoJMZKhelU5nj8w5jDSYwSf0rSuI5YmB25IPVR1FY18ADuJbI/u9TSZ2UJxb1ZVuicMBlW34OPSqmx9wKvxyBmknus9iM5HJ71VZnJ+YjGRS5Udjk7WTLgCwLuDFm6FiajUoy/MPnLcc1GufLVnztbt6U7duI2qB6HFaJHDNrdstfKyAEfdPFNbG0Hn6CnxxvJnt74qcAIdw5bGP8A9VWtDz6tVWsiCK084B7gkJ2QdT9atFlA2qAFHQAcCo2lKqFHAP41E0hCHJzTucrvIbPJz3OKoSYbkjj0qxISRj86ruCeBUsRF/FxVhAF6imlMcjBxT24XmmlYzk7jWCgk11nwgYH4jaZ9Jf/AEU9cg/UYFdd8Hx/xcbS+e0px/2yetCDxf8Aal/5Ln4j/wB22/8ASaKvKK9X/am/5Ln4j/3bb/0miryiqJClpKPegDs/hLpv2/xnbTOuYLFWun+qj5f/AB4rXtW1WDspO8kjOOpri/hTpw0rw217KMT6iwb6RLkL+ZyfyruYgWiOeCvIxUtjitbjIF2ux6joM/0rVWKMxjGR39qzo4yAzYIAPQ9qtfOpVVzjvg0jQtQR7XUDdjvV9d3Q8gDsazImMYUjd8pztPT86uLK0kZKsM56DtQDGsUExUE4HJ9D9KZcsGTJX5VwcAep6Gmz5IUnHXkZ6Gq7OyKx3fWlcdupYBMoLKrCMjo3WklYNjLYEa881DPJHvQksFY/dHpVKSVnUqfuZJz3zTBskR/MeRsqqKec8YHvXivxO8aHXZzp2mEppULnkf8ALdgfvfT0FdX8W/Ef9l6aNIs2KXd6gaYrxshz0+rY/L614t/KqSM5O4GijNLTJEoNFFABS0lHY0AFAo+tHegAooooAWt3whrr6HqO5wWtJsJMo9OxHuKwT+tFAH0BDcLKBNE6ssgDBl6MPWr6T5Yc9BgGvJfAviQWpTTb1ysLH9zIf4Cex9q9MhmV1DdCvBqbWNIy6GmsoTAwMj9asQtvj6YNZokzNuXPsDV6KQOPm+U+3c0i07k0YIBO48AnGasIoLZZiy/3fSq5kHRtoXGMmpIpysfz4DEYNA7kjqpdjjag5DHuadA65KgLu9O2arbUfau0hhznNXFiBXcNxb1P8hQJkwZz85YgAAbetVzJJsyQMHqaWMcDe4xv5J5ApZlQyhVOU+7x6+9MixWdvmYAArnArn/iHb/avAGsRxg+ZH5cv1CsCf0yfwrZaNg53PjB2/L3ps1tDcQ3FvOzBZkZGyeACCCfyNJaA0fM1FWtUsZtN1G5srlds1vIY2H0NVaszCvtb9i7/klWo/8AYYl/9Ew18U19rfsXf8kq1H/sMS/+iYaAPfKKKKAIb3/j1k9/8a+U/wBpHQ/JnF3GMGF8n6Gvq65CmFt/3e9eMfGXR5da0m7DQBVeE+W+eSV6VNSPNFpHVg6ns6il0PmXwtdfZtWtnBwNw6/WvpzRLnz7CMqf4a+VdPBjkUnO9WAI9CDX0n4DmFzpETk5O0GuSnsz3sekpxl3Oo6c89KglbcpAA49an7VBICTjHWmkcUmVJgT04x2qrICCKtuGJIzVZlIPTj1oaZmyuv3utJv5Kk8U+VAByKrOcAkDmhIzbJd2ecnIqlP5RBDRqzetK8rDI454xVSRwOO9UiLtFS4srZuGj96pNZQB0VEOOuSa0ZGyvHrVMnmnoVGpJdSD7PGgztOfQ0IQuMKo/CleUfdPX0qN2IYggAY45pohtskZ9q5Y5J4FRPMeBjOaiYjPXJHekYZHX86bI0FdixGaQNgdCaB0xScd2xQidhSQRTCnp0/lSgOXOB19asLFhGHUmqXmS2Q7AA2B3pjLuq3HH8vU1DImO2FPUVSIKj4yABkjg11fwfJ/wCFkaVxxib/ANFPXMNH5eT1rqvhENvxF0kHrib/ANFPVkni37U3/Jc/Ef0tv/SaKvKBXq/7Uv8AyXPxF9Lb/wBJoq8ooICruj2L6nqlpYxZ3TyKhPoO5/AZNUx1xXffCXTRNqd1qEg4t4/Li/33/wAFz+dAmevQRRRhI4UVbeJBHGuOiLwP0qU71YkfgMdaitHZuXOe5NXPvAuAeDyR1A9qTt0Lje2o6MqEIYYYjnJ6/SnxqOctheCRUEcau5LKTGw6k9KnWTYSAoZiMCpKvYlWVmAAXg9fahn2/Mv3R2Heo4QFcjJDZ5zUm1WO4Nx97GcUDCOMHJZtz9acxURMygA9B6E+9KZAo3ZXNV8oqndghjnANIYHIULIA7g/eqpLLBb291cXLbba2jaSRx2CjJ/HsPemtckFjwNw71w3xg1o2Hh6DSYTiXUCHl55ESHgfi3/AKCaaIZ5V4k1afXdcvNSueHuHLBeyL0VR7AACsyjoKKsgM0UdaKACil70lABQaM0UAGOKPpR3paAEoooNABRSmkoAK9B8D+JTLt0+/f970ikb+L2Pv6V59SqxVgykgg5BHY0Ae/wzLjIPz471bgkLrnpnp9a4nwbr39qWhjuGH2qMAOD/EOzV1aE/QEYxUWNYyNVcvERkEdPSpraOMjDE/XNU4XAiB780+EMcbmwSc8UizTwFZGGOOhqyZmJypAGAR/ntVDcgU9T07VIDlmUHG7t2xTAsXLKSp+Uk8fKOvvTEUsQSDtA4b1pIY8hjwBjCnNOVgAAxGVPT+tBLI5oiCHH+rHHPrUE0f72OQDgdx3q9NINuFbOefUAetQuu4EAjcep6UEnj/xh04G/g1mBT5c48ibjo6jgn6r/ACNedHrX0L4k0iPVNLubFwP34+U/3XH3T+f8zXz9dQSW1xLBOu2WNijKexFWZvci+lfa37F3/JKtR/7DEv8A6Jhr4pr7W/Yu/wCSVaj/ANhiX/0TDQB75RRRQAjAMCCMg1Vu9OtLxdtzbpKuMYYUUUAc1/wrPwZvZ/8AhHbDcxyTtPJ/Otey8L6JYxCO0023iQdAooopcqXQt1ZveTLX9jad/wA+kX5U06JppOTZxflRRRZC55dxDoWln/lyh/KkOgaUetjD+VFFFkHPLuNPh3ST1sIT+FN/4RrRj10+D8qKKLIXM+40+F9EPXTbf8qafCmhE86Zb/lRRRZD5n3GnwjoDddLtj+BpD4Q8P8AfSrb/vmiiiyFzPuNPg3w6eukWv8A3zSf8IX4c/6BFr/3yaKKLIOZ9w/4Qvw5/wBAi1/75NH/AAhfhz/oEWv5GiiiyC7D/hC/Dn/QItfyNH/CF+HP+gRa/wDfJooosguxf+EM8O/9Ai1/I0v/AAh3h7/oE235GiinYLi/8If4f/6BNt+Rpp8G+HT10m2/I0UUCuI3gvw4eukWv/fJqfT/AAroenXsd3Y6bbwXMedsiDkZGD+hoooAzNe+G/g/X9Vm1PWfD9leX820STyqSzbVCjPPYAD8Kz/+FP8Aw/8A+hU03/vg/wCNFFAB/wAKf+H/AP0Kmm/98H/GtHTvhz4Q02ExWGgWUEZbcVRTyfXrRRQBbHgvw4BgaRagf7pp/wDwh/h/j/iVW3HsaKKAHf8ACJaDjH9l22PpTT4P8Pn/AJhVt+RoooAd/wAIloOc/wBl22foaT/hEPD+f+QVbenSiigdw/4RDw/nP9lW3/fNI3g/w+x50q2P/AaKKAuRt4K8Nt97R7U/8BNZ+p/DDwVqlwJ9Q8OWFxMFCBnUkhR26+5oooEVP+FP/D//AKFTTf8Avg/40f8ACn/h/wD9Cppv/fB/xoooAP8AhT/w/wD+hU03/vg/40f8Kf8Ah/8A9Cppv/fB/wAaKKAD/hT/AMP/APoVNN/74P8AjR/wp/4f/wDQqab/AN8H/GiigBf+FP8Aw/8A+hU03/vg/wCNJ/wp/wCH/wD0Kmm/98H/ABoooAX/AIU/8P8A/oVNN/74P+NH/Cn/AIf/APQqab/3wf8AGiigBP8AhT/w/wD+hU03/vg/40f8Kf8Ah/8A9Cppv/fB/wAaKKAD/hT/AMP/APoVNN/74P8AjS/8Kf8Ah/8A9Cppv/fB/wAaKKAD/hT/AMP/APoVNN/74P8AjR/wp/4f/wDQqab/AN8H/GiigCa1+FPgW0l8228M6fHJjG5VPT860B4C8LgcaJaf98n/ABoooAB4D8Ljpotp/wB8n/GnDwN4ZGMaNa8f7J/xoooHdjv+EJ8N/wDQHtfyP+NPXwb4eXppNqP+AmiigLsB4O8PDppNt/3yaT/hDPDp66Ra/wDfJoooC7F/4Q3w9/0CbbpjoaX/AIQ/w9/0Cbb/AL5oooFca/gzw6/3tItT/wABrIvPhR4FvLmS4uvDGnSTSHc7lDlj+dFFAEX/AAp/4f8A/Qqab/3wf8a6Xwz4b0fwvYPY+H9PgsLR5DM0UIwC5ABb64UflRRQBr0UUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Heliotrope discolouration of the eyelids, and malar or facial erythema and (B) scaly, red rash on the knuckles with Gottron's papules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Feldman, BM, Rider, LG, Reed, AM, Pachman, LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008; 371:2201. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &copy;2008 Elsevier Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_3_8243=[""].join("\n");
var outline_f8_3_8243=null;
var title_f8_3_8244="Lymph node levels of the neck";
var content_f8_3_8244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Lymph node levels of the neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 499px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Level I, submental (IA) and submandibular (IB); level II, upper internal jugular nodes; level III, middle jugular nodes; level IV, low jugular nodes; level V, posterior triangle nodes; level VI, central compartment; level VII, superior mediastinal nodes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_3_8244=[""].join("\n");
var outline_f8_3_8244=null;
var title_f8_3_8245="Benign nephrosclerosis Light";
var content_f8_3_8245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F53909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F53909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Benign nephrosclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph in benign nephrosclerosis showing a completely sclerotic glomerulus (upper left) adjacent to two shrunken glomeruli that are still intact. There is also prominent tubular atrophy and dilatation with intratubular hyaline casts (arrows). These changes are induced by ischemia resulting from arterial and arteriolar thickening (not shown).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_3_8245=[""].join("\n");
var outline_f8_3_8245=null;
var title_f8_3_8246="Glucocorticoid-induced acne";
var content_f8_3_8246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Systemic glucocorticoid-induced acneiform eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 501px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Drug-induced acneiform eruption. This patient was taking prednisone for sarcoidosis. B) This patient is taking systemic glucocorticoids for severe asthma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_3_8246=[""].join("\n");
var outline_f8_3_8246=null;
var title_f8_3_8247="Management of familial Mediterranean fever";
var content_f8_3_8247=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of familial Mediterranean fever",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/3/8247/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8247/contributors\">",
"     Peter M Rosenberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8247/contributors\">",
"     Stephen E Goldfinger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/3/8247/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8247/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/3/8247/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8247/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/3/8247/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial Mediterranean fever (FMF) is characterized by sporadic, paroxysmal attacks of fever and serositis, with intervening asymptomatic periods that may range from as little as one week to many months. The major cause of mortality is the insidious development of secondary (AA) amyloidosis with eventual renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=see_link\">",
"     \"Pathogenesis of secondary (AA) amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goals of therapy for FMF are twofold:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prevention of acute attacks",
"     </li>",
"     <li>",
"      Prevention of the development and progression of amyloidosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early attempts to treat FMF with a variety of measures, including antibiotics, glucocorticoids, salicylates, antihistamines, antimalarials, and low-fat diets, used either prophylactically or during acute attacks, provided little benefit. It has now become clear that the disease can be managed successfully only by prophylactic treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVENTION OF ATTACKS WITH COLCHICINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first effective therapy for FMF was reported in 1972 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/1\">",
"     1",
"    </a>",
"    ]. Five patients with longstanding FMF were maintained on a regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , 0.6 to 1.8 mg daily. Prior to treatment with colchicine, the patients had had severe attacks every one to six weeks. By contrast, on colchicine, only four attacks were noted in 127 patient-months of treatment.",
"   </p>",
"   <p>",
"    Three double-blind, placebo-controlled trials with a crossover design published in 1974 confirmed the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    in decreasing the frequency of attacks in FMF [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Among 43 patients, the number of attacks fell from 178 during placebo to 29 with colchicine. There was also a dramatic reduction in the severity of attacks: 70 percent of attacks were mild with colchicine compared to 25 percent with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/3\">",
"     3",
"    </a>",
"    ]. The colchicine dose varied from 0.5 mg twice daily to 0.6 mg three times daily; one study using the latter dose had to decrease the dose to 0.6 mg twice daily because of side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These trials laid the foundation for a new standard of care in FMF, but the duration of follow-up (one to three months) was relatively brief. The largest series evaluating the long-term efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    was published in 1991 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/5\">",
"     5",
"    </a>",
"    ]. This report described the outcome with the prophylactic use of colchicine in 45 patients with FMF treated for 15 years. The dose of colchicine administered varied from 1.0 to 3.0 mg daily, with most patients taking 1.0 to 1.5 mg. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      72 percent had a good response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      , defined as less than one attack per six months",
"     </li>",
"     <li>",
"      15 percent had a partial response, with less than one attack per three months",
"     </li>",
"     <li>",
"      13 percent failed to respond",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Response consisted of reductions in the frequency, severity, and duration of attacks. Only the articular manifestations of FMF appeared to respond poorly to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    . Long-term colchicine therapy was established as quite safe, with only mild and infrequent side effects, and highly effective. In our experience, several FMF patients have required 2.4",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of colchicine to control their attacks. Treatment has generally been safe, although one patient developed neuromyopathic degenerative changes after three decades.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Colchicine unresponsiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be a subset of patients who are unresponsive to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/6\">",
"     6",
"    </a>",
"    ]. An initial step in evaluating such patients is to determine whether they have been compliant with therapy. A study of 21 colchicine \"nonresponders\" in California reported that 11 were, in fact, noncompliant [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/7\">",
"     7",
"    </a>",
"    ]. Eight others were described as alcoholic, addicted to opiates, or positioned for secondary gain from disability payments.",
"   </p>",
"   <p>",
"    It is also important to reconsider the diagnosis. Patients with presumed FMF judged to be nonresponders to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    should be evaluated for the possibility of two other hereditary autoinflammatory diseases that may mimic FMF: TRAPS (TNF Associated Periodic Fever) and hyperimmunoglobulin D syndrome, neither of which responds to the drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=see_link\">",
"     \"Periodic fever syndromes and other autoinflammatory diseases: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Characteristics of patients with FMF who are true",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    nonresponders are incompletely understood. One report compared 59 patients who did not respond to colchicine to 51 responders [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/8\">",
"     8",
"    </a>",
"    ]. Nonresponders tended to be from lower socioeconomic backgrounds, had less education, and more severe form of disease. In addition, they had a statistically lower concentration of colchicine in mononuclear cells. The authors speculated that nonresponders may be genetically predisposed to have a lower colchicine concentrating ability. One factor might be poorer gastrointestinal uptake of the drug, which has a wide range of absorption (24 to 88 percent) after oral ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/9\">",
"     9",
"    </a>",
"    ]. Its action may relate to its concentration within leukocytes rather than plasma levels [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal approach to patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    unresponsive FMF is unsettled but several strategies have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Intravenous colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pilot study suggested that they may respond to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    (1 mg given weekly for 12 weeks while patients continued oral colchicine) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/11\">",
"     11",
"    </a>",
"    ]. The long-term safety of this approach is unclear. Furthermore, it is conceivable that some of these patients had not been compliant with prior oral therapy. Intravenous colchicine is not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Interferon alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have described a potential role for interferon alfa in aborting or preventing attacks.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interferon alfa was useful in aborting FMF attacks when given early in a single dose 3 to 10 million IU subcutaneously [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/12\">",
"       12",
"      </a>",
"      ]. Eighteen of 21 attacks in seven patients were halted.",
"     </li>",
"     <li>",
"      A subsequent double-blind, placebo-controlled trial by the same group did not support these results: interferon reduced the levels of inflammatory markers during attacks but did not reduce the median attack duration. The authors speculated that interferon may still be useful in suppressing attacks if administered at their earliest phase [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An open-label crossover trial evaluated the effect of a single dose of 3 million IU of interferon alfa given subcutaneously at the onset of an attack in 10 patients with continued attacks despite oral plus intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/14\">",
"       14",
"      </a>",
"      ]. Compared to attacks that were untreated, attacks that were treated were significantly less painful. The most common side effects were chills and fatigue.",
"     </li>",
"     <li>",
"      Another study on eight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      -resistant patients who were also receiving immunosuppressive therapy for vasculitis or arthritis suggested that scheduled administration of interferon alfa was successful in preventing their FMF attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Miscellaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    -resistant FMF patients have shown responsiveness to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    (initial dose 100 mg daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (25 mg subcutaneously twice weekly),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    (an interleukin-1 receptor antagonist) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/21/16724?source=see_link\">",
"     rilonacept",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/16-21\">",
"     16-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are anecdotal reports that adherence to a low fat diet may benefit a minority of patients with refractory FMF but no published experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prodrome-initiated colchicine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For some patients, initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    therapy at the first sign of an impending attack can abort or significantly attenuate the attack. This strategy is well suited to patients with infrequent episodes who can recognize a distinctive prodromal phase that lasts several hours before the onset of the full-blown attack.",
"   </p>",
"   <p>",
"    To evaluate this approach, nine patients in one study were treated with randomly alternating courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    or placebo taken at the first sign of every attack over a 10-month period [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/22\">",
"     22",
"    </a>",
"    ]. The colchicine regimen was 0.6 mg every hour for four hours, then every two hours for four hours, then every 12 hours for two days. Seventy-five percent of the colchicine courses were followed by attacks considered to have been aborted, compared with only 10 percent of the placebo courses. The successful responses in this study were most dramatic in three patients who could consistently recognize the prodrome of their FMF attacks.",
"   </p>",
"   <p>",
"    Use of intermittent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    has been challenged by those who point to the need for continual colchicine therapy to protect against the development of amyloidosis resulting from low-grade inflammation that can occur during asymptomatic intervals. It is uncertain how often this complication arises in those with only occasional attacks, especially among patients with less virulent genotypes and in those who live in regions such as the United States where amyloidosis is relatively rare. If concern is sufficient, patients on prodrome-initiated colchicine can be monitored with periodic markers of inflammation (ESR, CRP, fibrinogen, SAA levels if available) and checks for proteinuria. Measurement of SAA levels appears to be the most sensitive marker of subclinical inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Possible mechanisms of colchicine in FMF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of FMF appears to involve the recruitment and activation of neutrophils at serosal surfaces. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32261?source=see_link\">",
"     \"Pathophysiology of familial Mediterranean fever\"",
"    </a>",
"    .) Because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    is known to suppress neutrophil phagocytosis in gout, possibly due to its binding of tubulin and other intracellular proteins or to inhibition of neutrophil and endothelial cell adhesion molecules, it is probable that the drug's beneficial effect in FMF is related to the same mechanism(s). If so, it remains curious that the advantage conferred by neutrophil suppression in these two diseases is unaccompanied by any evident impairment in host defense against common pathogens. The ability of colchicine to cause mitotic arrest is unlikely to play a role in its therapeutic action, because the dose required to suppress mitosis is in considerable excess of that used for FMF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREVENTION OF AMYLOIDOSIS WITH COLCHICINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among untreated patients with FMF, AA amyloidosis has been found to occur with variable frequency, depending upon the ethnic origin of the patient. Amyloidosis occurs in approximately 60 percent of Turkish patients with FMF, 30 percent of non-Askenazi Jews, and only 2 percent of Armenians.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    , as preventive therapy, can markedly reduce the incidence of clinical renal disease and stabilize the glomerular filtration rate in patients with mild proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In the largest study, for example, the rate of development of proteinuria at 9 to 11 years was 1.7 percent in 960 compliers versus 49 percent in 54 noncompliers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/24\">",
"     24",
"    </a>",
"    ]. Among 86 patients who already had nonnephrotic proteinuria prior to therapy, colchicine led to resolution of proteinuria in five and stabilization in 68; 13 had progressive disease. Because prophylactic colchicine use appears to be so effective in preventing amyloidosis, the drug is routinely prescribed at a dose of 0.5 mg twice daily in many countries where FMF is prevalent, even for patients with very mild or infrequent attacks of FMF.",
"   </p>",
"   <p>",
"    Among FMF patients with the nephrotic syndrome, prevention of disease progression and a reduction in protein excretion can be achieved. However, a higher",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    dose of 1.5 to 2.0",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    appears to be required and therapy should be instituted before the plasma creatinine concentration reaches 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (132",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Protein excretion in responders can be reduced to below 1 to 2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    with this regimen; the benefit is gradual, occurring over a one- to two-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    is not likely to be effective in patients who already have chronic renal failure, since irreversible glomerular injury is probably present [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, it can prevent recurrent disease (as manifested by proteinuria) in the transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/28\">",
"     28",
"    </a>",
"    ]. The optimal colchicine dose in this setting is 1.5 to 2.0",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    lower doses are less predictably effective. A report of three patients described improvement in proteinuria and the plasma creatinine level and reduction in the frequency of peritonitis attacks with the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    to colchicine [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SAFETY OF COLCHICINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;At doses of 1 to 2 mg per day,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    is safe even when given continuously over decades. Gastrointestinal toxicity is uncommon, mild, and resolves with dose reduction. One study, for example, found nausea in 9 percent and diarrhea in 7 percent, both of which resolved with dose reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/5\">",
"     5",
"    </a>",
"    ]. Another report noted mild steatorrhea in 3 of 12 patients and an abnormal D-xylose test in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone marrow suppression, which can be manifested as transient leukopenia, is rare at therapeutic doses, as are neuropathy and myopathy in patients with normal renal function. Another concern is gonadal toxicity in males. One study found either azoospermia or abnormal sperm penetration in up to 20 percent of males treated with long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/31\">",
"     31",
"    </a>",
"    ]; however, a second smaller study found no change in sperm count over six months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/32\">",
"     32",
"    </a>",
"    ]. Azoospermia can also be a complication of amyloidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Use in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 50 percent of FMF cases begin in the first decade of life. While there has been a theoretical concern over whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    delays the normal growth process, this has not been demonstrated in observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/5,33\">",
"     5,33",
"    </a>",
"    ]. We therefore consider colchicine to be both acceptable and indicated in children with FMF, whose growth and development could otherwise be retarded by frequent, debilitating FMF attacks. However, near fatal acute colchicine intoxication has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A series of 50 children with FMF evaluated the difference between height for chronological age and target height before and after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    therapy, and found that colchicine significantly improved height development [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/33\">",
"     33",
"    </a>",
"    ]. In another series of 153 children with FMF treated with colchicine, the only significant adverse effects were diarrhea following initiation of treatment (14 percent) and a transient elevation in transaminases (12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A group of investigators from Germany, Austria, and Turkey developed a consensus statement with the following recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continuous use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      for prophylaxis of attacks and prevention of amyloidosis is recommended for children with FMF.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"      should be introduced in children with FMF as soon as the diagnosis has been established and continued for life.",
"     </li>",
"     <li>",
"      A starting dose of &le;0.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (for children &lt;5), 1.0",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (for children 5 to 10) or 1.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (for children &gt;10) should be administered orally. In countries where",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      is available as a 0.6 mg tablet, the starting dose should be adapted as follows: &le;0.6",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in children younger than 6, 1.2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in those 6 to 12, and 1.8",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in those older than 10.",
"     </li>",
"     <li>",
"      In high-risk patients (eg, after kidney transplantation and those with amyloidosis), higher doses (up to 2",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      should be used independent of the dose needed for control of clinical symptoms.",
"     </li>",
"     <li>",
"      For patients with severe renal failure (GFR &lt;10",
"      <span class=\"nowrap\">",
"       mL/min),",
"      </span>",
"      the dosage should be reduced by 50 percent (eg, &le;1",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      Dose monitoring using SAA levels is advisable in the presence of impaired renal or liver function [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Use in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;FMF has been associated with a higher-than-normal rate of miscarriage and infertility even in the absence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    . One study of women on long-term colchicine therapy found a 25 percent miscarriage rate and a 36 percent infertility rate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/37\">",
"     37",
"    </a>",
"    ]. However, these rates were comparable to those reported in women with FMF prior to the introduction of colchicine therapy. The same study found that all the infants born to mothers with FMF on colchicine were healthy. Colchicine therapy has never been associated with an increased risk of fetal abnormalities.",
"   </p>",
"   <p>",
"    Thus, continued use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    is recommended for pregnant patients with FMF. There is no consensus on the advisability of amniocentesis and karyotyping such women.",
"   </p>",
"   <p>",
"    A separate issue is the safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    in nursing mothers. One report serially measured the colchicine concentrations in serum and breast milk in four women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8247/abstract/38\">",
"     38",
"    </a>",
"    ]. The concentrations in breast milk were low (1.9 to 8.6",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    and similar to those in serum; the low values reflect extensive peripheral tissue binding of colchicine. These findings and the authors' clinical experience suggest that nursing is safe in women with FMF who continue to take colchicine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"      is an effective and safe way of managing FMF when used as a continuous, preventive therapy. We recommend beginning this drug at a dose of 0.6 mg PO twice daily in all patients with FMF (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). A minority will require three times daily or rarely four times daily therapy to control attacks, but we do not go above this level. Patients who already have significant proteinuria should receive a dose of 1.6 to 2.4",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevention of attacks with colchicine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who achieve freedom from attacks at the 1.2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      dose may reduce it to 0.6 mg (a single daily pill) to see if they can remain attack-free on this lower dose. We encourage patients who are on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      and having occasional attacks to take an additional pill at the earliest prodomal symptom of an episode, since this often aborts an impending attack. Long term use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"       loperamide",
"      </a>",
"      or other antidiarrheals are used in patients who have diarrhea due to colchicine.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"      is apt to remain the mainstay of FMF therapy for years to come. For the few patients who do not respond, several approaches can be tried as described above. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Colchicine unresponsiveness'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/1\">",
"      Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med 1972; 287:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/2\">",
"      Zemer D, Revach M, Pras M, et al. A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med 1974; 291:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/3\">",
"      Dinarello CA, Wolff SM, Goldfinger SE, et al. Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med 1974; 291:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/4\">",
"      Goldstein RC, Schwabe AD. Prophylactic colchicine therapy in familial Mediterranean fever. A controlled, double-blind study. Ann Intern Med 1974; 81:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/5\">",
"      Ben-Chetrit E, Levy M. Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum 1991; 20:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/6\">",
"      Lidar, M, Scherrmann, JM, Chetrit, A, et al. Clinical, genetic, pharmacokinetic and socioeconomical characterization of colchicine nonresponsiveness in FMF (abstract). Clin Exp Rheumatol 2003; 29 (Suppl 26):88.",
"     </a>",
"    </li>",
"    <li>",
"     Peters, RS. Non-response to daily colchicine attack suppression in familial Mediterranean fever. Proceedings, 1st International Conference on FMF, Jerusalem, Israel 1997. p.8.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/8\">",
"      Lidar M, Scherrmann JM, Shinar Y, et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 2004; 33:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/9\">",
"      Niel E, Scherrmann JM. Colchicine today. Joint Bone Spine 2006; 73:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/10\">",
"      Tufan A, Babaoglu MO, Akdogan A, et al. Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol 2007; 34:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/11\">",
"      Lidar M, Kedem R, Langevitz P, et al. Intravenous colchicine for treatment of patients with familial Mediterranean fever unresponsive to oral colchicine. J Rheumatol 2003; 30:2620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/12\">",
"      Tunca M, Tankurt E, Akbaylar Akpinar H, et al. The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study. Br J Rheumatol 1997; 36:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/13\">",
"      Tunca M, Akar S, Soyt&uuml;rk M, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double-blind, placebo-controlled trial. Clin Exp Rheumatol 2004; 22:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/14\">",
"      Tweezer-Zaks N, Rabinovich E, Lidar M, Livneh A. Interferon-alpha as a treatment modality for colchicine- resistant familial Mediterranean fever. J Rheumatol 2008; 35:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/15\">",
"      Calguneri M, Apras S, Ozbalkan Z, et al. The efficacy of continuous interferon alpha administration as an adjunctive agent to colchicine-resistant familial Mediterranean fever patients. Clin Exp Rheumatol 2004; 22:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/16\">",
"      Seyahi E, Ozdogan H, Celik S, et al. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol 2006; 24:S99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/17\">",
"      Ozgocmen S, Oz&ccedil;akar L, Ardicoglu O, et al. Familial Mediterranean fever responds well to infliximab: single case experience. Clin Rheumatol 2006; 25:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/18\">",
"      Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR. Infliximab treatment of Familial Mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheumatol 2004; 10:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/19\">",
"      Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 2008; 167:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/20\">",
"      Belkhir R, Moulonguet-Doleris L, Hachulla E, et al. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 2007; 146:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/21\">",
"      Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 2012; 157:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/22\">",
"      Wright DG, Wolff SM, Fauci AS, Alling DW. Efficacy of intermittent colchicine therapy in familial Mediterranean fever. Ann Intern Med 1977; 86:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/23\">",
"      Duzova A, Bakkaloglu A, Besbas N, et al. Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 2003; 21:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/24\">",
"      Zemer D, Pras M, Sohar E, et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986; 314:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/25\">",
"      Saatci U, Bakkaloglu A, Ozen S, Besbas N. Familial Mediterranean fever and amyloidosis in children. Acta Paediatr 1993; 82:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/26\">",
"      Livneh A, Zemer D, Langevitz P, et al. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum 1994; 37:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/27\">",
"      Zemer D, Livneh A, Langevitz P. Reversal of the nephrotic syndrome by colchicine in amyloidosis of familial Mediterranean fever. Ann Intern Med 1992; 116:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/28\">",
"      Livneh A, Zemer D, Siegal B, et al. Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever. Nephron 1992; 60:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/29\">",
"      Sayarlioglu H, Erkoc R, Sayarlioglu M, et al. Successful treatment of nephrotic syndrome due to FMF amyloidosis with azathioprine: report of three Turkish cases. Rheumatol Int 2006; 27:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/30\">",
"      Ehrenfeld M, Levy M, Sharon P, et al. Gastrointestinal effects of long-term colchicine therapy in patients with recurrent polyserositis (familial mediterranean fever). Dig Dis Sci 1982; 27:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/31\">",
"      Ehrenfeld M, Levy M, Margalioth EJ, Eliakim M. The effects of long-term colchicine therapy on male fertility in patients with familial Mediterranean fever. Andrologia 1986; 18:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/32\">",
"      Bremner WJ, Paulsen CA. Colchicine and testicular function in man. N Engl J Med 1976; 294:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/33\">",
"      Oz&ccedil;akar ZB, Kadiolu G, Siklar Z, et al. The effect of colchicine on physical growth in children with familial mediterranean fever. Eur J Pediatr 2010; 169:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/34\">",
"      Goldbart A, Press J, Sofer S, Kapelushnik J. Near fatal acute colchicine intoxication in a child. A case report. Eur J Pediatr 2000; 159:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/35\">",
"      Padeh S, Gerstein M, Berkun Y. Colchicine is a safe drug in children with familial Mediterranean fever. J Pediatr 2012; 161:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/36\">",
"      Kallinich T, Haffner D, Niehues T, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 2007; 119:e474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/37\">",
"      Ehrenfeld M, Brzezinski A, Levy M, Eliakim M. Fertility and obstetric history in patients with familial Mediterranean fever on long-term colchicine therapy. Br J Obstet Gynaecol 1987; 94:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8247/abstract/38\">",
"      Ben-Chetrit E, Scherrmann JM, Levy M. Colchicine in breast milk of patients with familial Mediterranean fever. Arthritis Rheum 1996; 39:1213.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2574 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-C3CD4DCF74-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_3_8247=[""].join("\n");
var outline_f8_3_8247=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVENTION OF ATTACKS WITH COLCHICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Colchicine unresponsiveness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Intravenous colchicine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Interferon alfa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Miscellaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prodrome-initiated colchicine therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Possible mechanisms of colchicine in FMF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREVENTION OF AMYLOIDOSIS WITH COLCHICINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SAFETY OF COLCHICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Use in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Use in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=related_link\">",
"      Pathogenesis of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/32/32261?source=related_link\">",
"      Pathophysiology of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=related_link\">",
"      Periodic fever syndromes and other autoinflammatory diseases: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_3_8248="Cervical cancer screening tests: Evidence of effectiveness";
var content_f8_3_8248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cervical cancer screening tests: Evidence of effectiveness",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/3/8248/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8248/contributors\">",
"     Brenda E Sirovich, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8248/contributors\">",
"     Sarah Feldman, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8248/contributors\">",
"     Anne Kathryn Goodman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/3/8248/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8248/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8248/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/3/8248/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8248/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/3/8248/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3955225\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Papanicolaou (Pap) smear screening test for cervical cancer was introduced in the United States in 1941 and led to the first systematic effort to detect early cancer. It has been associated with a sustained reduction in cervical cancer incidence and mortality.",
"   </p>",
"   <p>",
"    The Pap smear has become a model for cancer screening. However, the effectiveness of Pap smear screening for cervical cancer has never been demonstrated in a randomized trial. Cervical cancer screening remains an evolving field with ongoing re-evaluation of Pap smear screening practices, the role of HPV testing, and development of new technologies.",
"   </p>",
"   <p>",
"    The conventional Pap smear consists of cells, sampled from the cervix and vagina using a brush or spatula, which are placed directly on a slide and fixed with a chemical fixative in the office or clinic. Newer technology (liquid-based cytology) consists of cells that are sampled similarly, but then suspended in a liquid transport medium, to be subsequently spun or filtered in the laboratory and plated as thin layers on slides. Cytologists review the slides for both techniques. Both the conventional Pap smear and liquid-based cytology are in current practice. Collectively, these tests are referred to as Pap tests or cervical cytology.",
"   </p>",
"   <p>",
"    More recently, testing for human papillomavirus (HPV) has been proposed as an adjunct or alternative to Pap test screening, and the role of HPV testing in cervical cancer screening for women over age 30 is emerging.",
"   </p>",
"   <p>",
"    This discussion will focus on the effectiveness of screening tests for detecting cervical cancer and cervical cancer precursors. Discussion of how to perform these tests and specific recommendations for screening are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"       \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"       \"Screening for cervical cancer: Rationale and recommendations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36934?source=see_link\">",
"       \"Screening for cervical cancer in HIV infected women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3955621\">",
"    <span class=\"h1\">",
"     THE PAPANICOLAOU SMEAR",
"    </span>",
"    &nbsp;&mdash;&nbsp;George N. Papanicolaou, a zoologist by training, developed a microscopic technique to examine vaginal debris in guinea pigs. The technique, which he extended to human volunteers, led to a chance discovery of malignant cells, and he recognized its potential to detect cervical cancer in humans through examination of cervical scrapings [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Pap test aims to identify abnormal cells sampled from the transformation zone, the junction of the ecto- and endocervix, where cervical dysplasia and cancers arise. For conventional Pap smears, cervical samples obtained by brush and spatula are plated on a microscope slide and preserved with fixative. Thin layer (or liquid-based) cytology is an alternative to conventional cytologic sampling. Liquid-based cytology has been widely implemented in the US. Systematic reviews of studies comparing conventional and liquid-based cytology, however, have not shown that liquid-based cytology detects significant cancer precursors more effectively than conventional cytology [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Papanicolaou test yields cytologic results, permitting examination of cells but not tissue structure. The diagnosis of cervical intraepithelial neoplasia or cervical carcinoma requires a tissue sample, obtained by biopsy of suspicious lesions, to make a histologic diagnosis. Pap smear results are classified according to the Bethesda system to standardize and improve the clinical usefulness of Pap smear reports (",
"    <a class=\"graphic graphic_table graphicRef71416 \" href=\"UTD.htm?18/51/19261\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/6\">",
"     6",
"    </a>",
"    ]. There is clearly some correlation between abnormal cytologic results (eg, LSIL) and the histology subsequently demonstrated by biopsy (eg, CIN I), but direct correspondence occurs only in about half of patients. Particularly among young women, LSIL often regresses and represents a self-limited infection with HPV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40185?source=see_link\">",
"     \"Cervical cytology: Interpretation of results\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3955649\">",
"    <span class=\"h2\">",
"     Test characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Pap smear is intended as a screening test (to be administered to asymptomatic patients), rather than a diagnostic test (to confirm or refute the suspicion of disease). Reports of test sensitivity and specificity vary significantly, and the screening test is far from perfectly accurate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/7\">",
"     7",
"    </a>",
"    ]. Considerable interobserver variability in smear interpretation is seen, although variability decreases for smears with more severe abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sources of potential error in sampling and evaluating the Pap smear include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The clinician may not sample the area of cervical abnormality.",
"     </li>",
"     <li>",
"      The abnormal cells may not be plated on the slide or transferred to the liquid medium.",
"     </li>",
"     <li>",
"      The cells may not be adequately preserved with fixative.",
"     </li>",
"     <li>",
"      The cytopathologist may not identify the abnormal cells.",
"     </li>",
"     <li>",
"      The cytologist may inaccurately report the findings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3955656\">",
"    <span class=\"h2\">",
"     Effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the US, cases of invasive cervical cancer are more likely to represent failure to perform appropriate screening than inaccuracies of screening when performed. More than half of women who develop cervical cancer either have never had cervical cytology, have been screened sporadically, or have not been screened within the previous five years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/9-12\">",
"     9-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among women with invasive cancer who did receive prior screening, one study noted a failure of original cervical cytology interpretations to detect dysplastic cells that could be identified retrospectively in up to two-thirds of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/11\">",
"     11",
"    </a>",
"    ]. This study, however, contained no control group.",
"   </p>",
"   <p>",
"    Cytologic screening for cervical cancer has never been evaluated in a randomized controlled trial. Evidence of its effectiveness in reducing the incidence of and mortality from cervical cancer comes exclusively from observational studies. Such studies provide consistent and compelling evidence that has led to the adoption of cervical cytology screening in all developed and many developing nations worldwide.",
"   </p>",
"   <p>",
"    Evidence of conventional cervical cytology (Pap smear) effectiveness includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study in Sweden, cure rates were higher for women with cervical cancer detected by screening than for women whose cervical cancer was diagnosed by symptoms (difference in cure rates of 26 percent, 95% CI 16-36 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/13\">",
"       13",
"      </a>",
"      ]. Women who developed interval symptomatic cancer between recommended screening rounds had a 14 percent higher cure rate than women with symptomatic cancer who had been overdue for screening, suggesting that the improved cure rates could not be attributed to screening selecting for more indolent cancers (length time bias). &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Pap smear screening was introduced sequentially over time into five Canadian provinces. Analysis of mortality data from carcinoma of the uterus (including carcinoma of the cervix) found a strong inverse correlation across the provinces between intensity of cervical screening and change in mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/14\">",
"       14",
"      </a>",
"      ]. For screening rates below 2.5 percent, mortality from uterine and cervical cancer increased by 27.5 per 100,000 women; for screening rates above 25 percent, mortality decreased by 28.7 per 100,000 women.",
"     </li>",
"     <li>",
"      In an early study, 212 cases of invasive cervical cancer were compared with 1060 age-matched neighborhood controls. Absence of a cervical smear over the five years prior to the cancer diagnosis or study enrollment almost tripled the risk for invasive cervical cancer (odds ratio 2.7); this effect persisted in analyses stratified by age, smoking, income, education, and access to care [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The International Agency for Research on Cancer (IARC) combined data from national programs in eight countries and projected a 90 percent reduction in cervical cancer incidence for periodic screening of the entire (non-elderly) adult female population [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Programs for population screening were implemented in Finland, Sweden, and Iceland in the 1960s, but not in neighboring (and demographically similar) Norway. Incidence rates for cervical cancer in the four countries were comparable at baseline but fell by 50 percent within 20 years in the three countries that implemented screening while Norway saw no such decrease [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/17-20\">",
"       17-20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reductions in cervical cancer incidence and mortality have been observed as screening is implemented in other countries, including Australia, Norway, and Japan [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/21-24\">",
"       21-24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3955663\">",
"    <span class=\"h3\">",
"     Diagnosis of adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cytology appears to be less sensitive for detecting endocervical glandular dysplasia and adenocarcinoma than for detecting squamous malignancy. The sensitivity of cervical cytology screening for glandular neoplasia is 50 to 72 percent versus 30 to 87 percent for squamous lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/7,25,26\">",
"     7,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adenocarcinoma involves the glandular tissue of the internal cervical canal, in contrast to squamous lesions that are more likely to be visually apparent. Adenocarcinomas may occur at several sites within the canal (\"skip lesions\") and can be more difficult to detect by routine Pap screening. In a case control study, the rate of cervical screening in the 10 years prior to the diagnosis of adenocarcinoma (82 percent) was similar to the screening rate in control patients without cancer and significantly higher than in women with squamous cell carcinoma (57 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3956630\">",
"    <span class=\"h1\">",
"     HPV TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of testing for high-risk HPV types is evolving [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/5\">",
"     5",
"    </a>",
"    ]. It has been proposed both as a primary screening modality (either as an adjunct to, or instead of, cervical smear testing) and as a method to triage Pap smear results that are equivocal or show low-grade abnormalities.",
"   </p>",
"   <p>",
"    In the US, four types of HPV tests, listed below, are approved by the US Food and Drug Administration (FDA) for primary screening [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/28\">",
"     28",
"    </a>",
"    ]. These tests are approved for primary screening (as a co-test with a Pap) in women over age 30 and for reflex testing after an ASCUS result in women 21 years and older. These tests will be referred to as &ldquo;HPV testing.&rdquo;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hybrid Capture 2 (the first test to receive FDA approval, in 2003) &mdash; Identifies the presence of any of 13 high-risk HPV types",
"     </li>",
"     <li>",
"      Cervista HPV HR test (approved in 2009) &mdash; Identifies the presence of any of 14 high-risk HPV types",
"     </li>",
"     <li>",
"      cobas HPV test &mdash; Detects HPV16 and 18 as well as a pooled result for an additional 12 high-risk subtypes.",
"     </li>",
"     <li>",
"      Aptima mRNA test &mdash; Detects 14 high-risk subtypes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, Cervista has a test (Cervista",
"    <span class=\"nowrap\">",
"     16/18)",
"    </span>",
"    that detects only the HPV16 and HPV18 high-risk subtypes and is approved only for use in women 30 and over as a follow-up test after a positive HPV screen for the 14 high-risk types. These two HPV types are responsible for 70 percent of cervical cancer in the US and confer higher rates of development of HSIL than other high-risk HPV types. The HPV",
"    <span class=\"nowrap\">",
"     16/18",
"    </span>",
"    test (hereafter referred to as \"HPV genotyping\") is intended to be used, adjunctively with cytology, as follow-up to a less-specific HPV test.",
"   </p>",
"   <p>",
"    Other HPV tests (not approved by the FDA) that may be in use by individual laboratories have not been validated adequately, may have significant error, and should not be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3956637\">",
"    <span class=\"h2\">",
"     Primary HPV screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;HPV testing, either alone or in combination with cervical cytology, has been shown in multiple studies to be more sensitive than cervical cytology alone in detecting high or low-grade cervical histopathology [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/5,29-35\">",
"     5,29-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Poor specificity and correspondingly poor positive predictive value, however, limit the use of HPV testing alone as a primary screening modality, particularly in younger women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/5\">",
"     5",
"    </a>",
"    ]. The prevalence of high-risk HPV among a geographically diverse group of 9657 US women, measured by Hybrid Capture 2 testing, ranged from 35 percent for women aged 14 to 19 years, to 6 percent for women aged 50 to 65 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/36\">",
"     36",
"    </a>",
"    ]. If colposcopy were performed for all women with high-risk HPV, the majority would be performed in young women with transient HPV infections.",
"   </p>",
"   <p>",
"    HPV testing has better specificity in women over age 30 than in younger women. Additionally, HPV infection in older women is more likely to be persistent and, therefore, has a greater likelihood of clinical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HPV and Pap screening have been compared in several large trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Canadian Cervical Cancer Screening Trial (CCCaST) compared the sensitivity and specificity of HPV testing with conventional Pap smears in 10,154 women aged 30 to 69 years who underwent both tests [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/34\">",
"       34",
"      </a>",
"      ]. Women with an abnormal Pap smear (ASCUS, AGC, or worse) or a positive HPV test were advised colposcopy. A random sample of 15 percent of women whose results were normal were also invited for colposcopy, to overcome verification bias that results when only positive screening tests are evaluated with a \"gold standard\" procedure.",
"      <br/>",
"      <br/>",
"      Sensitivity (corrected for verification bias) for the detection of confirmed CIN grade 2 or worse was significantly higher with HPV testing than with conventional Pap smears (94.6 versus 55.4 percent). Specificity was significantly lower with HPV testing (94.1 versus 96.8 percent). Sensitivity and specificity of different test combinations was estimated; no testing strategy proved dominant (ie, both superior specificity and sensitivity). Because all women in this study underwent intervention based on the results of both tests, outcomes of different screening strategies cannot be determined.",
"     </li>",
"     <li>",
"      The ARTISTIC trial in England compared screening by liquid based cytology with or without HPV testing in a cohort of women aged 20 to 64 [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/38\">",
"       38",
"      </a>",
"      ]. In the first round of screening, there was a slight (statistically nonsignificant) increase in high-grade lesions for women who had HPV testing. At three years, women who had undergone HPV testing had fewer high-grade (CIN 3+) lesions (OR 0.64, 95% CI 0.30-0.96). However, similar to the POBASCAM trial, overall rates of CIN 3 or worse were equivalent in the two groups over two rounds of screening (OR 0.85, 0.67-1.08).",
"     </li>",
"     <li>",
"      A randomized trial in Italy also assessed the efficacy of HPV screening versus cytology in reducing the incidence of high-grade lesions and invasive cancer in women aged 25 to 60 years [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/39\">",
"       39",
"      </a>",
"      ]. Although strategies shifted across two phases of the trial, two significant findings were consistent:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Initial screening for HPV (with or without cytology) reduced the occurrence of invasive cervical cancer at a second round of screening (zero cases among patients who were assigned to HPV screening versus nine in the group without HPV testing).",
"     </li>",
"     <li>",
"      An excess of high-grade lesions (CIN 2+) was detected in HPV-screened patients (RR 1.64, 95% CI 1.18-2.24 for all women, and RR 2.78, 1.96-3.92 for women aged 25 to 34) over two rounds of screening.",
"     </li>",
"     <li>",
"      The findings from the Italian trial represented the first direct evidence of reduced cancer incidence through HPV screening in developed countries, but also suggest that HPV screening identifies large numbers of women whose lesions would have spontaneously regressed without treatment. Authors of an accompanying editorial propose that, before referring patients with an initial positive HPV test and normal cytology for colposcopy, a second HPV test be performed at 12 months to confirm persistence of HPV infection (as was required in the ARTISTIC trial) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Population Based Screening Study Amsterdam (POBASCAM) trial analyzed data on nearly 40,000 women aged 30 to 59 randomly assigned to initial screening with conventional Pap plus HPV (intervention group, n = 19,579), or Pap alone (control group, n = 19,731) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/41\">",
"       41",
"      </a>",
"      ]. At five years (the routine screening interval in the Netherlands), all women underwent both Pap and HPV testing. The primary endpoint, CIN 3 or worse, was detected less commonly at the second screening round in the intervention compared with the control group (88 versus 122 cases, relative risk [RR] 0.73, 95% CI 0.55-0.96). Cervical cancer was also less common at follow-up in the intervention than control group (4 versus 14 cancers, RR 0.29, 95% CI 0.10-0.87). The cumulative detection of CIN 3 or worse over the two testing rounds, however, did not differ between the two groups (259 versus 272 cases, RR 0.96, 95% CI 0.81-1.14). The cumulative incidence of cervical cancer was also no different (16 cancers in the intervention group versus 20 cancers in the control group [RR 0.80, 95% CI 0.42-1.55]).",
"      <br/>",
"      <br/>",
"      Thus, HPV testing led to earlier detection (but not reduced incidence) of high-grade cervical lesions, including cancer. The reduction in second-round lesions appeared to be directly attributable to a reduction in HPV16-positive lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The strategy of initial screening by HPV testing with cytology triage (for positive tests) was compared with conventional cytology screening in a randomized trial of over 100,000 women aged 25 to 65 years in Finland [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/42\">",
"       42",
"      </a>",
"      ]. Pap smears were performed on all participants in the",
"      <span class=\"nowrap\">",
"       HPV/cytology",
"      </span>",
"      triage arm, but were only read for the 7.3 percent who were positive for high-risk HPV. Results from baseline screening found that the",
"      <span class=\"nowrap\">",
"       HPV/cytology",
"      </span>",
"      triage strategy detected a greater number of histologic abnormalities than conventional screening in all age groups; this measure was used as a surrogate for sensitivity, which was not evaluated. The proportion of women who went on to colposcopy (1.2 percent) was equal in the two groups; however, the positive predictive value of an abnormal screening test was consistently higher for the",
"      <span class=\"nowrap\">",
"       HPV/cytology",
"      </span>",
"      triage arm compared with conventional Pap for all histologic outcomes. Among young women (25 to 34 years old), the",
"      <span class=\"nowrap\">",
"       HPV/cytology",
"      </span>",
"      screening strategy resulted in 27 percent more colposcopies and, among the youngest women (25 to 29 years old), a higher proportion of women recommended for intensified follow-up (21.9 versus 10.0 percent).",
"      <br/>",
"      <br/>",
"      Prior to the second screening round (at 5 years; average follow-up of 3.6 years), women invited to the",
"      <span class=\"nowrap\">",
"       HPV/cytology",
"      </span>",
"      triage arm showed an excess in the cumulative detection rate of CIN of all grades compared to those invited to the conventional Pap smear arm: hazard ratio (HR) 1.53 (95% CI 1.28&ndash;1.84) for CIN grade 1; HR 1.54 (95% CI 1.33&ndash;1.78) for CIN 2; and HR 1.32 (1.09&ndash;1.59) for CIN 3. Detection of invasive cervical cancer was comparable across the two arms (HR 0.81, 95% CI 0.48&ndash;1.37). These effects were similar for younger (aged 25 to 34 years) and older (aged 35 to 65 years) women; however, detection of each grade of CIN (1, 2, and 3) was higher (more than double) in the younger age group compared with the older group in both screening arms [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/35\">",
"       35",
"      </a>",
"      ]. The study&rsquo;s authors infer that while &ldquo;triage use of Pap smears after a positive HPV result has been seen as the best screening strategy in countries that undertake cytology of good quality,&rdquo; high rates of CIN 2 detection, particularly among younger women, may necessitate consideration of surveillance rather than colposcopy as the standard approach for CIN 2. &nbsp;",
"     </li>",
"     <li>",
"      The HPV FOCAL Study is a large trial underway in British Columbia in which over 18,000 women (aged 25 to 65 years) have been randomly assigned to one of three arms: initial HPV testing with cytology triage for positive HPV tests and retesting at four years; initial HPV testing with cytology triage for positive HPV tests and retesting at two years (safety check); and cytology at entry and two years, with HPV triage for ASC-US (control arm) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/43\">",
"       43",
"      </a>",
"      ]. At baseline testing, rates of CIN 2 were greater for women randomized to the HPV arms (with reflex cytology) compared with those in the cytology arm (with reflex HPV), consistent with results from other studies. A population-based study reported the results of screening with HPV testing and Pap smear in the setting of routine practice in a managed care population of 331,818 women aged 30 and older [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/44\">",
"       44",
"      </a>",
"      ]. The five-year cumulative incidence of cervical cancer per 100,000 was 3.2, 3.8, and 7.5 for women who were negative for both HPV and cytology, negative for HPV, or negative for cytology, respectively. Women who had positive HPV testing and negative cytology accounted for 29 percent of the 87 cancers detected and 63 percent of the 27 adenocarcinomas, again indicating poorer sensitivity of cytology in the detection of adenocarcinoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, the findings of the studies summarized above do not suggest a clearly dominant screening strategy. However, they do lead to the following conclusions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary HPV testing in women under 30 years of age results in substantial detection of transient HPV infections and unnecessary colposcopies.",
"     </li>",
"     <li>",
"      Adding HPV testing to routine primary Pap smear screening, or primary HPV testing alone, appears to result in earlier diagnosis of high-grade lesions.",
"     </li>",
"     <li>",
"      One trial has demonstrated a decrease in the overall incidence of cancer with HPV testing, although a mortality benefit has not been demonstrated.",
"     </li>",
"     <li>",
"      Any strategy that includes HPV screening (with or without Pap smears, or with Pap smear as triage) increases the number of positive results from screening and the number of colposcopies performed; long-term outcomes remain uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2011 systematic review of HPV screening, prepared for the US Preventive Services Task Force, concluded that although primary HPV screening for women over age 30 detected more cases of CIN 3 or cancer than cytology, evidence to date is too limited to determine the net benefit of HPV testing strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/5\">",
"     5",
"    </a>",
"    ]. The authors concluded that primary HPV testing was &ldquo;very promising&rdquo; as a screening strategy, particularly when coupled with cytology triage prior to colposcopy, but that data from ongoing randomized trials are needed to determine the balance of benefits and harms from an HPV strategy, including the potential for overdiagnosis and excess colposcopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3956665\">",
"    <span class=\"h2\">",
"     HPV testing as triage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reflex HPV testing for equivocal cytology test results (atypical squamous cells of undetermined significance, ASC-US) or those with low-grade abnormalities (low-grade squamous intraepithelial lesion, LSIL) has been evaluated as an alternative to conventional follow-up (immediate colposcopy or repeat cytology every six months) in randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/29,45,46\">",
"     29,45,46",
"    </a>",
"    ]. THE ASCUS-LSIL Triage Study (ALTS) found that immediate colposcopy was the preferred strategy for LSIL [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/29\">",
"     29",
"    </a>",
"    ]; for ASC-US, however, HPV triage was a promising strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/45\">",
"     45",
"    </a>",
"    ]. The TOMBOLA trial in the United Kingdom found that a single HPV test in women over age 40 could help in the decision regarding colposcopy or cytologic surveillance for low-grade lesions, but was not useful for triage in younger women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One modeling study, designed to characterize the tradeoff between risks and benefits of various screening strategies, predicted that screening women with both cytology and HPV would result in nearly three times as many colposcopies as any other strategy, but would result in a modestly lower lifetime risk of cervical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8248/abstract/47\">",
"     47",
"    </a>",
"    ]. In this model, HPV testing followed by reflex cytology resulted in the fewest colposcopies and second highest efficacy among the four strategies evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52789454\">",
"    <span class=\"h1\">",
"     SCREENING RECOMMENDATIONS AND PARAMETERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific screening recommendations and parameters of screening (when to start and stop screening, the frequency of screening, and screening in special populations of women) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link&amp;anchor=H20#H20\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Screening parameters'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148133186\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the US, cases of invasive cervical cancer are more likely to represent failure to perform appropriate screening than inaccuracies of screening when performed. More than half of women who develop cervical cancer either have never had cervical cytology, have been screened sporadically, or have not been screened within the previous five years. (See",
"      <a class=\"local\" href=\"#H3955656\">",
"       'Effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cytologic screening for cervical cancer has never been evaluated in a randomized controlled trial. Evidence of conventional cervical cytology screening derives from multiple observational studies that have demonstrated marked reductions in cervical cancer mortality following the implementation of national or regional Pap smear screening programs. (See",
"      <a class=\"local\" href=\"#H3955656\">",
"       'Effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The sensitivity of cervical cytology for the detection of adenocarcinoma is lower than for the more common squamous cell carcinoma. (See",
"      <a class=\"local\" href=\"#H3955663\">",
"       'Diagnosis of adenocarcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HPV testing can be used for primary screening or for reflex testing to follow-up an abnormal cytology test. Genotyping to identify HPV",
"      <span class=\"nowrap\">",
"       16/18,",
"      </span>",
"      the two HPV types responsible for 70 percent of cervical cancer in the US, can be performed either by the Cervista",
"      <span class=\"nowrap\">",
"       16/18",
"      </span>",
"      test as follow-up to an abnormal HPV test, or as part of the cobas HPV test. (See",
"      <a class=\"local\" href=\"#H3956630\">",
"       'HPV testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HPV infection is common in younger women (under age 30) and is usually transient. As only persistent HPV infection is likely to result in neoplasia, HPV testing in women under age 30 has low predictive value for cervical cancer or cancer precursors. HPV infection in older women is more likely to be persistent. (See",
"      <a class=\"local\" href=\"#H3956637\">",
"       'Primary HPV screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several trials have compared HPV and Pap screening. HPV screening (with or without concurrent Pap testing) is more sensitive than Pap screening but has lower specificity. Adding HPV testing to routine primary Pap smear screening results in earlier diagnosis of high-grade lesions. Trials have demonstrated a decrease in the overall incidence of cancer with HPV testing, although a mortality benefit has not been demonstrated. Strategies that include HPV screening increase the number of positive results and the number of colposcopies performed; long-term outcomes remain uncertain. (See",
"      <a class=\"local\" href=\"#H3956637\">",
"       'Primary HPV screening'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/1\">",
"      Papanicolaou, GN, Traut, FH. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 1941; 42:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/2\">",
"      Vilos GA. The history of the Papanicolaou smear and the odyssey of George and Andromache Papanicolaou. Obstet Gynecol 1998; 91:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/3\">",
"      Zachariadou-Veneti S. George Papanicolaou (1883-1962). Cytopathology 2000; 11:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/4\">",
"      Arbyn M, Bergeron C, Klinkhamer P, et al. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008; 111:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/5\">",
"      Whitlock EP, Vesco KK, Eder M, et al. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/6\">",
"      Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/7\">",
"      Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000; 132:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/8\">",
"      Stoler MH, Schiffman M, Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/9\">",
"      Hildesheim A, Hadjimichael O, Schwartz PE, et al. Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol 1999; 180:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/10\">",
"      Janerich DT, Hadjimichael O, Schwartz PE, et al. The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health 1995; 85:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/11\">",
"      Coleman DV, Poznansky JJ. Review of cervical smears from 76 women with invasive cervical cancer: cytological findings and medicolegal implications. Cytopathology 2006; 17:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/12\">",
"      Abed Z, O'Leary M, Hand K, et al. Cervical screening history in patients with early stage carcinoma of the cervix. Ir Med J 2006; 99:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/13\">",
"      Andrae B, Andersson TM, Lambert PC, et al. Screening and cervical cancer cure: population based cohort study. BMJ 2012; 344:e900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/14\">",
"      Cervical cancer screening programs. I. Epidemiology and natural history of carcinoma of the cervix. Can Med Assoc J 1976; 114:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/15\">",
"      Clarke EA, Anderson TW. Does screening by \"Pap\" smears help prevent cervical cancer? A case-control study. Lancet 1979; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/16\">",
"      Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programmes. Br Med J (Clin Res Ed) 1986; 293:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/17\">",
"      Johannesson G, Geirsson G, Day N. The effect of mass screening in Iceland, 1965-74, on the incidence and mortality of cervical carcinoma. Int J Cancer 1978; 21:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/18\">",
"      Cannistra SA, Niloff JM. Cancer of the uterine cervix. N Engl J Med 1996; 334:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/19\">",
"      Nieminen P, Kallio M, Hakama M. The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteri. Obstet Gynecol 1995; 85:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/20\">",
"      Bergstr&ouml;m R, Spar&eacute;n P, Adami HO. Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer 1999; 81:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/21\">",
"      Benedet JL, Anderson GH, Matisic JP. A comprehensive program for cervical cancer detection and management. Am J Obstet Gynecol 1992; 166:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/22\">",
"      Nyg&aring;rd JF, Skare GB, Thoresen S&Oslash;. The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. J Med Screen 2002; 9:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/23\">",
"      Taylor R, Morrell S, Mamoon H, et al. Decline in cervical cancer incidence and mortality in New South Wales in relation to control activities (Australia). Cancer Causes Control 2006; 17:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/24\">",
"      Aklimunnessa K, Mori M, Khan MM, et al. Effectiveness of cervical cancer screening over cervical cancer mortality among Japanese women. Jpn J Clin Oncol 2006; 36:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/25\">",
"      Wright TC Jr, Cox JT, Massad LS, et al. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/26\">",
"      Schoolland M, Segal A, Allpress S, et al. Adenocarcinoma in situ of the cervix. Cancer 2002; 96:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/27\">",
"      Sasieni P, Castanon A, Cuzick J. Screening and adenocarcinoma of the cervix. Int J Cancer 2009; 125:525.",
"     </a>",
"    </li>",
"    <li>",
"     American Society for Colposcopy and Cervical Pathology. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. 2009 addendum. Available at: www.guideline.gov/summary/summary.aspx?doc_id=14698&amp;nbr=007268&amp;string=HPV (Accessed on August 24, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/29\">",
"      ASCUS-LSIL Traige Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003; 188:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/30\">",
"      Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/31\">",
"      Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst 2005; 97:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/32\">",
"      Denny LA, Wright TC Jr. Human papillomavirus testing and screening. Best Pract Res Clin Obstet Gynaecol 2005; 19:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/33\">",
"      Koliopoulos G, Arbyn M, Martin-Hirsch P, et al. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007; 104:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/34\">",
"      Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/35\">",
"      Leinonen MK, Nieminen P, L&ouml;nnberg S, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ 2012; 345:e7789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/36\">",
"      Datta SD, Koutsky LA, Ratelle S, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med 2008; 148:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/37\">",
"      Vesco KK, Whitlock EP, Eder M, et al. Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/38\">",
"      Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009; 10:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/39\">",
"      Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/40\">",
"      Castle PE, Katki HA. Benefits and risks of HPV testing in cervical cancer screening. Lancet Oncol 2010; 11:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/41\">",
"      Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012; 13:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/42\">",
"      Leinonen M, Nieminen P, Kotaniemi-Talonen L, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009; 101:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/43\">",
"      Ogilvie GS, Krajden M, van Niekerk DJ, et al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study. Br J Cancer 2012; 107:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/44\">",
"      Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011; 12:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/45\">",
"      ASCUS-LSIL Traige Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/46\">",
"      Cotton S, Sharp L, Little J, et al. The role of human papillomavirus testing in the management of women with low-grade abnormalities: multicentre randomised controlled trial. BJOG 2010; 117:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8248/abstract/47\">",
"      Stout NK, Goldhaber-Fiebert JD, Ortendahl JD, Goldie SJ. Trade-offs in cervical cancer prevention: balancing benefits and risks. Arch Intern Med 2008; 168:1881.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 82921 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-3C008BD0A1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_3_8248=[""].join("\n");
var outline_f8_3_8248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H148133186\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3955225\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3955621\">",
"      THE PAPANICOLAOU SMEAR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3955649\">",
"      Test characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3955656\">",
"      Effectiveness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3955663\">",
"      - Diagnosis of adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3956630\">",
"      HPV TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3956637\">",
"      Primary HPV screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3956665\">",
"      HPV testing as triage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H52789454\">",
"      SCREENING RECOMMENDATIONS AND PARAMETERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148133186\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/82921\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/82921|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/51/19261\" title=\"table 1\">",
"      Bethesda class cervix cytol",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40185?source=related_link\">",
"      Cervical cytology: Interpretation of results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=related_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36934?source=related_link\">",
"      Screening for cervical cancer in HIV infected women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_3_8249="Patient-centered interviewing";
var content_f8_3_8249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Patient-centered interviewing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/3/8249/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8249/contributors\">",
"     Auguste H Fortin, VI, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8249/contributors\">",
"     Francesca C Dwamena, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8249/contributors\">",
"     Robert C Smith, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/3/8249/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8249/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/3/8249/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8249/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/3/8249/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical interviewing is the exchange of relevant information about the patient and the development of a therapeutic relationship with the patient. Interviewing is the fundamental medical skill; it is the vehicle for the clinician-patient interaction in virtually all circumstances, through which is obtained most of the information about an individual patient [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/1\">",
"     1",
"    </a>",
"    ]. Interviewing generates the information needed for diagnoses more often than the physical examination and laboratory investigation combined [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. In addition, interviewing produces the most data needed for treatment and prevention and is the major way in which information of all types is transmitted to the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Finally, interviewing itself determines how the clinician-patient relationship evolves and the therapeutic potential of the encounter [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. Conversely, the quality of the relationship with the patient influences the quality of data exchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians will perform more than 150,000 medical interviews during a career [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/11\">",
"     11",
"    </a>",
"    ]. This topic review will consider how to improve interviewing skills and, in so doing, make medicine more scientific and humanistic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE INTEGRATED PATIENT-CENTERED MEDICAL INTERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the interview is to elicit relevant personal and symptom data about the patient. The interviewer interprets this information in light of her or his medical knowledge and formulates a description of the patient in biopsychosocial terms, and makes an integrated biological, psychological, and social diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     The biopsychosocial model",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biomedical model (often called the disease model or biotechnical model) describes patients in terms of diseases and excludes most psychological and social aspects of the person [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. This model has been responsible for many of medicine's successes but has often neglected the psychosocial dimension of care.",
"   </p>",
"   <p>",
"    The biopsychosocial model describes the person in biological, psychological, and social dimensions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/13\">",
"     13",
"    </a>",
"    ]. It is both a humanistic and scientific model for medicine, including the person with the disease as well as the disease itself [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/6,7,9,13\">",
"     6,7,9,13",
"    </a>",
"    ]. The biopsychosocial model explicitly acknowledges the connections between mind and body and that the patient can be adequately understood and described only as a whole person [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This review will summarize an approach to the medical interviewing process, known as patient-centered interviewing, which allows clinicians to obtain a biopsychosocial description of the patient, thereby operationalizing the biopsychosocial model [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/7,14\">",
"     7,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patient-centered interviewing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most physicians have been trained to elicit symptoms of disease using an isolated \"clinician-centered\" interviewing method. Clinician-centered interviewing focuses on the clinician&rsquo;s own needs to elicit symptoms, their details, and other data that will help make a diagnosis. Personal concerns of the patient are largely ignored and discouraged so that the interviewer can focus upon making a disease diagnosis. A clinician-centered interview takes the lead away from the patient and relegates most personal information about the patient to the background, thereby limiting the clinician&rsquo;s ability to develop an adequate psychosocial description [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/12\">",
"     12",
"    </a>",
"    ]. This style of interviewing focuses the clinician on the disease rather than the person who has the disease.",
"   </p>",
"   <p>",
"    Patient-centered interviewing has evolved over the last few decades to address this problem [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/15-21\">",
"     15-21",
"    </a>",
"    ]. Patients are encouraged to express what is most important to them, including personal concerns and emotions. The clinician avoids an isolated focus on disease while allowing the patient to lead and direct the conversation to important psychosocial data, usually the personal context of the patient's symptoms and disease(s) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/9\">",
"     9",
"    </a>",
"    ]. The patient's ideas and concerns, rather than the clinician's, are most important. As a result, the clinician develops an understanding of the patient as a person. This interviewing method was developed to complement clinician-centered interviewing, not to replace it.",
"   </p>",
"   <p>",
"    The integrated medical interview uses patient-centered and clinician-centered interviewing skills to elicit symptom, personal, and emotional data [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/7\">",
"     7",
"    </a>",
"    ]. Physicians then interpret and synthesize these data, along with data from the physical examination and laboratory testing, to formulate a biopsychosocial description, the patient's story [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Effects of patient-centered care on a variety of outcomes have been evaluated in multiple randomized trials; a systematic review found significant heterogeneity among trials and small to moderate pooled effects on patient satisfaction, health behaviors, and health status [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients develop a sense of self-sufficiency and a feeling of responsibility as their involvement in care increases; they are then more likely to simultaneously share power with the clinician and feel more autonomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/23\">",
"     23",
"    </a>",
"    ]. Patient-centered interviewing recognizes that the patient is the expert on her or his symptoms and needs while the clinician is the expert at translating these into diagnoses and recommendations for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/6,9,23\">",
"     6,9,23",
"    </a>",
"    ]. Physicians also benefit from a patient-centered approach; they can begin to express their own frequently suppressed humane attributes like respect, empathy, humility, sensitivity, compassion, and curiosity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/24\">",
"     24",
"    </a>",
"    ]. A feeling of profound connectedness between clinician and patient sometimes develops with patient-centered interviewing [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Perhaps most importantly, patient-centered interviews take virtually the same amount of time as those that are clinician-centered [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The deficiencies of an isolated clinician-centered approach are illustrated in a review of the literature:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study found that physicians did not allow patients to complete their opening statement of symptoms and concerns in 69 percent of visits, interrupting patients after a mean time of 18 seconds [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/29\">",
"       29",
"      </a>",
"      ]. Information was obtained almost entirely through isolated clinician-centered inquiry.",
"     </li>",
"     <li>",
"      Another report found that isolated clinician-centered interviewing revealed only 6 percent of the primary problems that were later determined to be psychosocial [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third review, an incomplete data base resulted from omitting personal information and using a \"high control\" style [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By comparison, patient-centered interviewing produces better quality personal and emotional information [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/32-34\">",
"     32-34",
"    </a>",
"    ] and also elicits much of the symptom description ordinarily obtained via clinician-centered inquiry [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/5\">",
"     5",
"    </a>",
"    ]. Some of these symptom data are not elicited at all using isolated clinician-centered approaches.",
"   </p>",
"   <p>",
"    Patient satisfaction and adherence increase significantly when patient-centered approaches are integrated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/26,27,35\">",
"     26,27,35",
"    </a>",
"    ]. A decreased risk of malpractice suits [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/36-38\">",
"     36-38",
"    </a>",
"    ], less \"doctor shopping\" [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/39\">",
"     39",
"    </a>",
"    ], and improved patient knowledge and recall also result [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/26,27,35\">",
"     26,27,35",
"    </a>",
"    ]. Improved recall, satisfaction, trust [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/40\">",
"     40",
"    </a>",
"    ], and compliance are associated with better health outcomes. As an example, patient-centered approaches are associated with better blood pressure and diabetes control [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], improved perinatal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/43\">",
"     43",
"    </a>",
"    ], and shortened and less complicated postoperative courses [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/44-46\">",
"     44-46",
"    </a>",
"    ] . Physicians who use patient-centered interviewing skills provide more indicated preventive services [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/47\">",
"     47",
"    </a>",
"    ] and utilize fewer referrals and diagnostic tests [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No studies have compared the consistency of data obtained by either the isolated clinician-centered or the integrated approach [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/6\">",
"     6",
"    </a>",
"    ]. Theoretically, information elicited by patient-centered interviewing should be more consistent and less biased because it is influenced less by the interviewer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient-centered portion of an integrated medical interview precedes an often longer clinician-centered component [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. We discourage interviewers from starting with the clinician-centered process; even if they later introduce the patient-centered process, this ordering suggests that the clinician's agenda is more important. Later in the interview when a clinician-centered style predominates, the interviewer may need to return to a patient-centered approach if pressing personal issues arise. After the patient-centered beginning, the interviewer moves freely back and forth between using patient-centered and clinician-centered interviewing skills, although the latter will be the major focus and where most time is spent.",
"   </p>",
"   <p>",
"    The patient's needs always take precedence in the integrated medical interview [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. A patient can have many different needs, such as expressing symptoms, concerns, fears, interests, and the need for information. Occasionally, patients may have urgent or life-threatening needs that require immediate action, such as loss of consciousness, active gastrointestinal bleeding, psychosis, or suicidal ideation. The clinician should scrutinize the patient for symptoms of an urgent disease problem before the interview begins and during the first few minutes and take appropriate action if urgency is present.",
"   </p>",
"   <p>",
"    Most ambulatory patients do not have acutely threatening problems, are able to communicate, are not prohibitively anxious, and want to talk about their symptoms, interests, fears, and concerns. In these more common situations, the interviewer initially allows the patient to lead the conversation and discuss the symptoms or personal issues she or he prefers. Ideas in this part of the dialogue originate as part of the patient's agenda rather than the clinician&rsquo;s. The clinician will insert ideas into the exchange later, when using clinician-centered interviewing skills.",
"   </p>",
"   <p>",
"    Integrated medical interviewing should be the basis for most interactions, including new or return patients, inpatient or outpatient, surgery or medicine, tertiary or primary care, emergency department, or consultation visits. The patient-centered process can be conducted in 10 to 20 percent of the total time available on average, although the specific amount of time spent should be determined by the extent and urgency of an individual patient's personal issues.",
"   </p>",
"   <p>",
"    Integrated interviewing of a new patient generates the following content, usually obtained in this order [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chief concern(s)",
"     </li>",
"     <li>",
"      History of present illness; other active problems",
"     </li>",
"     <li>",
"      Past medical history",
"     </li>",
"     <li>",
"      Social history",
"     </li>",
"     <li>",
"      Family history",
"     </li>",
"     <li>",
"      Review of systems",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interviewers often need only the chief concern(s) and history of present illness in patients who are already familiar to them.",
"   </p>",
"   <p>",
"    The chief complaint or chief concern is the patient's most bothersome issue. The history of present illness usually is the most helpful historical component where the patient gives both symptoms and the personal context in which they occur. Most patients have more than one current medical concern, however, and the interviewer obtains these in the history of other active problems. In the past medical history, the patient gives important past information not germane to the history of present illness or other active problems. In the social history the patient provides routine personal data such as occupation, health promoting behaviors, exposures, substance use, and other relevant information such as personal relationships, sexuality, ethical-social-spiritual issues, and functional capacity. The family history elicits genetic and environmental health risks and provides insight into family relationships. The review of systems is the lowest priority; the clinician screens for any physical symptoms or other problems not already discussed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chief concern(s) and initial portions of the history of present illness and other active problems are developed using patient-centered interviewing skills, while the past medical history, social history, family history, and review of systems are elicited largely through the use of clinician-centered interviewing skills.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATIENT-CENTERED INTERVIEWING SKILLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several basic facilitating skills the interviewer must master in order to conduct the patient-centered portion of the interview. The two main categories of facilitating skills are questioning skills and relationship-building skills; the latter are divided into emotion-seeking and emotion-handling skills (",
"    <a class=\"graphic graphic_table graphicRef55927 \" href=\"UTD.htm?13/6/13420\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Questioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open-ended questions encourage the patient to describe symptoms and personal concerns from the patient's agenda rather than the interviewer's. Open-ended questions result in a spontaneous and synthetic expression by the patient of what is on",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    mind, rather than the",
"    <span class=\"nowrap\">",
"     yes/no",
"    </span>",
"    responses often elicited by closed-ended questions.",
"   </p>",
"   <p>",
"    The six open-ended skills include (",
"    <a class=\"graphic graphic_table graphicRef55927 \" href=\"UTD.htm?13/6/13420\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Silence",
"     </li>",
"     <li>",
"      Nonverbal encouragement",
"     </li>",
"     <li>",
"      Neutral utterances",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Reflection/echoing",
"      </span>",
"     </li>",
"     <li>",
"      Requests",
"     </li>",
"     <li>",
"      Summarizing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first three are \"nonfocusing\" skills; they encourage the patient to continue talking without the clinician interrupting or shaping the flow of information. These skills are employed primarily during the brief initial portions of the interview when the interviewer is encouraging the patient to talk. The last three are the \"focusing\" skills; they are used to draw out more details about what the patient has said.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Silence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Silence implies attentive listening and an invitation for the patient to continue talking.",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient: &ldquo;I also had this pain here&mdash;&rdquo; (patient pauses)",
"     </li>",
"     <li>",
"      Clinician: (interviewer is attentive but silent for three seconds)",
"     </li>",
"     <li>",
"      Patient: &ldquo;&mdash;and I got to wondering if the two went together.&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Silence is a powerful nonfocusing facilitating skill, but it can make some patients uncomfortable, which they might exhibit by shifting about or looking away. The interviewer should use another skill if three to five seconds of silence does not prompt a response, even sooner if the patient seems uncomfortable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Nonverbal encouragement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonverbal encouragement is the use of everyday gestures that simply encourage patients to talk. It is often used with silence. The interviewer typically gestures with the hand (rotatory motion to continue), makes a sympathetic facial expression (of expectation to continue), nods the head, or simply indicates by body language that the patient should continue speaking (leaning forward).",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient: &ldquo;Well, sometimes it makes me feel kind of, you know&mdash;&rdquo; (patient pauses)",
"     </li>",
"     <li>",
"      Clinician: (with an attentive facial expression, gently rotates hand to signal the patient to continue)",
"     </li>",
"     <li>",
"      Patient: &ldquo;Well, upset, even angry.&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Neutral utterances or continuers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutral utterances are brief, noncommittal statements such as \"Oh,\" \"Uh-huh,\" \"Yes,\" or \"Mmm.\" Similar to nonverbal encouragement, they are used reflexively by most clinicians and will encourage patients to continue talking and expressing their personal interests and concerns. These skills often are used in conjunction with the other two nonfocusing skills.",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient: &ldquo;She previously said I should take three&mdash;&rdquo; (patient pauses)",
"     </li>",
"     <li>",
"      Clinician: &ldquo;Uh-huh.&rdquo;",
"     </li>",
"     <li>",
"      Patient: &ldquo;&mdash;but this time she said only two.&rdquo;",
"     </li>",
"     <li>",
"      Clinician: &ldquo;Mmm.&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Reflection or echoing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reflection or echoing means repeating almost exactly what the patient has just said, using the same words or phrases. It indicates that the interviewer has heard what was said and also encourages the patient to continue with the same line of thought by focusing on the word or phrase echoed.",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient: &ldquo;Even when the diarrhea quit, I still couldn't go to work.&rdquo;",
"     </li>",
"     <li>",
"      Clinician: &ldquo;The diarrhea&hellip;.&rdquo; (will focus patient on symptom and encourage a somatic focus); OR &ldquo;Couldn't go to work&hellip;.&rdquo; (will focus patient on personal aspects and encourage that part of the story)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Open-ended requests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open-ended requests also maintain a focus on a topic the patient has mentioned. The clinician can use phrases such as \"tell me more\" or \"go on.\" Requests also can be quite specific in focusing the patient on an already mentioned area that the interviewer wants to expand upon, such as \"Tell me more about your headache (or, your worry about a brain tumor).\"",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient: &ldquo;Then my wife got involved when the pain got worse.&rdquo;",
"     </li>",
"     <li>",
"      Clinician: &ldquo;Go on&rdquo; (encourages patient to continue without focusing in either area just mentioned); OR &ldquo;Tell me about your wife getting involved&rdquo; (focuses patient on the personal issues); OR &ldquo;Say more about the pain&rdquo; (focuses patient on symptom).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Summarizing or paraphrasing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Here the interviewer recaps a wider range of talk instead of echoing only words or phrases. Summarizing refocuses the patient upon the material summarized, encouraging deeper expression of the stories. It signals that the patient has been heard and should proceed beyond that point [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient: (long story about recurring symptoms of a cold)",
"     </li>",
"     <li>",
"      Clinician: &ldquo;So, first was the sore throat last Friday, then came the stuffy nose, but the fever didn't begin until today and you were getting worried.&rdquo;",
"     </li>",
"     <li>",
"      Patient: &ldquo;Yeah, I was really more upset.&rdquo; (patient chooses the emotional dimension to respond to)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Closed-ended skills",
"    </span>",
"    &nbsp;&mdash;&nbsp;Closed-ended questions are relied upon during the clinician-centered portion of the interview and are answerable by &ldquo;yes,&rdquo; &ldquo;no,&rdquo; or a brief response. The clinician often uses them to ask about specific issues the patient has not previously introduced (eg, relieving factors for chest pain, past surgical history).",
"   </p>",
"   <p>",
"    Closed-ended questions enhance the precision of information, but when used alone are counterproductive. They force the patient to respond to the clinician's concerns and ideas, which often are narrowly focused upon making disease diagnoses and determining treatments. Closed-ended skills used in isolation can have a deleterious effect upon the clinician-patient relationship by preventing the patient from fully expressing the impact of symptoms on",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    life and the attendant emotions.",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient: &ldquo;My pain is right here, and I'm kind of worried about it.&rdquo;",
"     </li>",
"     <li>",
"      Clinician: &ldquo;Are you coughing up any blood?&rdquo;; OR &ldquo;Does it hurt to take a breath?&rdquo;; OR &ldquo;Did you come here from work?&rdquo;",
"     </li>",
"     <li>",
"      Patient: &ldquo;No.&rdquo;",
"     </li>",
"     <li>",
"      Clinician: &ldquo;Did you come in to the hospital this morning?&rdquo;",
"     </li>",
"     <li>",
"      Patient: &ldquo;Yes.&rdquo;",
"     </li>",
"     <li>",
"      Clinician: &ldquo;How old are you?&rdquo;",
"     </li>",
"     <li>",
"      Patient: &ldquo;29.&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Relationship building",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relationship building is the general name given to emotion-seeking and empathy skills (",
"    <a class=\"graphic graphic_table graphicRef55927 \" href=\"UTD.htm?13/6/13420\">",
"     table 1",
"    </a>",
"    ). The former elicit patients' emotions, while the latter respond to them after they have been elicited. Emotions can be expressed through actions (laughing), nonverbal expression (frowning), and verbal statements (\"I was angry\").",
"   </p>",
"   <p>",
"    Empathically addressing emotion leads to the strongest possible clinician-patient relationships and is the quickest way to elicit data on the patient's personal life [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/6,51\">",
"     6,51",
"    </a>",
"    ]. Interviewers must be certain that they have established a safe, caring environment if they are to effectively address emotions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Emotion-seeking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emotions are so important that the interviewer must actively seek them, even when the patient does not overtly exhibit them or gives only a small clue. Emotion-seeking skills include direct and indirect inquiry; the former typically suffices to elicit the initial emotion while the latter further develops it.",
"   </p>",
"   <p>",
"    The classic and perhaps most important question in patient-centered interviewing is: \"How did that make you feel?\" The interviewer inquires with this direct question when emotion is suspected from the patient's statement (\"he just left me\"), nonverbal behavior (clenches fist), or when the patient shows no reaction in a situation where emotion is likely (loss of job).",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient: (has just mentioned she lost her job)",
"     </li>",
"     <li>",
"      Clinician: &ldquo;So, how's that make you feel, you know, personally, emotionally?&rdquo;",
"     </li>",
"     <li>",
"      Patient: &ldquo;Oh, I don't know (but looking angry).&rdquo;",
"     </li>",
"     <li>",
"      Clinician: &ldquo;How are you feeling right now, talking about it?&rdquo;",
"     </li>",
"     <li>",
"      Patient: &ldquo;I'm so frustrated! I put seven years of my life into that job.&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Emotional expression does not always follow direct inquiry. The interviewer can then inquire about the following areas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Impact &mdash;",
"      </strong>",
"      Asking how the illness (or other situation) has affected the patient's or family&rsquo;s life encourages emotional expression (\"How has your wife's going back to work affected your life?\" or \"How has your wife's new job affected your daughter?\").",
"     </li>",
"     <li>",
"      <strong>",
"       Belief &mdash;",
"      </strong>",
"      Inquiring about what the patient thinks caused the problem often leads to emotional expression (\"Why do you think you keep getting colds?\").",
"     </li>",
"     <li>",
"      <strong>",
"       Triggers &mdash;",
"      </strong>",
"      Determining why the patient is seeking care at this time can uncover the underlying reason for the visit and lead to the patient&rsquo;s expression of emotion (&ldquo;What made you decide to see me today for this [symptom]?&rdquo;). Interpersonal crisis is another common trigger that can lead to emotional expression [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/52\">",
"       52",
"      </a>",
"      ]. People in crisis are worried and distressed, which increases their sensitivity to pain and awareness of symptoms. They often do not make the link between their stress and their symptoms. Asking, &ldquo;What else is going on in your life?&rdquo; can uncover the distress and allow for emotional expression.",
"     </li>",
"     <li>",
"      <strong>",
"       Self-disclosure",
"      </strong>",
"      may be useful in encouraging emotional expression (\"I had a similar experience, and I was really down\" or &ldquo;I think lots of people in your situation would feel upset.&rdquo;). The interviewer will be more effective if she or he avoids strong emotional terms (angry, depressed) and uses less loaded terms for emotions such as upset, unhappy, or frustrated. To avoid damaging the clinician-patient relationship, it is important to quickly bring the focus back to the patient [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These questions have value in their own right but are used here as indirect ways of eliciting an emotional expression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Empathy skills",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empathy skills are employed to respond to emotion once it has been expressed. These skills are essential in developing a positive clinician-patient relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/7\">",
"     7",
"    </a>",
"    ]. The mnemonic NURS has been effective in helping learners recall them:",
"    <strong>",
"     N",
"    </strong>",
"    aming,",
"    <strong>",
"     U",
"    </strong>",
"    nderstanding,",
"    <strong>",
"     R",
"    </strong>",
"    especting, and",
"    <strong>",
"     S",
"    </strong>",
"    upporting. In other words, one NURS(es) the emotion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Naming, labeling the emotion &mdash; The interviewer simply names the emotion already identified: \"That was sad for you.\" The interviewer usually uses the same word(s) the patient used to name the emotion. Alternatively, if the patient is expressing emotion nonverbally, the clinician can name it, &ldquo;You seem sad.&rdquo; Naming conveys that the emotion has been recognized.",
"     </li>",
"     <li>",
"      Understanding, legitimization &mdash; The interviewer straightforwardly states that the emotional reaction just named is understandable: \"So that was frustrating (naming). I can sure understand why.\" The emotion is legitimized, accepted, and validated. The interviewer's statement must be genuine, which means both having heard enough about the story and having sufficient experience with the particular issue to satisfactorily understand it.",
"     </li>",
"     <li>",
"      Respecting, praising &mdash; Respecting and praising statements clearly acknowledge how difficult things have been for the patient (\"You've really been through a lot\") or that praise them for their efforts (\"I like the way you've hung in there and kept fighting\") and nurture the clinician-patient relationship.",
"     </li>",
"     <li>",
"      Supporting, partnership &mdash; The interviewer clearly states that she or he, and perhaps others, are available for support and are willing to do whatever they can to help. In addition to expressing and providing support, the interviewer connotes this attitude by the joining nature of the language used: \"Together, you and I, we can get to the bottom of this.\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A brief vignette illustrating the four NURS elements is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient: (has just indicated feeling lonely since his wife died)",
"     </li>",
"     <li>",
"      Clinician: &ldquo;So, that's been pretty lonesome for you.&rdquo; (Naming)",
"     </li>",
"     <li>",
"      Patient: &ldquo;We were together for a long time.&rdquo;",
"     </li>",
"     <li>",
"      Clinician: &ldquo;I've not had that happen, but I think I have some understanding of how difficult it must be for you.&rdquo; (Understanding)",
"     </li>",
"     <li>",
"      Patient: &ldquo;There were so many things, just going shopping together, you know.&rdquo;",
"     </li>",
"     <li>",
"      Clinician: &ldquo;She meant a lot to you. It's been a tough time. You've been through a lot.&rdquo; (Respecting)",
"     </li>",
"     <li>",
"      Patient: &ldquo;It really has.&rdquo;",
"     </li>",
"     <li>",
"      Clinician: &ldquo;Sometimes you and I working together like this can be helpful.&rdquo; (Supporting)",
"     </li>",
"     <li>",
"      Patient: &ldquo;It does feel better to talk about it.&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     THE FIVE-STEP METHOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The five-step patient-centered interview is a method that synthesizes facilitating skills into five steps that are performed sequentially [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/54\">",
"     54",
"    </a>",
"    ]. Addressing concerns about the absence of systematic, behaviorally defined patient-centered approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/55,56\">",
"     55,56",
"    </a>",
"    ], this method emphasizes specific, behaviorally-defined skills and specifies their sequence and priorities of usage [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/57\">",
"     57",
"    </a>",
"    ]. The method also includes clinician-centered interviewing skills used in the middle of the interview (steps 6 to 10), but these are addressed elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Step 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Step 1 involves setting the stage for the interview.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Welcome the patient",
"     </li>",
"     <li>",
"      Use the patient's name",
"     </li>",
"     <li>",
"      Introduce self and identify specific role",
"     </li>",
"     <li>",
"      Ensure patient readiness and privacy",
"     </li>",
"     <li>",
"      Remove barriers to communication",
"     </li>",
"     <li>",
"      Ensure comfort and put the patient at ease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The specific skills often are conducted in the order given. Welcomes and introductions can be achieved in a sentence or two, such as \"Welcome to the clinic, Mr. Brown. I'm Dr. Black, and I'll be the one caring for you here.\" Making certain that the patient is ready and ensuring privacy applies primarily to inpatient settings, although these need to be monitored in outpatients as well. Sitting down during the interview, at approximately eye level with the patient, removes an important barrier to communication [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Step 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Step 2 involves eliciting the chief concern (chief complaint) and setting the agenda for the visit.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Indicate the time available",
"     </li>",
"     <li>",
"      Forecast what you would like to have happen in the visit (eg, check the cholesterol and blood pressure)",
"     </li>",
"     <li>",
"      Obtain a list of all issues the patient wants to discuss (eg, specific symptoms, requests, expectations, understanding)",
"     </li>",
"     <li>",
"      Summarize and finalize the agenda; negotiate specifics if there are too many agenda items",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Determining all the reasons for the patient's visit is key to preventing important issues from arising at the end of the visit [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/59\">",
"     59",
"    </a>",
"    ]. Saying, \"Let's start by making a list of all the things you want to discuss today\" orients the patient to the task. Following up with \"Is there something else?\" or &ldquo;What else?&rdquo; will ensure that all the patient's concerns are verbalized [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/60-62\">",
"     60-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interviewer typically can begin with a sentence such as \"We have about 20 minutes together today, and I'd like to ask some questions and examine you, but first let's make a list of what you'd like to cover.\" Occasionally patients indicate a problem and continue expanding upon it, potentially spending excessive time on an issue that ends up not being the major focus of the visit. The interviewer should politely interrupt and refocus the patient on generating a list of concerns. If there are too many problems to address in the time allotted, the interviewer should negotiate with the patient about what is most important and schedule another appointment to address the others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Step 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Step 3 is the nonfocused portion of the interview.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ask an open-ended beginning question and link it to the chief concern.",
"     </li>",
"     <li>",
"      Use nonfocusing open-ended skills such as silence, neutral utterances, and nonverbal encouragement to encourage the patient to say more.",
"     </li>",
"     <li>",
"      Obtain additional data from the following sources: nonverbal cues, physical characteristics, autonomic changes, accoutrements, environment, and the interviewer's own feelings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The interviewer begins with an open-ended question such as \"So, how are you doing with that?\" or a statement \"So it sounds like your headache is the most troublesome thing for you; tell me all about that.\" The patient is then allowed to talk and go wherever he or she wishes with the conversation for about 15 to 30 seconds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Step 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;Step 4 is the focused portion of the interview. This is where the interviewer and patient will spend the most patient-centered time. The task is to elicit three things:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Symptom story",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obtain the patient's narrative of his or her symptom(s) using focusing open-ended skills (echoing, requests summarizing).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Personal context of symptom(s)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Develop the more general",
"    <span class=\"nowrap\">",
"     personal/psychosocial",
"    </span>",
"    context of the symptom(s) (eg, the impact of the symptom[s] on the patient's life), using focusing open-ended skills.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Emotional context of symptom(s)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Develop an emotional focus using direct",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    indirect emotion-seeking skills, and address the emotion(s) with empathy skills.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Expand the story",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use the \"core dynamic skills\" (focused open-ended skills, emotion-seeking skills, empathy skills) to better identify and deepen the personal and emotional context of the patient&rsquo;s symptom story with additional \"chapters.\"",
"   </p>",
"   <p>",
"    The interviewer uses the focusing open-ended skills to obtain the patient's description of the symptoms. Then",
"    <span class=\"nowrap\">",
"     she/he",
"    </span>",
"    guides the patient to talk more about personal aspects of the problem by selectively echoing, summarizing, or making direct requests about the patient&rsquo;s non-symptom utterances. Next, emotion-seeking skills are used to learn the patient's emotional reactions to the symptoms and their personal context. Finally, empathy skills are utilized to respond to the emotional expression. This cycle of skills is repeatedly deployed until there is an understanding of the patient's story. Closed-ended questions are generally avoided until after Step 5.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Step 5",
"    </span>",
"    &nbsp;&mdash;&nbsp;Step 5 is a transition to the middle (clinician-centered) portion of the interview.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Give a brief summary.",
"     </li>",
"     <li>",
"      Check accuracy.",
"     </li>",
"     <li>",
"      Indicate that both the content and style of inquiry will change if the patient is ready.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The interviewer simply informs the patient that a different style of questioning is about to occur before moving into the clinician-centered part of the interview. If the patient agrees, the interviewer begins the standard clinician-centered inquiry by eliciting those cardinal features of the symptom not already mentioned by the patient as he or she related the symptom story. Much of the remainder of the interview will be spent here, using clinician-centered interviewing skills to complete the HPI and to generate the routine database (eg, past medical history). The interviewer may need to use patient-centered interviewing skills periodically (eg, if the patient expresses emotion).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Validity of the method",
"    </span>",
"    &nbsp;&mdash;&nbsp;The validity of this five-step method has been evaluated in a trial in which medical residents were randomly assigned to intensive training in the techniques described above or to a control group that did not receive interview training [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/14\">",
"     14",
"    </a>",
"    ]. Trained residents exhibited improved attitudes in multiple areas (",
"    <a class=\"graphic graphic_table graphicRef53532 \" href=\"UTD.htm?5/44/5837\">",
"     table 2",
"    </a>",
"    ). They also interviewed simulated and real patients (in residents' actual clinic settings) more skillfully than untrained residents (",
"    <a class=\"graphic graphic_table graphicRef63274 \" href=\"UTD.htm?24/20/24908\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75076 \" href=\"UTD.htm?5/16/5390\">",
"     table 4",
"    </a>",
"    ). There was a trend toward improved satisfaction and decreased somatic symptoms and social dysfunction in the patients of trained residents, although the study was not designed to test patient outcomes and differences were not statistically significant.",
"   </p>",
"   <p>",
"    Studies have demonstrated retention of patient-centered interview skills in residents two years after training in this method [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/63\">",
"     63",
"    </a>",
"    ]. The technique has also been successfully taught to family practice residents [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/64\">",
"     64",
"    </a>",
"    ] and medical students [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/65\">",
"     65",
"    </a>",
"    ]. The method was used as a key part of a multidimensional treatment that led to improved outcomes for somatizing patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other approaches to patient-centered interviewing have also been developed and evaluated for specific applications [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/67-75\">",
"     67-75",
"    </a>",
"    ]. A patient-centered method similar to the five-step method presented here has been demonstrated to be effectively taught and learned in a randomized trial, making it the second evidence-based interviewing model [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8249/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most physicians have been trained to elicit symptoms using an isolated \"clinician-centered\" interviewing method, focusing on establishing a disease diagnosis and limiting sharing of personal information or emotions. Patient-centered interviewing complements clinician-centered interviewing and enhances the therapeutic alliance through recognition of emotional and social concerns that influence patients' perception, understanding, acceptance, and treatment of their condition. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Patient-centered interviewing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The integrated medical interview uses both patient-centered and clinician-centered interviewing skills. One technique for this interview incorporates a five step method:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; - Step 1: Setting the stage",
"   </p>",
"   <p>",
"    - Step 2: Determining the agenda and chief concern",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; - Step 3: History of present illness, non-focused inquiry",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; - Step 4: History of present illness, focused, inquiring about the symptom story, personal context, and emotional context, and responding empathically",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; - Step 5: Transition to clinician-centered middle portion of the interview",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H19\">",
"     'The five-step method'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When a patient expresses emotion, or expresses a difficult problem evoking an empathic response, appropriate empathy skills, essential in establishing the clinician-patient relationship, can be recalled with the mnemonic NURS:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; -",
"    <strong>",
"     N",
"    </strong>",
"    ame the emotion or situation",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; - express",
"    <strong>",
"     U",
"    </strong>",
"    nderstanding",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; -",
"    <strong>",
"     R",
"    </strong>",
"    espect the patient",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; -",
"    <strong>",
"     S",
"    </strong>",
"    upport the patient",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Empathy skills'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The five-step method is easily learned and has demonstrated better outcomes for somatizing patients as part of a multidimensional treatment program. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Validity of the method'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/1\">",
"      Simpson M, Buckman R, Stewart M, et al. Doctor-patient communication: the Toronto consensus statement. BMJ 1991; 303:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/2\">",
"      Peterson MC, Holbrook JH, Von Hales D, et al. Contributions of the history, physical examination, and laboratory investigation in making medical diagnoses. West J Med 1992; 156:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/3\">",
"      Schmitt BP, Kushner MS, Wiener SL. The diagnostic usefulness of the history of the patient with dyspnea. J Gen Intern Med 1986; 1:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/4\">",
"      Hampton JR, Harrison MJ, Mitchell JR, et al. Relative contributions of history-taking, physical examination, and laboratory investigation to diagnosis and management of medical outpatients. Br Med J 1975; 2:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/5\">",
"      Linfors EW, Neelon FA. Interrogation and interview: strategies for obtaining clinical data. J R Coll Gen Pract 1981; 31:426.",
"     </a>",
"    </li>",
"    <li>",
"     Smith, RC: Evidence-Based Interviewing: (DVD/Tape) 1) Patient-Centered Interviewing; 2) Doctor-Centered Interviewing. Produced by Michigan State University Broadcasting Services, Eric Schultz (Producer) 2001. Available at: file://shop.msu.edu/ProductDetails.asp?ProductCode=MSUT%2D17 (Accessed on February 01, 2001).",
"    </li>",
"    <li>",
"     Fortin AH, Dwamena FC, Frankel RM, Smith RC. Smith's Patient-Centered Interviewing: An Evidence-Based Method, 3rd ed, McGraw-Hill, New York 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/8\">",
"      Fortin AH 6th. Communication skills to improve patient satisfaction and quality of care. Ethn Dis 2002; 12:S3.",
"     </a>",
"    </li>",
"    <li>",
"     Watzlawick P, Bavelas JB, Jackson DD. Pragmatics of Human Communication: A Study of Interactional Patterns, Pathologies, and Paradoxes, WW Norton &amp; Company, New York 1967.",
"    </li>",
"    <li>",
"     Foss L, Rothenberg K. The Second Medical Revolution: From Biomedicine to Infomedicine, Shambhala, Boston 1987.",
"    </li>",
"    <li>",
"     Davidoff F, Deutsch S, Egan KL, Ende J. Who Has Seen a Blood Sugar? Reflections On Medical Education, American College of Physicians, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/12\">",
"      Feinstein AR. The intellectual crisis in clinical science: medaled models and muddled mettle. Perspect Biol Med 1987; 30:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/13\">",
"      Engel GL. The need for a new medical model: a challenge for biomedicine. Science 1977; 196:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/14\">",
"      Smith RC, Lyles JS, Mettler J, et al. The effectiveness of intensive training for residents in interviewing. A randomized, controlled study. Ann Intern Med 1998; 128:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/15\">",
"      Levenstein JH, McCracken EC, McWhinney IR, et al. The patient-centred clinical method. 1. A model for the doctor-patient interaction in family medicine. Fam Pract 1986; 3:24.",
"     </a>",
"    </li>",
"    <li>",
"     McWhinney I. The need for a transformed clinical method. In: Communicating with Medical Patients, Stewart M, Roter D (Eds), Sage Publications, London 1989. p.25.",
"    </li>",
"    <li>",
"     Levenstein JH, Brown JB, Weston WW, et al.. Patient centered clinical interviewing. In: Communicating with Medical Patients, Stewart M, Roter D (Eds), Sage Publications, London 1989. p.107.",
"    </li>",
"    <li>",
"     McWhinney I. An Introduction to Family Medicine, Oxford University Press, New York 1981.",
"    </li>",
"    <li>",
"     Rogers CR. Client-Centered Therapy, Houghton Mifflin Company, Boston 1951.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/20\">",
"      ENGEL GL, GREEN WL Jr, REICHSMAN F, et al. A graduate and undergraduate teaching program on the psychological aspects of medicine. J Med Educ 1957; 32:859.",
"     </a>",
"    </li>",
"    <li>",
"     Tresolini CP, Pew-Fetzer Task Force. Health Professions Education and Relationship-Centered Care. Pew Health Professions Commission, San Francisco 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/22\">",
"      Dwamena F, Holmes-Rovner M, Gaulden CM, et al. Interventions for providers to promote a patient-centred approach in clinical consultations. Cochrane Database Syst Rev 2012; 12:CD003267.",
"     </a>",
"    </li>",
"    <li>",
"     Brody H. The Healer's Power, Yale University Press, New Haven 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/24\">",
"      Brody H. The biopsychosocial model, patient-centered care, and culturally sensitive practice. J Fam Pract 1999; 48:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/25\">",
"      Suchman AL, Matthews DA. What makes the patient-doctor relationship therapeutic? Exploring the connexional dimension of medical care. Ann Intern Med 1988; 108:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/26\">",
"      Roter DL, Hall JA, Katz NR. Relations between physicians' behaviors and analogue patients' satisfaction, recall, and impressions. Med Care 1987; 25:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/27\">",
"      Hall JA, Roter DL, Katz NR. Meta-analysis of correlates of provider behavior in medical encounters. Med Care 1988; 26:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/28\">",
"      Stewart M, Brown JB, Weston WW. Patient-Centred Interviewing Part III: Five Provocative Questions. Can Fam Physician 1989; 35:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/29\">",
"      Beckman HB, Frankel RM. The effect of physician behavior on the collection of data. Ann Intern Med 1984; 101:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/30\">",
"      Burack RC, Carpenter RR. The predictive value of the presenting complaint. J Fam Pract 1983; 16:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/31\">",
"      Platt FW, McMath JC. Clinical hypocompetence: the interview. Ann Intern Med 1979; 91:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/32\">",
"      Cox A, Holbrook D, Rutter M. Psychiatric interviewing techniques. VI. Experimental study: eliciting feelings. Br J Psychiatry 1981; 139:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/33\">",
"      Hopkinson K, Cox A, Rutter M. Psychiatric interviewing techniques. III. Naturalistic study: eliciting feelings. Br J Psychiatry 1981; 138:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/34\">",
"      Cox A, Rutter M, Holbrook D. Psychiatric interviewing techniques. A second experimental study: eliciting feelings. Br J Psychiatry 1988; 152:64.",
"     </a>",
"    </li>",
"    <li>",
"     Roter D. Which facets of communication have strong effects on outcome: A meta-analysis. In: Communicating with Medical Patients, Stewart M, Roter D (Eds), Sage Publications, London 1989. p.183.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/36\">",
"      Huycke LI, Huycke MM. Characteristics of potential plaintiffs in malpractice litigation. Ann Intern Med 1994; 120:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/37\">",
"      Levinson W, Roter DL, Mullooly JP, et al. Physician-patient communication. The relationship with malpractice claims among primary care physicians and surgeons. JAMA 1997; 277:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/38\">",
"      Vaccarino JM. Malpractice. The problem in perspective. JAMA 1977; 238:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/39\">",
"      Kasteler J, Kane RL, Olsen DM, Thetford C. Issues underlying prevalence of \"doctor-shopping\" behavior. J Health Soc Behav 1976; 17:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/40\">",
"      Fiscella K, Meldrum S, Franks P, et al. Patient trust: is it related to patient-centered behavior of primary care physicians? Med Care 2004; 42:1049.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplan SH, Greenfield S, Ware JE. Impact of the doctor-patient relationship on the outcomes of chronic disease. In: Communicating with Medical Patients, Stewart M, Roter D (Eds), Sage Publications, London 1989. p.228.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/42\">",
"      Hojat M, Louis DZ, Markham FW, et al. Physicians' empathy and clinical outcomes for diabetic patients. Acad Med 2011; 86:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/43\">",
"      Shear CL, Gipe BT, Mattheis JK, Levy MR. Provider continuity and quality of medical care. A retrospective analysis of prenatal and perinatal outcome. Med Care 1983; 21:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/44\">",
"      EGBERT LD, BATTIT GE, WELCH CE, BARTLETT MK. REDUCTION OF POSTOPERATIVE PAIN BY ENCOURAGEMENT AND INSTRUCTION OF PATIENTS. A STUDY OF DOCTOR-PATIENT RAPPORT. N Engl J Med 1964; 270:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/45\">",
"      Kiecolt-Glaser JK, Page GG, Marucha PT, et al. Psychological influences on surgical recovery. Perspectives from psychoneuroimmunology. Am Psychol 1998; 53:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/46\">",
"      de Groot KI, Boeke S, van den Berge HJ, et al. The influence of psychological variables on postoperative anxiety and physical complaints in patients undergoing lumbar surgery. Pain 1997; 69:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/47\">",
"      Flach SD, McCoy KD, Vaughn TE, et al. Does patient-centered care improve provision of preventive services? J Gen Intern Med 2004; 19:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/48\">",
"      Stewart M, Brown JB, Donner A, et al. The impact of patient-centered care on outcomes. J Fam Pract 2000; 49:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/49\">",
"      Hoffbrand BI. Away with the system review: a plea for parsimony. BMJ 1989; 298:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/50\">",
"      Boyle D, Dwinnell B, Platt F. Invite, listen, and summarize: a patient-centered communication technique. Acad Med 2005; 80:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/51\">",
"      Holmes J. Attachment theory: a biological basis for psychotherapy? Br J Psychiatry 1993; 163:430.",
"     </a>",
"    </li>",
"    <li>",
"     Billings JA, Stoeckle JD. The Clinical Encounter: A Guide to the Medical Interview and Case Presentation, Mosby Year Book, Chicago 1989. p.103.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/53\">",
"      McDaniel SH, Beckman HB, Morse DS, et al. Physician self-disclosure in primary care visits: enough about you, what about me? Arch Intern Med 2007; 167:1321.",
"     </a>",
"    </li>",
"    <li>",
"     Smith RC. Patient-Centered Interviewing: An Evidence-Based Method, Lippincott Williams and Wilkins, Philadelphia 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/55\">",
"      Headly A. Communication skills: a call for teaching to the test. Am J Med 2007; 120:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/56\">",
"      Mead N, Bower P. Patient-centredness: a conceptual framework and review of the empirical literature. Soc Sci Med 2000; 51:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/57\">",
"      Cegala DJ, Lenzmeier Broz S. Physician communication skills training: a review of theoretical backgrounds, objectives and skills. Med Educ 2002; 36:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/58\">",
"      Frankel RM, Morse DS, Suchman AL, Beckman HB. Can I really improve my listening skills with only 15 minutes to see my patients. HMO Practice 1991; 5:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/59\">",
"      White J, Levinson W, Roter D. \"Oh, by the way ...\": the closing moments of the medical visit. J Gen Intern Med 1994; 9:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/60\">",
"      Barrier PA, Li JT, Jensen NM. Two words to improve physician-patient communication: what else? Mayo Clin Proc 2003; 78:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/61\">",
"      Platt FW, Gaspar DL, Coulehan JL, et al. \"Tell me about yourself\": The patient-centered interview. Ann Intern Med 2001; 134:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/62\">",
"      Heritage J, Robinson JD, Elliott MN, et al. Reducing patients' unmet concerns in primary care: the difference one word can make. J Gen Intern Med 2007; 22:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/63\">",
"      Oh J, Segal R, Gordon J, et al. Retention and use of patient-centered interviewing skills after intensive training. Acad Med 2001; 76:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/64\">",
"      Olson J, Kent K, et al. Role of resident attitudes in learning and using skills in patient-centered interviewing. Seminars Medical Practice 2002; 5:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/65\">",
"      Fortin AH, Haeseler FD, Angoff N, et al. Teaching pre-clinical medical students an integrated approach to medical interviewing: half-day workshops using actors. J Gen Intern Med 2002; 17:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/66\">",
"      Smith RC, Lyles JS, Gardiner JC, et al. Primary care clinicians treat patients with medically unexplained symptoms: a randomized controlled trial. J Gen Intern Med 2006; 21:671.",
"     </a>",
"    </li>",
"    <li>",
"     Kern DE, Thomas PA, Hughes MT. urriculum Development For Medical Education: A Six-Step Approach, Johns Hopkins University Press, Baltimore 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/68\">",
"      Bieber C, M&uuml;ller KG, Blumenstiel K, et al. Long-term effects of a shared decision-making intervention on physician-patient interaction and outcome in fibromyalgia. A qualitative and quantitative 1 year follow-up of a randomized controlled trial. Patient Educ Couns 2006; 63:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/69\">",
"      Chassany O, Boureau F, Liard F, et al. Effects of training on general practitioners' management of pain in osteoarthritis: a randomized multicenter study. J Rheumatol 2006; 33:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/70\">",
"      Heaven C, Clegg J, Maguire P. Transfer of communication skills training from workshop to workplace: the impact of clinical supervision. Patient Educ Couns 2006; 60:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/71\">",
"      Hobma S, Ram P, Muijtjens A, et al. Effective improvement of doctor-patient communication: a randomised controlled trial. Br J Gen Pract 2006; 56:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/72\">",
"      Longo MF, Cohen DR, Hood K, et al. Involving patients in primary care consultations: assessing preferences using discrete choice experiments. Br J Gen Pract 2006; 56:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/73\">",
"      Morriss R, Dowrick C, Salmon P, et al. Turning theory into practice: rationale, feasibility and external validity of an exploratory randomized controlled trial of training family practitioners in reattribution to manage patients with medically unexplained symptoms (the MUST). Gen Hosp Psychiatry 2006; 28:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/74\">",
"      Rubak S, Sandbaek A, Lauritzen T, et al. An education and training course in motivational interviewing influence: GPs' professional behaviour--ADDITION Denmark. Br J Gen Pract 2006; 56:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/75\">",
"      S&oslash;rlie T, Busund R, Sexton J, et al. Video information combined with individualized information sessions: Effects upon emotional well-being following coronary artery bypass surgery--A randomized trial. Patient Educ Couns 2007; 65:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/76\">",
"      Fossli Jensen B, Gulbrandsen P, Dahl FA, et al. Effectiveness of a short course in clinical communication skills for hospital doctors: results of a crossover randomized controlled trial (ISRCTN22153332). Patient Educ Couns 2011; 84:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8249/abstract/77\">",
"      Gulbrandsen P, Krupat E, Benth JS, et al. \"Four Habits\" goes abroad: report from a pilot study in Norway. Patient Educ Couns 2008; 72:388.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2787 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-BD9846CABD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_3_8249=[""].join("\n");
var outline_f8_3_8249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE INTEGRATED PATIENT-CENTERED MEDICAL INTERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      The biopsychosocial model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patient-centered interviewing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATIENT-CENTERED INTERVIEWING SKILLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Questioning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Silence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Nonverbal encouragement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Neutral utterances or continuers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Reflection or echoing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Open-ended requests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Summarizing or paraphrasing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Closed-ended skills",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Relationship building",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Emotion-seeking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Empathy skills",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      THE FIVE-STEP METHOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Step 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Step 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Step 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Step 4",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Symptom story",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Personal context of symptom(s)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Emotional context of symptom(s)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Expand the story",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Step 5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Validity of the method",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2787\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2787|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/6/13420\" title=\"table 1\">",
"      Facilitating skills",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/44/5837\" title=\"table 2\">",
"      Resident attitude questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/20/24908\" title=\"table 3\">",
"      Resident rating actual patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/16/5390\" title=\"table 4\">",
"      Resident rating simulated pts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_3_8250="Treatment of early and locoregionally advanced nasopharyngeal carcinoma";
var content_f8_3_8250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of early and locoregionally advanced nasopharyngeal carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/3/8250/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8250/contributors\">",
"     Edwin P Hui, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8250/contributors\">",
"     Anthony TC Chan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8250/contributors\">",
"     Quynh-Thu Le, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/3/8250/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8250/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8250/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8250/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/3/8250/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/3/8250/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/3/8250/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngeal carcinoma arises from the lining of the nasopharynx, the narrow tubular passage behind the nasal cavity. Worldwide, there are about 80,000 incident cases and 50,000 deaths annually, but there is remarkable variation in racial and geographic distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/1\">",
"     1",
"    </a>",
"    ]. While rare in most parts of the world, nasopharyngeal cancer is endemic in southern China, Southeast Asia, North Africa, and the arctic, where undifferentiated, nonkeratinizing squamous cell carcinoma is the predominant histology.",
"   </p>",
"   <p>",
"    The treatment of locoregional nasopharyngeal cancer is presented here. Related topics include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=see_link\">",
"       \"Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16280?source=see_link\">",
"       \"Treatment of recurrent and metastatic nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STAGING AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngeal carcinoma is staged according to the tumor node metastasis (TNM) system of the International Union Against Cancer (UICC) and American Joint Committee on Cancer (AJCC) (",
"    <a class=\"graphic graphic_table graphicRef57392 \" href=\"UTD.htm?34/8/34957\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 2010 version of the TNM system, changes were made to primary site staging to reflect the prognostic importance of involvement of the parapharyngeal space [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/2\">",
"     2",
"    </a>",
"    ]. Specifically, lesions previously staged as T2a are now classified as T1, and lesions previously staged T2b are T2. Therefore, previous stage IIA is now included in stage I and stage IIB is now stage II. However, much of the literature is based upon studies using the older staging system.",
"   </p>",
"   <p>",
"    The World Health Organization (WHO) classifies nasopharyngeal cancer into three histopathologic types [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Keratinizing squamous cell carcinoma (WHO Type I)",
"     </li>",
"     <li>",
"      Nonkeratinizing carcinoma: differentiated (WHO Type II) and undifferentiated (WHO Type III)",
"     </li>",
"     <li>",
"      Basaloid squamous cell carcinoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL TREATMENT PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngeal carcinoma differs from other head and neck squamous cell carcinomas in its epidemiology, pathology, natural history, and response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Radiation therapy (RT) remains the mainstay of treatment for nasopharyngeal cancer, but RT has evolved over the last decade due to advances in high precision RT delivery, the integration of chemotherapy, and improvement in tumor imaging and disease monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link\">",
"     \"General principles of radiation therapy for head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery at the primary site is not typically used as first-line treatment because of the deep anatomical location of the nasopharynx and its close proximity to critical neurovascular structures. However, neck dissection may be indicated after RT for residual nodal disease or for an isolated neck recurrence, and nasopharyngectomy may be an option for a small localized recurrence and are more commonly practiced in Asia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16280?source=see_link\">",
"     \"Treatment of recurrent and metastatic nasopharyngeal carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prognostic risk groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the risk of treatment failure, three prognostic groups can be defined according to the TNM staging system for nasopharyngeal cancer (",
"    <a class=\"graphic graphic_table graphicRef57392 \" href=\"UTD.htm?34/8/34957\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I - Early stage",
"     </li>",
"     <li>",
"      Stage II - Intermediate stage",
"     </li>",
"     <li>",
"      Stage III, IVA, IVB - Advanced stage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although patients with early stage disease have good outcomes with RT alone, more intensive treatment strategies are required to manage intermediate and advanced stage disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Management of the neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngeal cancer has a propensity for early, bilateral spread to regional lymph nodes in the neck. Thus, all patients, including those with a clinically negative neck, are treated with bilateral neck irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Endemic vs nonendemic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endemic nasopharyngeal cancer (WHO type III, undifferentiated carcinoma) appears to be particularly radiosensitive and may be associated with higher overall survival rates than WHO type I, keratinizing squamous cell carcinoma (the histology typically encountered in the United States and Western Europe) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, there is insufficient evidence to suggest that treatment should differ based upon histopathologic classification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EARLY (STAGE I) DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngeal carcinoma has traditionally been treated with RT because it is a radiosensitive tumor and because its anatomic location limits a surgical approach. Early (stage I) cancers are treated with RT alone with good locoregional control. Five-year overall survival rates of 90 percent for stage I have been reported (",
"    <a class=\"graphic graphic_table graphicRef77156 \" href=\"UTD.htm?6/42/6827\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/12\">",
"     12",
"    </a>",
"    ]. Evidence from retrospective studies suggests that outcomes have improved due to advances in RT planning and delivery; improved staging, particularly the use of magnetic resonance imaging (MRI) rather than computed tomography (CT), also appears to have contributed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. This improvement may reflect stage migration as much as an actual improvement in treatment.",
"   </p>",
"   <p>",
"    External beam RT typically is given to a total dose of 70 to 72 Gray (Gy) to the primary tumor and 50 Gy to the uninvolved neck in single daily fractions of 2.0 Gy, five days per week over six to seven weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/5,14\">",
"     5,14",
"    </a>",
"    ]. A similar dosing schedule is used for more advanced disease, with 66 to 70 Gy to involved lymph nodes.",
"   </p>",
"   <p>",
"    Until recently, three-dimensional conformal radiation therapy (3D-CRT) techniques were considered the standard of care. However, two randomized studies have shown that intensity modulated radiation therapy (IMRT) is superior to conventional RT in preserving parotid function and resulted in less severe late xerostomia without affecting local control in patients with early stage nasopharyngeal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Similarly, a cooperative group phase II study showed that it was feasible to implement IMRT across multiple institutions with an excellent two-year locoregional-progression-free rate of 91 percent and a 14 percent rate of grade 2 xerostomia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/17\">",
"     17",
"    </a>",
"    ]. These data have converted IMRT into the most commonly accepted method of radiation delivery in the United States.",
"   </p>",
"   <p>",
"    Since the dose gradient for IMRT is quite steep, it is important to ensure adequate patient immobilization and verify daily treatment set-up accuracy. Image-guided radiation therapy (IGRT) is often used with IMRT for verification of set-up accuracy and for consideration of adaptive replanning in cases where there is a significant change in the patient&rsquo;s anatomy due to rapid tumor shrinkage or weight loss. Although some institutions have performed dosimetric comparisons between IMRT and intensity modulated proton therapy (IMPT) for nasopharyngeal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], clinical data on the use of IMPT in nasopharyngeal carcinoma is lacking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link&amp;anchor=H3#H3\">",
"     \"General principles of radiation therapy for head and neck cancer\", section on 'External beam radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Significant numbers of patients with early stage disease have not been included in trials of induction chemotherapy, adjuvant chemotherapy, or concurrent chemoradiotherapy, and it is unclear whether this group would benefit from combined modality therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INTERMEDIATE (STAGE II) DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined modality treatment strategies are generally recommended for stage II disease because of the elevated distant failure rates seen in these patients (",
"    <a class=\"graphic graphic_table graphicRef57392 \" href=\"UTD.htm?34/8/34957\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most extensive data come from a phase III trial in which 230 previously untreated patients with stage II nasopharyngeal cancer were randomly assigned to RT plus concurrent weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    versus RT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/24\">",
"     24",
"    </a>",
"    ]. All patients had T1-2N1M0 or T2N0M0 disease with parapharyngeal space involvement. When patients were restaged according to the 2010 TNM staging system, 31 patients (13 percent) were reclassified as stage III. &nbsp;",
"   </p>",
"   <p>",
"    With a median follow-up of five years, overall survival was significantly improved by the addition of concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (five-year overall survival rate of 94.5 versus 85.8 percent, hazard ratio [HR] 0.30, 95% CI 0.12-0.76). This difference was mainly due to an improvement in distant metastasis free survival (94.8 versus 83.9 percent) and there was no statistically significant difference in locoregional relapse free survival (93.0 versus 91.1 percent). Multivariate analysis showed that the number of chemotherapy cycles delivered was the only independent factor that was associated with survival, progression, and distant control in this study.",
"   </p>",
"   <p>",
"    In this trial, the addition of weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    to RT was associated with a statistically significant increase in severe (grade 3 or 4)",
"    <span class=\"nowrap\">",
"     leukopenia/neutropenia,",
"    </span>",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    and mucositis compared with RT alone (12 versus 0, 8.6 versus 0, and 46 versus 33 percent, respectively). There was no significant increase in late toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ADVANCED (STAGE III AND IV) DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses of randomized controlled trials concluded that the addition of any chemotherapy (concurrent, induction, or adjuvant) to definitive radiation therapy (RT) reduces the risk of death by 18 percent and increases overall five-year survival by 4 to 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Most of this survival benefit is due to a reduction in distant failure; concurrent chemoradiotherapy as opposed to induction chemotherapy or adjuvant chemotherapy demonstrated the most pronounced benefit (",
"    <a class=\"graphic graphic_table graphicRef64805 \" href=\"UTD.htm?27/50/28459\">",
"     table 3",
"    </a>",
"    ). Thus, concurrent chemoradiotherapy, with or without induction chemotherapy or post-chemoradiotherapy adjuvant treatment, now is the standard of care for patients with advanced, nonmetastatic nasopharyngeal carcinoma (stages III, IVA, and IVB).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Concurrent chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concurrent chemotherapy has been used in patients with locoregionally advanced head and neck cancer to sensitize tumor to the effects of RT and to thereby improve tumor control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28649?source=see_link\">",
"     \"Methods to overcome radiation resistance in head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The United States Intergroup 0099 trial was the first to demonstrate a benefit from concurrent chemoradiotherapy for the management of locoregionally advanced nasopharyngeal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/27\">",
"     27",
"    </a>",
"    ]. In this trial, 193 patients with stage III and IV nasopharyngeal cancer were randomly assigned to concurrent chemoradiotherapy followed by adjuvant chemotherapy or RT alone. RT consisted of 70 Gy in 35 to 39 fractions of 1.8 to 2.0 Gy daily. Chemotherapy consisted of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 22, and 43) concurrent with RT followed by adjuvant cisplatin (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily, days 1 through 4) repeated every four weeks for three cycles.",
"   </p>",
"   <p>",
"    The study was terminated at the first planned interim analysis. Based upon analysis of 147 patients, concurrent chemoradiotherapy and adjuvant chemotherapy significantly increased three-year progression-free survival compared with RT alone (69 versus 24 percent) and overall survival (78 versus 47 percent). This benefit persisted at five years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently, meta-analyses of multiple randomized trials (most conducted in endemic regions) in patients with locoregionally advanced nasopharyngeal carcinoma confirmed an advantage with this approach for locoregional control, disease-free survival, and in some studies, overall survival advantage (",
"    <a class=\"graphic graphic_table graphicRef64805 \" href=\"UTD.htm?27/50/28459\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/25,26,29,30\">",
"     25,26,29,30",
"    </a>",
"    ]. Based upon these results, concurrent chemoradiotherapy has become the standard of care for advanced nasopharyngeal cancer in both nonendemic and endemic areas. The role of adjuvant chemotherapy following concurrent chemoradiotherapy remains uncertain. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Adjuvant chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Concurrent chemotherapy regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chemotherapy regimen used in United States Intergroup Study 0099 (concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 22, and 43] followed by three cycles of adjuvant cisplatin [80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1] plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    [1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily days 1 through 4], given every four weeks) is considered by many to be the standard [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/27\">",
"     27",
"    </a>",
"    ]. However, this regimen can be difficult to administer because it is associated with frequent severe acute and late toxicities, and compliance with the treatment protocol is suboptimal even in the clinical trials setting [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/27,31,32\">",
"     27,31,32",
"    </a>",
"    ]. Therefore, alternative regimens have been investigated.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     Carboplatin",
"    </a>",
"    has a more favorable toxicity profile than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and appears to have similar efficacy. In a phase III trial, 206 patients were randomly assigned to cisplatin concurrent with RT followed by three cycles of adjuvant cisplatin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    as in the Intergroup 0099 study, or to carboplatin (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 8, 15, 22, 29, and 36) concurrent with RT and followed by three cycles of adjuvant chemotherapy consisting of carboplatin (area under the concentration x time curve [AUC] of 5 on day 1) plus 5-fluorouracil (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over 96 hours) every four weeks, beginning four weeks after the end of RT [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/33\">",
"     33",
"    </a>",
"    ]. Key results included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fewer patients assigned to the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      arm compared with the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      arm completed concurrent chemoradiotherapy (59 versus 73 percent) plus three cycles of adjuvant chemotherapy (42 versus 70 percent).",
"     </li>",
"     <li>",
"      Patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      had more renal toxicity, nausea and vomiting, and anemia compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      (26 versus 0, 59 versus 34, and 47 versus 18 percent, respectively). Weight loss and the need for enteral nutritional support were also more frequent with cisplatin. Thrombocytopenia was less frequent with cisplatin (4 versus 12 percent).",
"     </li>",
"     <li>",
"      At a median follow-up of 26 months, three-year disease-free survival and overall survival were similar on both regimens (63 versus 61 and 78 versus 79 percent, respectively). However, this is very short follow-up for a disease that has a much longer natural history than other head and neck cancers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be cautioned that the confidence interval of the survival estimates in the above trial were wide, and confirmatory trials are needed before",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    -containing regimens can be recommended with the same confidence as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -containing regimens.",
"   </p>",
"   <p>",
"    Weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    has demonstrated good efficacy, but has not been directly compared to high-dose bolus cisplatin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/29,34,35\">",
"     29,34,35",
"    </a>",
"    ]. Weekly cisplatin has been shown to be more effective than RT alone in at least two randomized trials with similar efficacy to that reported for high-dose cisplatin. Weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (70",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over two hours) as concurrent chemoradiotherapy is superior to RT alone, but has not been compared to cisplatin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appropriate alternatives for patients with borderline renal function, older age, or marginal performance status (ECOG 2 or worse (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 4",
"    </a>",
"    )) include the substitution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    or lower dose weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Although still investigational, the role of molecularly targeted agents is being studied as a component of concurrent chemoradiotherapy and sequential therapy regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"       Cetuximab",
"      </a>",
"      &ndash; A phase II study of concurrent cetuximab plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , given with intensity-modulated radiotherapy (IMRT) in advanced nasopharyngeal carcinoma, demonstrated that this strategy is promising [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/37\">",
"       37",
"      </a>",
"      ]. The preliminary survival outcome compares favorably with historic data, and further evaluation in a randomized phase III trial is warranted. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link&amp;anchor=H281027372#H281027372\">",
"       \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Epidermal growth factor inhibition'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       Bevacizumab",
"      </a>",
"      &ndash; In a phase II multi-institutional trial, the addition of six doses of bevacizumab to a standard chemoradiation treatment (the intergroup regimen of concurrent high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and adjuvant cisplatin-5FU) in patients with stage IIB-IVB nasopharyngeal carcinoma was feasible [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/37\">",
"       37",
"      </a>",
"      ]. Further research is needed to identify those at risk of distant metastasis and hence those who might benefit from the addition of bevacizumab.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three cycles of adjuvant chemotherapy following concurrent chemoradiotherapy is often used for patients who are fit and have good performance status, based upon the results of the Intergroup Study 0099 trial [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Concurrent chemoradiotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The most relevant data on the role of adjuvant chemotherapy following concurrent chemoradiotherapy come from a Chinese phase III trial in 508 patients with nonmetastatic advanced nasopharyngeal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients were randomly assigned to adjuvant chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus 5-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    ) or observation following concurrent chemoradiotherapy with weekly cisplatin. In an initial report from that trial at a median follow-up of 38 months, there was no statistically significant improvement in the failure free survival (two-year rate 86 versus 84 percent, HR 0.74, 95% CI 0.49-1.10).",
"   </p>",
"   <p>",
"    However, this trial is subject to a number of limitations that may have limited the ability of this trial to demonstrate a benefit from adjuvant chemotherapy following chemoradiotherapy. These include the relatively short follow-up, the exclusion of patients with T3 or T4 node negative disease (",
"    <a class=\"graphic graphic_table graphicRef57392 \" href=\"UTD.htm?34/8/34957\">",
"     table 1",
"    </a>",
"    ), and the variability of RT techniques used for patient treatment.",
"   </p>",
"   <p>",
"    The Hong Kong Nasopharyngeal Cancer Study Group is conducting a phase III randomized trial (NPC-0501) comparing concurrent-adjuvant chemotherapy with induction-concurrent chemotherapy regimen (NCT00379262) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, the Hong Kong Nasopharyngeal Cancer Study group is conducting a phase III randomized trial (NPC-0502) of adjuvant chemotherapy in high-risk patients defined by residual EBV DNA following completion of RT or chemoradiotherapy (NCT00370890) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Induction chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction chemotherapy for squamous cell carcinomas in other head and neck sites appears to reduce the incidence of distant metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, trials of induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma followed by RT alone have failed to show an improvement in overall survival or pattern of relapse compared to RT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. A pooled analysis of two of the largest trials found that the addition of induction chemotherapy to RT modestly improved relapse-free and disease-specific survival, although overall survival was not significantly improved [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Sequential therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sequential therapy, the administration of induction chemotherapy followed by concurrent chemoradiotherapy, appears promising and may represent an alternative to concurrent chemoradiotherapy with adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/44-50\">",
"     44-50",
"    </a>",
"    ]. Furthermore, induction chemotherapy preceding concurrent chemoradiotherapy is more likely to be successfully administered than adjuvant chemotherapy following concurrent chemoradiotherapy.",
"   </p>",
"   <p>",
"    Several uncontrolled phase II studies have explored the sequential use of induction chemotherapy followed by concurrent chemoradiation approach in nasopharyngeal carcinoma (",
"    <a class=\"graphic graphic_table graphicRef79686 \" href=\"UTD.htm?18/57/19358\">",
"     table 5",
"    </a>",
"    ). The results are encouraging and toxicity has been acceptable. Except for the feasibility of this approach, it is difficult to draw further conclusion from these uncontrolled phase II data. There is a concern about the additional toxicity, cost, prolonged treatment duration, compliance, and impact on late physical function and quality of life that could result from this approach. Whether sequential therapy improves survival compared with concurrent chemoradiotherapy alone or concurrent chemoradiotherapy followed by adjuvant chemotherapy is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized phase II trial in patients with advanced nasopharyngeal carcinoma compared sequential therapy (induction chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    followed by weekly cisplatin during RT) to concurrent chemoradiotherapy alone (with weekly cisplatin) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/50\">",
"     50",
"    </a>",
"    ]. Although induction chemotherapy was associated with high rates of grade 3 and 4 neutropenia (97 percent), patients assigned to sequential therapy were treated with comparable dose intensities of concurrent cisplatin and had similar acute and late toxicities and quality of life scores. There was a trend toward improved three-year progression-free survival with sequential therapy compared with concurrent chemoradiotherapy alone (88 versus 60 percent, p=0.12), and there was a statistically significant increase in overall survival (94 versus 68 percent).",
"   </p>",
"   <p>",
"    Several phase III trials are comparing sequential regimens with concurrent chemoradiotherapy alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Radiotherapy Oncology Group for Head and Neck Cancer trial is comparing induction chemotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , and 5-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      (TPF) followed by weekly cisplatin during RT to concurrent chemoradiotherapy with weekly cisplatin alone (GORTEC-NPC2006, NCT00828386) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Sun Yat-sen University is studying induction TPF followed by concurrent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus RT compared with RT plus concurrent cisplatin without induction in stage III-IVB disease (NCT01245959).",
"     </li>",
"     <li>",
"      The National Cancer Center of Singapore completed a randomized phase II trial using a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      , plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      regimen followed by weekly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      during RT compared with weekly cisplatin plus RT alone in stage III-IVB nasopharyngeal carcinoma. This has been expanded into a phase III trial (NCT00997906).",
"     </li>",
"     <li>",
"      The Taiwan Cooperative Oncology Group has been testing a multi-agent induction regimen MEPFL (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , 5-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      ) followed by weekly cisplatin during RT compared with weekly cisplatin plus RT in stage IV disease (NCT00201396).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the Hong Kong nasopharyngeal carcinoma study group 0501 trial is exploring the therapeutic gain by reversing the sequence of the intergroup regimen. It is a six-arm study that included a comparison of induction-concurrent chemotherapy versus concurrent-adjuvant chemotherapy in stage III-IVB nasopharyngeal carcinoma (NCT00379262).",
"   </p>",
"   <p>",
"    Until the results of phase III trials are available, sequential therapy should still be considered experimental in nasopharyngeal carcinoma. Some experts, however, choose sequential therapy for large primary tumors (T4 lesions), advanced nodal disease (large burden or supraclavicular location), or when delivery of a full course of RT is not possible because the tumor abuts the surrounding critical structures (eg, optic apparatus, brainstem, temporal lobes).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Alternative RT schedules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although RT is typically given on a schedule of five treatments per week in the United States, there is increasing evidence that outcomes in head and neck squamous cell carcinoma may be improved with alternative fractionation schedules, including hyperfractionation and accelerated fractionations regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential role of an accelerated RT regimen in nasopharyngeal cancer is illustrated by a randomized trial that included 189 patients with T3-4,N0-1 disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/52\">",
"     52",
"    </a>",
"    ]. Patients were randomly assigned to one of four treatment groups, accelerated versus conventional RT (six versus five treatments per week), with or without adjunctive chemotherapy (concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    followed by adjuvant cisplatin plus 5-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    versus no adjunctive chemotherapy). The combination of an accelerated course of RT plus adjunctive chemotherapy resulted in a significantly higher five-year failure-free rate compared with accelerated fractionation without chemotherapy, or conventional fractionation with or without chemotherapy (88 versus 56, 65, and 63 percent, respectively).",
"   </p>",
"   <p>",
"    The benefits of the moderately accelerated RT schedule used in this trial require confirmation before this approach can be widely accepted [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/52\">",
"     52",
"    </a>",
"    ]. At least two other trials with different schedules have either increased toxicity or not improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The five-year overall survival for nasopharyngeal carcinoma according to disease stage in a contemporary case series was 90, 84, 75, and 58 percent for stage I through IV, respectively (",
"    <a class=\"graphic graphic_table graphicRef77156 \" href=\"UTD.htm?6/42/6827\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to prognostic factors of T and N stage and location of neck nodes (above or within the supraclavicular fossa), pre- and posttherapy Epstein-Barr Virus (EBV) DNA levels have prognostic significance, with higher levels conferring a worse prognosis, stage for stage [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/10,55-57\">",
"     10,55-57",
"    </a>",
"    ]. Five-year survival rates according to TNM stage grouping and pretherapy EBV DNA levels from one case series are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/57\">",
"     57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I, II disease, low DNA (&lt;4000",
"      <span class=\"nowrap\">",
"       copies/mL)",
"      </span>",
"      - 91 percent",
"     </li>",
"     <li>",
"      Stage I, II disease, high DNA (&ge;4000",
"      <span class=\"nowrap\">",
"       copies/mL)",
"      </span>",
"      - 64 percent",
"     </li>",
"     <li>",
"      Stage III, IV disease, low DNA - 66 percent",
"     </li>",
"     <li>",
"      Stage III, IV disease, high DNA - 54 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of detectable posttreatment EBV DNA, which may reflect microscopic residual tumor, appears to provide an even greater estimate of the risk of disease recurrence and death than pretreatment EBV DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/45,56,58-60\">",
"     45,56,58-60",
"    </a>",
"    ]. Pretreatment serologic antienzyme level of EBV DNAse-specific neutralizing antibody (AER) was an independent prognostic factor of locoregional control, progression-free survival and overall survival in cohort of 1303 nasopharyngeal carcinoma patients. AER correlated strongly with EBV DNA levels, and its ease in measurement may make it easier to adopt in local laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     POSTTREATMENT FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H794941389\">",
"    <span class=\"h2\">",
"     Documentation of remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Documentation of complete remission in the nasopharynx and neck through clinical and endoscopic examination and imaging studies is important. Our preference is to obtain a posttreatment baseline MRI scan of the skull base and neck and a full body combined positron emission tomography",
"    <span class=\"nowrap\">",
"     (PET)/computed",
"    </span>",
"    tomography (CT) scan approximately three months after treatment completion.",
"   </p>",
"   <p>",
"    Distinguishing between viable residual tumor, slowly regressing tumor, and posttherapy changes may be difficult. MRI and PET-CT scans may achieve higher accuracy when combined rather than individually in detecting residual disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Obtaining imaging studies too early, in particular combined",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scans prior to 12 weeks following treatment, can lead to false positive results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H794941396\">",
"    <span class=\"h2\">",
"     Surveillance for recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttreatment surveillance is important for early detection of recurrent local or metastatic disease and for monitoring for toxicity. Follow-up includes periodic examination of the nasopharynx and neck, assessment of cranial nerve function, and evaluation of systemic complaints. In contrast to other head and neck cancers, periodic upper endoscopy is typically recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16280?source=see_link\">",
"     \"Treatment of recurrent and metastatic nasopharyngeal carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nasopharyngeal carcinoma is different from other head and neck cancers in its propensity to recur much later than tumors arising in other sites. Consequently, we follow patients every three months for the first two years, every four to six months for years 3 to 5, and annually thereafter. We suggest an annual chest x-ray, although other experts suggest reimaging only as indicated by signs and symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .) As noted above, posttherapy levels of Epstein Barr virus (EBV) DNA are of prognostic significance, although there is no consensus about what level to use as a cutoff (both 0 and 500",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    have been used) and the timing of posttreatment EBV DNA sampling [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/56,58\">",
"     56,58",
"    </a>",
"    ]. At present prospective data in support of routine monitoring by plasma EBV DNA is lacking, although measuring plasma EBV DNA can be a useful diagnostic aid in suspected recurrence. Posttreatment monitoring of patients by assay of a nasopharyngeal swab for detection of the EBNA-1 and latent membrane protein-1 genes by RT-PCR has also been suggested as a means of early detection of recurrent disease, but this methodology is expensive, not widely available, and has not been prospectively validated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surveillance after treatment for head and neck cancer is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT-RELATED COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucositis is the predominant acute toxicity associated with RT alone for nasopharyngeal carcinoma. Chemotherapy exacerbates this toxicity and introduces the risks of neuropathy, emesis, neutropenia, and other hematologic toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/27,29,50\">",
"     27,29,50",
"    </a>",
"    ]. Lhermitte&rsquo;s Syndrome is also common after chemoradiation for nasopharynx carcinoma.",
"   </p>",
"   <p>",
"    Xerostomia can be a long lasting or permanent problem, although it often improves with time. Small trials have suggested that acupuncture may decrease symptoms and increase salivary flow rate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Additional trials in larger numbers of patients are required to determine the role of acupuncture in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=see_link&amp;anchor=H29#H29\">",
"     \"Complementary and alternative therapies for cancer\", section on 'Pain control and xerostomia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A wide range of other serious, late treatment-related complications can be seen after RT or concurrent chemoradiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/30,53,68-79\">",
"     30,53,68-79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temporal lobe necrosis, characterized by memory loss, complex partial seizures, and hypodense areas in one or both temporal lobes on CT scanning occurs in two to three percent of patients and is significantly increased with higher doses of RT, some altered fractionation techniques, and shorter overall treatment times [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/53,68,76,79\">",
"       53,68,76,79",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H15#H15\">",
"       \"Complications of cranial irradiation\", section on 'Late reactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skull base osteoradionecrosis with bleeding from the internal carotid artery is an uncommon but potentially fatal complication of irradiation for nasopharyngeal carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/77\">",
"       77",
"      </a>",
"      ]. Pituitary dysfunction can occur, especially in settings of tumor involvement of the sphenoid sinus or middle cranial fossa. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link&amp;anchor=H3822453#H3822453\">",
"       \"Management of late complications of head and neck cancer and its treatment\", section on 'Osteoradionecrosis and soft tissue necrosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link&amp;anchor=H3822557#H3822557\">",
"       \"Management of late complications of head and neck cancer and its treatment\", section on 'Carotid artery rupture'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H38#H38\">",
"       \"Complications of cranial irradiation\", section on 'Endocrinopathies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Delayed bulbar palsy, developing 1 to 18 years post radiation, is reported in up to 20 percent of cases and can result in moderate to severe functional disability [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/73\">",
"       73",
"      </a>",
"      ]. Deficits may include any combination of deafness, dysarthria, dysphagia, tongue and palatal weakness, and motor weakness of the sternocleidomastoid, trapezius, supraspinatus, infraspinatus, and rarely, the deltoid muscle. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H15#H15\">",
"       \"Complications of cranial irradiation\", section on 'Late reactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neck irradiation places patients at risk for developing hypothyroidism, and thus monitoring of serum thyroid stimulating hormone (TSH) levels is routine [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/78\">",
"       78",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H40#H40\">",
"       \"Complications of cranial irradiation\", section on 'Hypothyroidism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiation-induced second cancers are frequently EBV-negative, squamous cell carcinomas and occur in the tongue and temporal bone [",
"      <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/70,71\">",
"       70,71",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H41#H41\">",
"       \"Complications of cranial irradiation\", section on 'Radiation-induced tumors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A range of other, less common toxicities can also be observed, which may be minimized with optimal RT technique. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"       \"Management of late complications of head and neck cancer and its treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5122900\">",
"    <span class=\"h2\">",
"     Late toxicity of chemoradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current practice of adding concurrent and adjuvant chemotherapy to RT to treat advanced nasopharyngeal carcinoma is based upon the initial report of the Intergroup-0099 Study [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Concurrent chemoradiotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The cumulative incidence of acute toxicity was significantly increased with chemoradiotherapy compared to RT alone (83 versus 53 percent). Deaths due to disease progression were significantly decreased (38 versus 24 percent). Although the addition of concurrent and adjuvant chemotherapy significantly reduced deaths attributable to disease progression (24 versus 38 percent), the increased deaths attributable to other causes (acute toxicity, infection, second malignancy, suicide) in the CRT group resulted in a similar five-year overall survival in the two groups (68 versus 64 percent, hazard ratio 0.81, 95%CI 0.58-1.13). In contrast, the difference in the long-term toxicity of the intergroup regimen was not statistically significant in the NPC 9901 trial (five-year incidence of late toxicity 30 versus 24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/3/8250/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the anatomical location of the nasopharynx and its proximity to critical neurovascular structures, radiation therapy (RT), rather than surgery, is the mainstay of first-line treatment for early stage nasopharyngeal carcinoma. For more advanced disease, concurrent chemoradiation reduces the rate of distant metastasis and improves local control and overall survival compared to RT alone.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment approaches are based upon the stage of the disease. Despite differences in prognosis, there is insufficient evidence to suggest that treatment should differ based upon WHO histopathologic classification. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prognostic risk groups'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with early (stage I, (",
"      <a class=\"graphic graphic_table graphicRef57392 \" href=\"UTD.htm?34/8/34957\">",
"       table 1",
"      </a>",
"      )) disease, we recommend RT alone rather than a combined modality approach (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Early (stage I) disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with intermediate (stage II) disease, we recommend concurrent chemoradiation rather than RT alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Concurrent weekly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      significantly increased acute but not late toxicity. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Intermediate (stage II) disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with advanced (stage III, IVA, and IVB) disease, we recommend concurrent chemoradiotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). While adjuvant chemotherapy has been a standard part of many concurrent chemoradiotherapy regimens, its benefit is uncertain and toxicity is substantial. Adjuvant chemotherapy may be a reasonable option for patients with high-risk disease and a good performance status. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Advanced (stage III and IV) disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For eligible patients being treated with concurrent chemoradiotherapy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1, 22, and 43) concurrent with RT is a standard option for patients with good performance status. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Concurrent chemotherapy regimen'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (30 to 40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly) concurrent with RT or the substitution of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      for cisplatin are options for patients with a poor performance status or comorbidities. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Concurrent chemotherapy regimen'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Until more data in support of sequential therapy are available, we suggest not using sequential therapy for most patients with advanced nasopharyngeal carcinoma (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, some experts do choose sequential therapy for large or extensive primary tumors or advanced nodal disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Sequential therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the propensity of nasopharyngeal carcinoma for early and bilateral spread to regional lymph nodes, we recommend bilateral neck irradiation for all patients, even those with a clinically negative neck (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Management of the neck'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We obtain a posttreatment MRI scan of the skull base and neck and a full body combined positron emission tomography",
"      <span class=\"nowrap\">",
"       (PET)/computed",
"      </span>",
"      tomography (CT) scan at approximately three months after treatment completion to evaluate treatment response and to serve as a baseline. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Posttreatment follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nasopharyngeal carcinoma has a propensity to recur much later than other head and neck cancer sites, both locally and distantly. Consequently, we follow patients every three months for the first two years, every four to six months for years 3 to 5, and annually, thereafter. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Posttreatment follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/1\">",
"      Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Staging Manual, 7th, Edge, SB, Byrd, DR, Compton, CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     Pathology and genetics of head and neck tumors. In: World Health Organization Classification of Tumours, Barnes, L, Eveson, JW, Reichart, P, Sidransky, D (Eds), IARC Press, Lyon 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/4\">",
"      Chan AT, Teo PM, Huang DP. Pathogenesis and treatment of nasopharyngeal carcinoma. Semin Oncol 2004; 31:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/5\">",
"      Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005; 365:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/6\">",
"      Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 2007; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/7\">",
"      Ma BB, Hui EP, Chan AT. Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci 2008; 99:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/8\">",
"      Lee AW, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992; 23:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/9\">",
"      Hsu MM, Tu SM. Nasopharyngeal carcinoma in Taiwan. Clinical manifestations and results of therapy. Cancer 1983; 52:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/10\">",
"      Geara FB, Sanguineti G, Tucker SL, et al. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. Radiother Oncol 1997; 43:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/11\">",
"      Sun LM, Li CI, Huang EY, Vaughan TL. Survival differences by race in nasopharyngeal carcinoma. Am J Epidemiol 2007; 165:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/12\">",
"      Lee AW, Sze WM, Au JS, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2005; 61:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/13\">",
"      Chua DT, Sham JS, Kwong DL, Au GK. Treatment outcome after radiotherapy alone for patients with Stage I-II nasopharyngeal carcinoma. Cancer 2003; 98:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/14\">",
"      Altun M, Fandi A, Dupuis O, et al. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys 1995; 32:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/15\">",
"      Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006; 66:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/16\">",
"      Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007; 25:4873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/17\">",
"      Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 2009; 27:3684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/18\">",
"      Taheri-Kadkhoda Z, Bj&ouml;rk-Eriksson T, Nill S, et al. Intensity-modulated radiotherapy of nasopharyngeal carcinoma: a comparative treatment planning study of photons and protons. Radiat Oncol 2008; 3:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/19\">",
"      Widesott L, Pierelli A, Fiorino C, et al. Intensity-modulated proton therapy versus helical tomotherapy in nasopharynx cancer: planning comparison and NTCP evaluation. Int J Radiat Oncol Biol Phys 2008; 72:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/20\">",
"      Chua DT, Ma J, Sham JS, et al. Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two Phase III trials. Int J Radiat Oncol Biol Phys 2006; 65:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/21\">",
"      Cheng SH, Tsai SY, Yen KL, et al. Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J Clin Oncol 2000; 18:2040.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/23\">",
"      Chan AT, Gr&eacute;goire V, Lefebvre JL, et al. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5:v187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/24\">",
"      Chen QY, Wen YF, Guo L, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst 2011; 103:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/25\">",
"      Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006; 64:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/26\">",
"      Langendijk JA, Leemans CR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 2004; 22:4604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/27\">",
"      Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/28\">",
"      Al-Sarraf M, LeBlanc M, Giri P, et al. Superiority of five year survival with chemo-radiotherapy vs radiotherapy in patients with locally advanced nasopharyngeal cancer. Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) Phase III study. Final Report (abstract #905). Proc Am Soc Clin Oncol 2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/29\">",
"      Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys 2008; 71:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/30\">",
"      Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2010; 102:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/31\">",
"      Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005; 23:6730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/32\">",
"      Lee AW, Lau WH, Tung SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 2005; 23:6966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/33\">",
"      Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J Cancer 2007; 43:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/34\">",
"      Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005; 97:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/35\">",
"      Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002; 20:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/36\">",
"      Zhang L, Zhao C, Peng PJ, et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol 2005; 23:8461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/37\">",
"      Lee NY, Zhang Q, Pfister DG, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol 2012; 13:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/38\">",
"      Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012; 13:163.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical Trials database. file://www.clinicaltrials.gov/ (Accessed on February 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/40\">",
"      Chua DT, Sham JS, Choy D, et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer 1998; 83:2270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/41\">",
"      Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(&gt; or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys 1996; 35:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/42\">",
"      Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 2005; 23:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/43\">",
"      Ma J, Mai HQ, Hong MH, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001; 19:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/44\">",
"      Rischin D, Corry J, Smith J, et al. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol 2002; 20:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/45\">",
"      Chan AT, Ma BB, Lo YM, et al. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol 2004; 22:3053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/46\">",
"      Al-Amro A, Al-Rajhi N, Khafaga Y, et al. Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2005; 62:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/47\">",
"      Yau TK, Lee AW, Wong DH, et al. Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma. Head Neck 2006; 28:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/48\">",
"      Lee AW, Lau KY, Hung WM, et al. Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. Radiother Oncol 2008; 87:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/49\">",
"      Oh JL, Vokes EE, Kies MS, et al. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol 2003; 14:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/50\">",
"      Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009; 27:242.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical Trials database file://clinicaltrials.gov/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/52\">",
"      Lee AW, Tung SY, Chan AT, et al. A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Radiother Oncol 2011; 98:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/53\">",
"      Teo PM, Leung SF, Chan AT, et al. Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications. Int J Radiat Oncol Biol Phys 2000; 48:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/54\">",
"      Daoud J, Toumi N, Siala W, et al. Results of a prospective randomised trial comparing conventional radiotherapy to split course bifractionated radiation therapy in patients with nasopharyngeal carcinoma. Radiother Oncol 2007; 85:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/55\">",
"      Le QT, Jones CD, Yau TK, et al. A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin Cancer Res 2005; 11:5700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/56\">",
"      Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350:2461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/57\">",
"      Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006; 24:5414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/58\">",
"      Chan AT, Lo YM, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002; 94:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/59\">",
"      Lin JC, Wang WY, Liang WM, et al. Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007; 68:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/60\">",
"      Wang WY, Twu CW, Chen HH, et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 2010; 16:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/61\">",
"      Xu J, Wan XB, Huang XF, et al. Serologic antienzyme rate of Epstein-Barr virus DNase-specific neutralizing antibody segregates TNM classification in nasopharyngeal carcinoma. J Clin Oncol 2010; 28:5202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/62\">",
"      Liu T, Xu W, Yan WL, et al. FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. Radiother Oncol 2007; 85:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/63\">",
"      Comoretto M, Balestreri L, Borsatti E, et al. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT. Radiology 2008; 249:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/64\">",
"      Chao SS, Loh KS, Tan LK. Modalities of surveillance in treated nasopharyngeal cancer. Otolaryngol Head Neck Surg 2003; 129:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/65\">",
"      Hao SP, Tsang NM, Chang KP. Monitoring tumor recurrence with nasopharyngeal swab and latent membrane protein-1 and epstein-barr nuclear antigen-1 gene detection in treated patients with nasopharyngeal carcinoma. Laryngoscope 2004; 114:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/66\">",
"      Meng Z, Garcia MK, Hu C, et al. Randomized controlled trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma. Cancer 2012; 118:3337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/67\">",
"      Meng Z, Kay Garcia M, Hu C, et al. Sham-controlled, randomised, feasibility trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma. Eur J Cancer 2012; 48:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/68\">",
"      Yeh SA, Tang Y, Lui CC, et al. Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 2005; 62:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/69\">",
"      Chen WC, Jackson A, Budnick AS, et al. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer 2006; 106:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/70\">",
"      Teo PM, Chan AT, Leung SF, et al. Increased incidence of tongue cancer after primary radiotherapy for nasopharyngeal carcinoma--the possibility of radiation carcinogenesis. Eur J Cancer 1999; 35:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/71\">",
"      Goh YH, Chong VF, Low WK. Temporal bone tumours in patients irradiated for nasopharyngeal neoplasm. J Laryngol Otol 1999; 113:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/72\">",
"      Lin YS, Jen YM, Lin JC. Radiation-related cranial nerve palsy in patients with nasopharyngeal carcinoma. Cancer 2002; 95:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/73\">",
"      Chew NK, Sim BF, Tan CT, et al. Delayed post-irradiation bulbar palsy in nasopharyngeal carcinoma. Neurology 2001; 57:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/74\">",
"      Aiken RD. Neurologic complications of head and neck cancers. Semin Oncol 2006; 33:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/75\">",
"      Bhandare N, Kennedy L, Malyapa RS, et al. Hypopituitarism after radiotherapy for extracranial head and neck cancers. Head Neck 2008; 30:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/76\">",
"      Lee AW, Kwong DL, Leung SF, et al. Factors affecting risk of symptomatic temporal lobe necrosis: significance of fractional dose and treatment time. Int J Radiat Oncol Biol Phys 2002; 53:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/77\">",
"      Lam HC, Abdullah VJ, Wormald PJ, Van Hasselt CA. Internal carotid artery hemorrhage after irradiation and osteoradionecrosis of the skull base. Otolaryngol Head Neck Surg 2001; 125:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/78\">",
"      Siala W, Mnejja W, Abid M, et al. Thyroid toxicity after radiotherapy of nasopharyngeal carcinoma. Ann Endocrinol (Paris) 2011; 72:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/3/8250/abstract/79\">",
"      Lam TC, Wong FC, Leung TW, et al. Clinical outcomes of 174 nasopharyngeal carcinoma patients with radiation-induced temporal lobe necrosis. Int J Radiat Oncol Biol Phys 2012; 82:e57.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3372 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.1.191.153-863D5741FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_3_8250=[""].join("\n");
var outline_f8_3_8250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STAGING AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL TREATMENT PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prognostic risk groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Management of the neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Endemic vs nonendemic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EARLY (STAGE I) DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INTERMEDIATE (STAGE II) DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ADVANCED (STAGE III AND IV) DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Concurrent chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Concurrent chemotherapy regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Induction chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Sequential therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Alternative RT schedules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      POSTTREATMENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H794941389\">",
"      Documentation of remission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H794941396\">",
"      Surveillance for recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT-RELATED COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5122900\">",
"      Late toxicity of chemoradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3372\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3372|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/8/34957\" title=\"table 1\">",
"      TNM stage nasopharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/42/6827\" title=\"table 2\">",
"      Treatment results NPC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/50/28459\" title=\"table 3\">",
"      Meta anal chemo plus RT NPC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 4\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/57/19358\" title=\"table 5\">",
"      Phase II induction concurrent CRT NPC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/13/40154?source=related_link\">",
"      Complementary and alternative therapies for cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=related_link\">",
"      Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=related_link\">",
"      Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=related_link\">",
"      General principles of radiation therapy for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28649?source=related_link\">",
"      Methods to overcome radiation resistance in head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=related_link\">",
"      Posttreatment surveillance of squamous carcinoma of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16280?source=related_link\">",
"      Treatment of recurrent and metastatic nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_3_8251="IPEX clinical features";
var content_f8_3_8251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F65512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F65512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of immunodysregulation, polyendocrinopathy, and enteropathy, X-linked (IPEX)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical features of IPEX",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic diarrhea due to autoimmune enteropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type 1 diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatitis, usually eczematous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe food allergies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immune mediated cytopenias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Failure to thrive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Developmental delay",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_3_8251=[""].join("\n");
var outline_f8_3_8251=null;
var title_f8_3_8252="Fluorescence bronchoscopes";
var content_f8_3_8252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fluorescence bronchoscopes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Manufacturer/device name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Excitation, nm",
"       </td>",
"       <td class=\"subtitle1\">",
"        Detection, nm",
"       </td>",
"       <td class=\"subtitle1\">",
"        Image",
"       </td>",
"       <td class=\"subtitle1\">",
"        Abnormality/background",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Pinpoint",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         395 to 445",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         470 to 710",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         Green fluorescence: red reflectance",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         Brown-red on green",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Storz D-light",
"       </td>",
"       <td>",
"        380 to 440",
"       </td>",
"       <td>",
"        475 to 800",
"       </td>",
"       <td>",
"        Dual fluorescence: blue reflectance",
"       </td>",
"       <td>",
"        Brown-purple on blue-grey",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         SAFE-1000",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         420 to 450",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         490 to 590",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         Green fluorescence",
"        </em>",
"       </td>",
"       <td>",
"        <em>",
"         Dark green on light green",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SAFE-3000",
"       </td>",
"       <td>",
"        408",
"       </td>",
"       <td>",
"        430 to 700",
"       </td>",
"       <td>",
"        Dual fluorescence",
"       </td>",
"       <td>",
"        Red-purple on blue-green",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wolf",
"       </td>",
"       <td>",
"        390 to 460",
"       </td>",
"       <td>",
"        500 to 590 and 600 to 700",
"       </td>",
"       <td>",
"        Dual fluorescence",
"       </td>",
"       <td>",
"        Purple on blue-grey",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Olympus",
"       </td>",
"       <td>",
"        390 to 440",
"       </td>",
"       <td>",
"        470 to 690",
"       </td>",
"       <td>",
"        Dual fluorescence",
"       </td>",
"       <td>",
"        Magenta on green",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Italics denote older devices.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_3_8252=[""].join("\n");
var outline_f8_3_8252=null;
var title_f8_3_8253="Methanol and ethylene glycol intoxication - Rapid overview";
var content_f8_3_8253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Methanol and ethylene glycol intoxication: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early toxicity: CNS sedation and inebriation similar to ethanol intoxication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Late toxicity: metabolic acidosis with elevated anion gap; compensatory tachypnea/hyperpnea; coma in severe cases, accompanied by ocular toxicity (methanol) or renal failure (ethylene glycol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arterial or venous blood gas (to determine extent of acidosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Basic chemistry (to determine anion gap and renal function)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum osmolality (to help determine diagnosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum ethanol concentration (to help determine osmolal gap)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum calcium concentration (to rule out ethylene-glycol associated hypocalcemia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum methanol, ethylene glycol, and isopropanol concentrations (to establish diagnosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinalysis (for oxalate crystals)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secure airway as necessary in severely intoxicated patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treat hypotension with intravenous crystalloid, followed by standard vasopressors as necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Block alchohol dehydrogenase with",
"        <strong>",
"         fomepizole",
"        </strong>",
"        , 15 mg/kg IV loading dose, followed by 10 mg/kg q 12 h x 4 doses. If patient requires further treatment after this regimen, increase dose to 15 mg/kg every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If fomepizole is unavailable or patient has a known allergy, block alcohol dehydrogenase with ethanol, 10 mL/kg of a 10 percent ethanol solution, followed by 1 mL/kg of 10 percent ethanol solution infused per hour. Titrate to serum ethanol concentration of 100 mg/dL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administer",
"        <strong>",
"         sodium bicarbonate",
"        </strong>",
"        , 1 to 2 meq/kg bolus followed by infusion of 132 meq NaHCO3 in 1 L D5W to run at 200 to 250 mL/hour for patients with pH below 7.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For patients with known or suspected methanol poisoning, administer",
"        <strong>",
"         folic acid",
"        </strong>",
"        , 50 mg IV every six hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For patients with known or suspected ethylene glycol poisoning, administer",
"        <strong>",
"         thiamine",
"        </strong>",
"        , 100 mg IV, and administer",
"        <strong>",
"         pyridoxine",
"        </strong>",
"        , 50 mg IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If the diagnosis is uncertain but clinical suspicion is high, the clinician should initiate antidotal treatment with alcohol dehydrogenase blockade and consultation for hemodialysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hemodialysis is indicated in severe toxicity, which we define as follows:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolic acidosis, regardless of drug level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated serum methanol or ethylene glycol levels (more than 50 mg/dL; or methanol 15.6 mmol/L, ethylene glycol 8.1 mmol/L), unless arterial pH is above 7.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evidence of end-organ damage (eg, visual changes, renal failure)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_3_8253=[""].join("\n");
var outline_f8_3_8253=null;
var title_f8_3_8254="International classification of ROP";
var content_f8_3_8254=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    International Classification of Retinopathy of Prematurity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 288px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The International Classification of Retinopathy of Prematurity is shown for the left eye. This diagram is used to document the location and extent of ROP.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from The International Committee for the Classification of Retinopathy of Prematurity. Arch Ophthalmol 1984; 102:1130",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_3_8254=[""].join("\n");
var outline_f8_3_8254=null;
var title_f8_3_8255="HUS IF IV";
var content_f8_3_8255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Immunofluorescence microscopy showing fibrin deposition in thrombotic microangiopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy in the hemolytic-uremic syndrome shows fibrin deposition (bright yellow areas) in branches of a muscular renal artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_3_8255=[""].join("\n");
var outline_f8_3_8255=null;
